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Abstract 
 
Pulmonary hypertension (PH) is a rare but serious condition that causes progressive right 
ventricular (RV) failure and death.  PH may be idiopathic, associated with underlying 
connective-tissue disease or hypoxic lung disease, and is also increasingly being observed 
in the setting of heart failure with preserved ejection fraction (HFpEF).  The management 
of PH has been revolutionised by the recent development of new disease-targeted therapies 
which are beneficial in pulmonary arterial hypertension (PAH), but can be potentially 
harmful in PH due to left heart disease, so accurate diagnosis and classification of patients 
is essential.  These PAH therapies improve exercise capacity and pulmonary 
haemodynamics, but their overall effect on the right ventricle remains unclear.  Current 
practice in the UK is to assess treatment response with 6-minute walk test and NYHA 
functional class, neither of which truly reflects RV function.  Cardiac magnetic resonance 
(CMR) imaging has been established as the gold standard for the evaluation of right 
ventricular structure and function, but it also allows a non-invasive and accurate study of 
the left heart.  The aims of this thesis were to investigate the use of CMR in the diagnosis 
of PH, in the assessment of treatment response, and in predicting survival in idiopathic and 
connective-tissue disease associated PAH.  In Chapter 3, a left atrial volume (LAV) 
threshold of 43 ml/m2 measured with CMR was able to distinguish idiopathic PAH from 
PH due to HFpEF (sensitivity 97%, specificity 100%).  In Chapter 4, disease-targeted PAH 
therapy resulted in significant improvements in RV and left ventricular ejection fraction 
(p<0.001 and p=0.0007, respectively), RV stroke volume index (p<0.0001), and left 
ventricular end-diastolic volume index (p=0.0015).  These corresponded to observed 
improvements in functional class and exercise capacity, although correlation coefficients 
between Δ 6MWD and Δ RVEF or Δ LVEDV were low.  Finally, in Chapter 5, one-year 
and three-year survival was worse in CTD-PAH (75% and 53%) than in IPAH (83% and 
74%), despite similar baseline clinical characteristics, lung function, pulmonary 
haemodynamics and treatment.  Baseline right ventricular stroke volume index was an 
independent predictor of survival in both conditions.  The presence of LV systolic 
dysfunction was of prognostic significance in CTD-PAH but not IPAH, and a higher LAV 
was observed in CTD-PAH suggesting a potential contribution from LV diastolic 
dysfunction in this group.  
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Chapter 1 
 
Introduction 
22 
1.  Introduction 
 
Pulmonary hypertension (PH), defined as a resting mean pulmonary artery pressure 
(mPAP) ≥ 25mmHg measured at right heart catheterisation, results from a variety of 
conditions that can affect the pulmonary circulation.  There is a progressive increase in 
pulmonary vascular resistance (PVR), from either obstruction or obliteration of the 
pulmonary vascular bed, which causes right ventricular failure and premature death.  In the 
prospective National Institutes of Health (NIH) study of 198 patients with PH conducted in 
the United States in 1980s, an era where there was no effective pharmacological therapy, 
median survival was only 2.8 years1.  Thankfully the last two decades have seen a 
substantial increase in our understanding of PH pathophysiology, and this has facilitated 
the development of several different classes of disease-targeted therapy.  These new 
therapeutic options, initially aimed at pulmonary arterial hypertension (PAH) but now 
being increasingly used in PH due to other conditions, have resulted in significant 
improvements in survival.  However, despite this progress PH remains an incurable 
condition, and is still associated with significant morbidity and mortality2.   
 
 
This chapter will discuss the background and rationale of the work undertaken in this 
thesis.  It will review the current PH classification, pathology and pathobiology of PH,   
and the normal and abnormal right ventricle.  Following this is a discussion on the 
diagnostic assessment of PH, with particular focus on the role of cardiac magnetic 
resonance (CMR) imaging, current therapeutic options and the changing demographic 
profile in PH.  Finally, the aims and hypothesis of this thesis are introduced.   
 
 
1.1  Classification of Pulmonary Hypertension 
 
Pulmonary Hypertension was previously classified into two categories: primary pulmonary 
hypertension (where there was no underlying cause for the PH), and secondary pulmonary 
hypertension (where an underlying risk factor or cause existed).    
 
In 1998 a new five-group clinical classification was proposed at the second World 
Symposium on Pulmonary Hypertension (Evian, France) which established individual PH 
groups based on similar clinical features, haemodynamics, pathological findings and 
therapeutic strategies.  The five groups identified were pulmonary arterial hypertension 
23 
(Group 1); pulmonary hypertension due to left heart disease (Group 2); pulmonary 
hypertension due to chronic lung disease and/or hypoxia (Group 3); chronic 
thromboembolic pulmonary hypertension (Group 4); and pulmonary hypertension due to 
unclear pathological mechanisms (Group 5).    
 
The Evian classification is now well established, but has been further refined at subsequent 
World Symposium(s) in Venice, Italy (2003), Dana Point, USA (2008), Nice, France 
(2013)3-5.  At the most recent World Symposium the consensus was reached that the 
current classification should be maintained, with only minimal modifications to Group 1. 
 
The Nice clinical classification is summarized in Table 1.1 
24 
Table 1.1  Clinical classification of pulmonary hypertension  
  (Nice Classification 2013) 
 
1 Pulmonary arterial hypertension 
   1.1 Idiopathic PAH 
   1.2 Heritable PAH 
   1.2.1 BMPR2 
   1.2.2 ALK-1, ENG, SMAD9, CAV1, KCNK3 
   1.2.3 Unknown 
   1.3 Drug and toxin induced 
   1.4 Associated with: 
   1.4.1 Connective tissue disease 
   1.4.2 HIV Infection 
   1.4.3 Portal hypertension 
   1.4.4 Congenital heart diseases 
   1.4.5 Schistosomiasis 
 
1′ Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis 
1′′ Persistent pulmonary hypertension of the newborn  
2. Pulmonary hypertension due to left heart disease 
   2.1 Left ventricular systolic dysfunction 
   2.2 Left ventricular diastolic dysfunction 
   2.3 Valvular disease 
   2.4 Congenital / acquired left heart inflow / outflow tract obstruction and congenital     
   cardiomyopathies 
3. Pulmonary hypertension due to lung diseases and/or hypoxia 
   3.1 Chronic obstructive pulmonary disease 
   3.2 Interstitial lung disease 
   3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern 
   3.4 Sleep-disordered breathing 
   3.5 Alveolar hypoventilation disorders 
   3.6 Chronic exposure to high altitude 
   3.7 Developmental lung diseases 
4. Chronic thromboembolic pulmonary hypertension (CTEPH) 
5. Pulmonary hypertension with unclear multifactorial mechanisms 
25 
   5.1 Haematologic disorders: chronic haemolytic anaemia, myeloproliferative 
disorders, splenectomy 
   5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis, 
lymphagioleiomyomatosis 
   5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid 
disorders 
   5.4 Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, 
segmental PH 
 
BMPR = bone morphogenic protein receptor type II; CAV1 = caveolin-1; ENG = 
endoglin; HIV = human immunodeficiency virus; PAH = pulmonary arterial hypertension 
26 
1.2  Pathology and Pathobiology of Pulmonary Hypertension 
 
In WHO Group 1 PAH, pathological lesions typically affect distal pulmonary arteries of < 
500µm diameter, with pulmonary veins usually unaffected6, 7.  The characteristic 
histopathological abnormalities in PAH are medial hypertrophy, fibrotic and proliferative 
intimal change, and thickening of the adventitia with moderate perivascular inflammatory 
infiltrates.  These changes result in luminal occlusion (pulmonary vascular remodelling), 
the formation of angioproliferative ‘plexiform’ lesions at pulmonary artery bifurcation 
sites, and in-situ thrombus formation.   
 
Different mechanisms contribute to the increased PVR observed in PAH, including 
vasoconstriction, proliferative and obstructive remodelling of the pulmonary vessel wall, 
inflammation, and thrombosis. The exact trigger for these pathological changes is unclear, 
but it is felt to be a multifactorial process involving several different biochemical pathways 
and cell types8-10.   Endothelial dysfunction leads to overexpression of vasoconstrictor and 
proliferative substances such as thromboxane A2 and endothelin-1, and impaired 
production of vasodilator and antiproliferative agents such as nitric oxide and prostacyclin.  
Excessive vasoconstriction has been related to abnormalities of potassium channels in the 
smooth muscle cells.  Within the adventitia, there is increased production of extracellular 
matrix including collagen, elastin, tenascin and fibronectin.  PAH is a prothrombotic state, 
where thrombi can be present in both the small distal pulmonary arteries and the proximal 
elastic pulmonary arteries, further reducing lumen calibre.  Other cell types that have been 
implicated in PAH include inflammatory cells, fibroblasts and platelets, and plasma 
mediators such as vasoactive intestinal peptide.   
 
The pathological lesions observed in chronic thromboembolic PH (CTEPH) are 
characterised by organised thrombi that cause thickening of the vessel wall and luminal 
occlusion in proximal pulmonary arteries.  They can also result in different grades of webs, 
bands and stenosis within elastic pulmonary arteries11.  In addition, a PAH-like 
arteriopathy can also affect occluded and non-occluded subsegmental pulmonary arteries.  
When CTEPH occurs following acute pulmonary embolism, non-resolution of the 
thromboembolic mass causes mechanical obstruction and pulmonary vascular remodelling, 
with increased shear force, pressure elevation and endothelial dysfunction in both occluded 
and non-occluded areas.  It is recognized that at least 25% of patients with CTEPH do not 
have a history of acute pulmonary embolism, with pulmonary vascular remodelling in 
27 
these patients thought to be triggered by thrombotic or inflammatory lesions within a 
procoagulant environment12, 13. 
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1.3  Right ventricular structure and function 
 
The right ventricle (RV) was previously thought to be simply a conduit to transfer systemic 
venous blood to the lungs, and that the cardiovascular system could operate adequately 
without RV contractile function14.  However, it has since become clear that the congenital 
RV hypoplasia can result in marked circulatory compromise and premature death.  
Advances in cardiovascular imaging with echocardiography and magnetic resonance have 
resulted in new opportunities to study RV structure and function, with particular interest in 
the pathophysiology of the RV in pulmonary hypertension.   
 
The RV is the most anteriorly situated cardiac chamber, lying almost in the midline 
immediately behind the sternum.  It has a complex shape, triangular when viewed from the 
side and crescent-shaped when viewed in cross section, unlike the ellipsoidal-shaped left 
ventricle (LV)15.  In normal conditions, the interventricular septum (IVS) bows into the RV 
in both systole and diastole, due to LV pressures being higher than those in the RV and the 
subsequent positive left-to-right trans-septal pressure gradient.   
 
The RV is often divided into three parts:  (1) the inlet portion comprising the tricuspid 
valve, the papillary muscles and their associated chordae tendinae ;  (2) the coarsely 
trabeculated apical myocardium; and (3) the outflow tract, also called the  infundibulum or 
conus, consisting of smooth myocardium and the pulmonary valve16.  The RV contains a 
prominent ridge of muscle known as the Moderator Band, which crosses the ventricular 
cavity from the apex to free wall, and is thought to assist in preventing over-distention of 
the RV.   
 
The right and left ventricles are composed of multiple layers of muscle fibres which 
interlace to form a three-dimensional network16.  The RV free wall is composed of 
superficial and deep muscle layers.  In the superficial layer, the fibres are arranged 
circumferentially, in a direction parallel to the atrio-ventricular groove, and are anchored to 
the fibroskeleton of the heart around the tricuspid valve ring.  These fibres turn obliquely 
near the cardiac apex, and continue into the superficial myofibres of the LV.  The deep 
muscle fibres of the RV are aligned longitudinally from base to apex.  In contrast, the LV 
is composed of obliquely oriented muscle fibres superficially, longitudinally oriented 
fibres in the deep (subendocardial) layer and intervening circumferential fibres.  
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Contraction of the RV commences at the inlet portion, and spreads sequentially to the 
trabeculated myocardium and then the infundibulum17.  It is composed of three distinct 
mechanisms:  (1) contraction of the circumferential fibres causes inward movement of the 
RV free wall; (2) shortening of the longitudinal fibres which draws the tricuspid annulus 
toward the apex; and (3) traction on the RV free wall at the points of attachment to the 
contracting LV.  In the RV there is greater longitudinal than circumferential shortening, 
and a much lower contribution from the twisting and rotational movements that occur in 
the LV.  The synchronous mechanical interaction between the ventricles throughout the 
cardiac cycle, “ventricular interdependence”, is achieved by the continuity in the muscle 
fibres of the RV and LV17. 
 
 
The blood supply to the right ventricle will depend on whether the coronary system is 
right-dominant (80% of population) or left-dominant (20%).  In the right-dominant system 
the right coronary artery supplies most of the RV, with marginal branches supplying the 
lateral wall, and the posterior descending artery supplying the posterior wall and the 
inferoseptal region18.  The anterior wall and anteroseptal region are usually supplied by 
branches of the left anterior descending artery.  In the normal RV, blood flow within the 
proximal right coronary artery occurs during both systole and diastole, with predominantly 
diastolic flow beyond the RV marginal branches19.  It is felt that the RV is less vulnerable 
to irreversible ischaemic damage due to the combination of its extensive collateral system, 
lower oxygen consumption and ability to increase oxygen extraction.   
 
In normal conditions, the RV is a low pressure/volume pump that moves desaturated blood 
out into the pulmonary circulation via the pulmonary valve.  Desaturated blood returns 
from the systemic circulation via the superior and inferior vena cavae and right atrium, 
crosses the tricuspid valve and enters the inlet region of the RV 
 
Differences in the function of the normal RV and LV can be explained by differences in 
muscle mass, orientation of myocardial fibres and chamber geometry20-22, and the key 
differences are presented in Table 1.2 
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Table 1.2 Comparison of right and left ventricular structure and function 
 
 Right Ventricle Left Ventricle 
Shape crescentic in cross-section; 
triangular from the side 
elliptic 
Structure inflow region, trabeculated 
apical myocardium and 
infundibulum 
inflow region and 
myocardium and outflow 
tract 
Muscle fibre 
orientation 
superficial: circumferential 
deep: longitudinal 
superficial: oblique 
middle: circumferential 
deep: longitudinal 
Contractile pattern long axis shortening, inward 
movement of RV free wall 
twisting, rotation, wall 
thickening 
End-Diastolic Volume 
(ml/m2) 
75 ± 13 66 ± 12 
Ejection fraction, % 61 ± 7 67 ± 5 
Mass (g/m2) 26 ± 5 87 ± 12 
Wall thickness, mm 2 to 5 7 to 11 
Ventricular pressure, 
(mmHg) 
average 25/4 average 130/8 
PVR vs SVR 
(dyne · s · cm−5) 
70 1100 
Compliance at end-
diastole 
higher lower 
Filling profiles starts earlier and finishes 
later, lower filling velocities 
starts later and finishes 
earlier, higher filling 
velocities 
Resistance to 
Ischaemia 
greater resistance to 
ischaemia 
more susceptible to 
ischaemia 
Adaptation to disease 
state 
more sensitive to pressure 
overload 
more sensitive to volume 
overload 
 
Modified from Haddad et al. Right ventricular function in cardiovascular disease, Part I. 
Circulation. 2008;117:1436-1448
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1.3.1  Right ventricular response to increased afterload 
 
RV systolic function is a reflection of preload, contractility and afterload.  RV preload 
represents the load on the RV that is present before contraction, and the Frank-Starling 
mechanism dictates that under normal physiological conditions an increase in RV preload 
will improve myocardial contraction.  However, excessive RV volume loading outwith 
normal physiological limits can result in LV compression and global impairment of 
ventricular function through the mechanism of ventricular interdependence23.  Filling of 
the RV can be influenced by active and passive atrial characteristics, heart rate, 
intravascular volume status, ventricular relaxation and chamber compliance, and the degree 
of pericardial constraint24.   
 
RV afterload represents the load that must be overcome during RV ejection.  Since resting 
pulmonary vascular resistance (PVR) is only one-fifteenth of normal systemic vascular 
resistance, the RV is able to eject the equivalent volume of blood per contraction as the LV 
at a far lower energy cost, and this low pressure environment within the pulmonary 
circulation helps to prevent fluid migrating into the interstitial space, providing optimal 
conditions for gas exchange.  However, the disadvantage is that the RV is more vulnerable 
to changes in afterload than the LV, with small increases in PVR causing in a marked 
reduction in RV stroke volume23, 25.   
 
In pulmonary hypertension there is a progressive increase in pulmonary vascular 
resistance, and extent of right ventricular adaptation to this increased afterload will 
determine the clinical course and outcome of the patient.   Right ventricular adaptation to 
disease is a complex and multi-factorial process.  It can be influenced by the time of onset 
of the disease (paediatric vs adult-onset heart disease), the time course of the disease (acute 
or chronic), and the severity of the myocardial stress or injury.  The right ventricle can be 
affected by volume overload or pressure overload, ischaemia, pericardial constraint, or 
intrinsic pericardial disease26.   Volume-overload conditions (e.g. atrial septal defect, 
tricuspid regurgitation, anomalous pulmonary venous drainage) can be tolerated for 
prolonged periods without significant impairment of RV systolic function, although do 
eventually lead to increased morbidity and mortality27, 28.  In contrast, pressure-overload 
conditions (left-sided heart failure, pulmonary embolism, other causes of PH, RV outflow 
tract obstruction) are poorly tolerated in adult patients and often lead to RV dilatation and 
failure23.  In an acute pressure-overload state such as pulmonary embolism, even a  
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previously normal RV may be unable to adapt to the rapid increase in afterload caused by 
the embolic burden, and rapid right ventricular failure can ensue29.   
 
When chronic pressure-overload occurs in the setting of idiopathic PAH, there is an initial 
adaptive response of RV myocardial hypertrophy followed by progressive contractile 
dysfunction30.  Dilatation of the RV then occurs to facilitate compensatory preload, and to 
maintain preserved stroke volume despite reduced ejection fraction.  As RV dysfunction 
progresses there is rising filling pressures, diastolic dysfunction and cardiac output 
continues to deteriorate31.  This can be exacerbated by tricuspid regurgitation due to 
annular dilatation and poor leaflet coaptation, whilst increased RV size and pressure can 
also impair LV diastolic function32.  In congenital heart diseases with left-to-right shunting, 
there is early exposure of the RV to systemic pressures thus allowing the RV to undergo 
hypertrophic growth in parallel to the LV.  When increased afterload eventually occurs due 
to pulmonary vasculopathy and consequent shunt reversal, the hypertrophied RV is able to 
function normally for many years, and this can explain why survival in PH due to 
congenital heart disease is much greater than in PH due to other aetiologies33-35.  The 
effects of altered gene expression, neurohormonal and cytokine activation on the pattern of 
RV modelling are thought to explain why the same degree of PH can cause early or late 
RV failure in different patients36.   
 
The initial response of the RV to an increased afterload is concentric hypertrophy, and this 
is predominantly caused by increased protein synthesis and an increase in cardiomyocyte 
size through the addition of sacromeres37, 38.  Protein synthesis occurs in response to 
increased stretch, with a contribution from autocrine, paracrine and neurohumoral 
influences.  Adaptive RV hypertrophy cannot preserve cardiac output indefinitely, and 
there is eventually transition to RV dilatation and failure.  Functional, structural or 
numerical changes in cardiomyocytes lead to a reduction in cardiac contractile force and 
the RV dilates.  Whilst the precise explanation for this phenotypic change is unknown, the 
increased wall tension that results from RV dilatation increases myocardial oxygen 
demand and simultaneously decreases RV perfusion.  Increased afterload results in the RV 
returning to a fetal gene expression pattern, with a shift from α- to β-mysoin heavy chain 
expression, phosphodiesterase type-5 expression, and an increase in adrenergic receptors36, 
39.    
 
Impaired RV systolic function results in a longer contraction time and subsequent 
interventricular mechanical asynchrony, with the RV still contracting as the LV enters 
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diastole40-42.  The result is a positive right to left trans-septal pressure gradient during early 
diastole which causes leftward bowing of the interventricular septum into the LV cavity, 
impairment of LV diastolic filling, and reduced cardiac output.  Available RV filling time 
(i.e. diastolic duration) is severely shortened, with compromise of RV filling, RV stroke 
volume and subsequent LV filling43.  This vicious circle of worsening contractility,  
increasing dilatation and falling cardiac output can be accelerated by abnormal 
neurohormonal signaling, immune activation and inflammatory responses, and 
cardiomyoctye apoptosis38, 44, 45.  
 
The extent of right ventricular dysfunction beyond which recovery is unlikely to occur 
remains unknown.  Improvements in RV function have been demonstrated after single lung 
transplantation for pulmonary hypertension46.  Following living-donor lobar lung 
transplantation for PAH, right ventricular function recovered early (by 8 weeks) whereas 
recovery of left ventricular function required 6 to 12 months47.  Resolution of right 
ventricular dysfunction has been demonstrated after thrombolytic therapy for acute 
pulmonary embolism48, and after balloon pulmonary angioplasty49 or pulmonary 
endarterectomy for CTEPH50.   
 
In PAH, right ventricular function is the most important determinant of survival, with the 
prognostic significance of variables reflecting RV function (e.g. cardiac index, right atrial 
pressure, VO2 max) far exceeding that of mean pulmonary artery pressure1, 23, 51, 52.  This 
may reflect the fact that pulmonary artery pressure can often decrease as RV failure 
progresses.  The presence of right heart failure prior to the initiation of PAH therapy is 
associated with poor survival53.   
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1.4  Clinical Presentation of Pulmonary Arterial Hypertension 
 
Most patients with PAH present with exertional dyspnoea, developing over months or 
years54. This classical, although non-specific, symptom is thought to be due to the inability 
of the right heart to raise output on exertion. Chest pain, syncope and peripheral oedema 
are more common in advanced PAH, and indicate right ventricular failure.  
 
The clinical signs of PAH, whilst subtle, can include right ventricular heave, loud 
pulmonary component of the second heart sound, a pansystolic murmur of tricuspid 
regurgitation and a right ventricular third sound.  The lungs are typically clear.  Jugular 
venous distension, hepatomegaly, peripheral oedema, ascites and cold extremities indicate 
patients in a more advanced state with right ventricular failure at rest. Central cyanosis may 
also be present in advanced cases. 
 
Clinical examination may also help identify the aetiology of the pulmonary hypertension.  
In PAH due to scleroderma there may be digital ulceration, telangiectasia and 
sclerodactyly.  In PAH associated with portal hypertension there may be stigmata of 
chronic liver disease, such as palmar erythema, spider naevi, gynaecomastia and testicular 
atrophy.  PH due to underlying interstitial lung disease may be suggested by the presence 
of fine inspiratory crackles55.     
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1.5  Diagnostic Assessment of Pulmonary Arterial Hypertension 
 
The diagnostic assessment of a patient with suspected pulmonary arterial hypertension 
requires a series of investigations that will confirm the diagnosis, clarify the clinical group 
of PH (i.e. WHO Group 1-5) and the specific aetiology within the PAH (Group 1) group, 
and evaluate the functional and haemodynamic impairment. 
 
The ECG may provide evidence of right ventricular hypertrophy or strain, with right axis 
deviation, large p-waves especially in lead II, tall R waves and ST depression in the right-
sided chest leads.  Right axis deviation is present on ECG in 79% of patients with 
idiopathic PAH, and RV hypertrophy is present in 87%54.  Most patients with PAH will be 
in sinus rhythm, however the presence of supraventricular arrhythmias such as atrial flutter 
can indicate advanced disease, and are often associated with rapid clinical deterioration56.  
Atrial fibrillation is common in patients with pulmonary hypertension associated with left 
heart disease57 
 
The chest X-ray will be abnormal in most patients with pulmonary arterial hypertension54.  
Common findings include enlargement of the main pulmonary arteries and rapid tapering 
of the vessels as they extend to the periphery of the lungs, giving rise to peripheral 
oligaemia.  Right ventricular and right atrial enlargement may also be visible in advanced 
disease.   The chest X-ray can demonstrate upper lobe venous diversion and pleural 
effusions in pulmonary venous hypertension, and evidence of moderate-to-severe 
interstitial lung disease in Group 3 PH.   
 
Pulmonary function tests (PFTs) in PAH often reveal normal or only mildly impaired 
spirometry, but a markedly reduced diffusion capacity for carbon monoxide.  If clinically 
suspected, screening polysomnography or overnight oximetry should be used to exclude 
significant sleep-disordered breathing.  A decrease in lung volume together with a decrease 
in diffusion capacity for carbon monoxide may indicate a diagnosis of interstitial lung 
disease, whereas non-reversible airflow obstruction together with increased residual 
volumes and reduced diffusion capacity for carbon monoxide suggests COPD as a cause of 
hypoxic pulmonary hypertension. 
 
The key features of pulmonary arterial hypertension on CT are: enlargement of the main 
pulmonary artery (i.e. main pulmonary artery diameter >29mm)58; right ventricular 
dilatation and hypertrophy, and enlargement of the right atrium; flattening or ‘bowing’ of 
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the interventricular septum; the presence of pericardial effusions; small centrilobular 
ground-glass nodules; reflux of contrast from the right atrium into the inferior vena cava 
when CT pulmonary angiography is performed.  This last feature occurs as a result of 
tricuspid regurgitation and the extent of reflux correlates with mean pulmonary artery 
pressure, however it can be observed in normal patients59.    
 
High-resolution CT scanning can facilitate the diagnosis of emphysema and interstitial 
lung disease, and can be useful when the clinical history suggests possible pulmonary 
veno-occlusive disease (PVOD).  Characteristic changes of PVOD include interstitial 
oedema with diffuse central ground-glass opacification and thickening of interlobular 
septa, whilst lymphadenopathy and pleural effusions may also be present.   
 
The hallmark of CTEPH on CT pulmonary angiography is the absence or sudden loss of 
contrast filled vessels.  Abnormalities in the main pulmonary artery may be highly 
suggestive of CTEPH, with the most common finding being the eccentric location of 
thrombus, resulting in a crescentic filling defect adjacent to the vessel wall60.  Bronchial 
artery hypertrophy occurs in approximately half the patients with CTEPH and only rarely 
in IPAH61.  In CTEPH there is “mosaic oligaemia” visible on high resolution scanning, 
caused by obliteration of parts of the vascular bed.  This results in hypoperfusion with 
arteries of diminished size in some areas, with normal or increased perfusion and enlarged 
arteries in others.  Peripheral lung parenchymal opacities are another common finding in 
CTEPH62. They represent pulmonary infarcts due to occlusion of segmental and smaller 
pulmonary arteries and therefore occur more commonly in “peripheral type” CTEPH than 
“central type”.   
 
Conventional pulmonary angiography is still used in some centres for the diagnosis and 
assessment of surgically correctable CTEPH.  The typical findings include vascular cut-
offs representing complete occlusion of the vessel, and vascular webs which result from 
organisation of thromboembolic material in the vessel lumen with subsequent scar 
formation.  Smaller pulmonary arteries can appear tortuous and taper rapidly, particularly 
in patients with distal inoperable CTEPH.  Magnetic resonance angiography does not 
require exposure to radiation, and is becoming increasingly important in the diagnosis, 
assessment and long-term follow-up of patients with CTEPH.   
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The role of ventilation perfusion (V/Q) scintigraphy is to distinguish IPAH from CTEPH.  
In IPAH, the VQ scan is usually normal or shows heterogeneous perfusion63.  Occasionally 
larger mismatch perfusion defects may be seen IPAH, thought to be as a result of 
thrombosis in situ.  With CTEPH, the VQ scan is usually high probability, showing 
multiple mismatched segmental or larger perfusion defects.  A normal or low probability 
scan effectively excludes CTEPH64, 65.  Whilst VQ scintigraphy is a safe and highly 
sensitive test for suspected CTEPH, large mismatch perfusion defects may arise in other 
processes that result in obliteration of the central arteries and veins.  These “CTEPH 
mimics” include large vessel vasculitis, pulmonary artery sarcoma, extrinsic compression 
due to cancer, lymphadenopathy, fibrosing mediastinitis and pulmonary veno-occlusive 
disease (PVOD)66. 
   
Blood testing including routine haematology, biochemistry and thyroid function tests is 
performed in all patients.  Serological testing is used to detect HIV, hepatitis and 
underlying connective-tissue disease, although up to 40% of patients with idiopathic PAH 
have elevated anti-nuclear antibodies, usually in low titre (1:80)67.  It is particularly 
important to exclude underlying systemic sclerosis (SSc) due to the poor survival 
associated with SSc-PAH.  Anti-centromere antibodies are usually positive in limited 
scleroderma, and anticardiolipin antibodies may suggest a diagnosis of systemic lupus 
erythematosus.  When a diagnosis of CTEPH is being considered then thrombophilia 
screening with anti-phospholipid antibodies, lupus anticoagulant, and anti-cardiolipin 
antibodies should be performed2.   
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1.5.1  Echocardiography 
 
The use of echocardiography in the assessment of pulmonary arterial hypertension focuses 
on detection of elevated pulmonary artery pressure, evaluation of the right ventricle and 
exclusion of other possible differential diagnosis. 
 
In PAH chronic progressive pressure-loading results in right ventricular remodelling, 
particularly RV hypertrophy and later RV dilatation.  RV dilatation can result in tricuspid 
annular dilatation, causing significant tricuspid regurgitation.  Application of continuous 
wave Doppler mapping on this jet allows calculation of the TR velocity.  This velocity 
represents the RV to right atrial pressure difference, and can be used to estimate pulmonary 
artery systolic pressure (PASP) through the Bernoulli equation: 
  
PASP = RV Systolic Pressure = 4 (VTR)2 + RAP 
  
(VTR = tricuspid regurgitant velocity, RAP = right atrial pressure) 
 
Whilst calculation of mean PAP from PA systolic pressure is possible (mean PAP = 0.61 x 
PA systolic pressure + 2 mmHg), doppler echocardiography has been found to be 
inaccurate at assessment of pulmonary artery pressure in nearly 50% of cases68.  Use of the 
Bernoulli equation can lead to over- or under-estimations of PA systolic pressure by up to 
10mmHg, and therefore pulmonary hypertension cannot be reliably defined by a cut-off 
value of Doppler-derived PA systolic pressure.  
 
As PAH progresses there is impaired RV diastolic function, increased RV end-diastolic 
pressure, with displacement or “bowing” of the interventricular septum towards the left 
ventricle, and dilation of the main pulmonary artery.  
 
Tricuspid annular plane systolic excursion (TAPSE) represents the basal to apical 
shortening of the right ventricle during systole.  TAPSE will be reduced when there is 
impaired RV systolic function, and a TAPSE of less than 1.5cm is associated with poor 
prognosis in pulmonary arterial hypertension (≤1.7cm in SSc-PAH) 69, 70.  Other 
echocardiographic indices with prognostic significance include the presence of a 
pericardial effusion71, 72, indexed right atrium area72 and the RV Doppler index73, 74. 
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Echocardiography can also help identify the cause of suspected or confirmed PH. Doppler 
and contrast examinations can be used to detect underlying congenital heart disease.  
Pulmonary blood flow assessment and assessment of proximal pulmonary artery diameter 
can be used in the diagnosis of sinus venosus-type atrial septal defect or anomalous 
pulmonary venous drainage.   
 
 
1.5.2  Exercise Capacity 
 
The two commonly used methods for assessing exercise capacity in suspected or 
confirmed PAH are the 6-minute walk test (6MWT) and cardiopulmonary exercise testing 
(CPET). 
 
The 6MWT is a non-invasive and reproducible assessment of exercise capacity.  It is a 
self-paced test determining submaximal exercise capacity that is technically simple and 
inexpensive.  Patients are asked to walk on a flat surface for 6 minutes, covering as much 
distance as possible at their own pace, with encouragement at 1-min intervals75, 76.  Total 
distance walked (6MWD), oxygen saturations and dyspnoea (Borg scale) are recorded.  % 
predicted 6MWD can also be measured, adjusting the total distance walked for age, sex, 
height and weight, but its prognostic value was not superior to absolute 6MWD77.   
 
The 6 minute walk distance (6MWD) can also be affected by other factors including 
learning effect, patient motivation, general fitness, and coexisting musculoskeletal or 
rheumatological conditions.   This can be of particular importance in patients with PAH 
associated with connective-tissue disease or hypoxic lung disease.  The utility of the 
6MWT may be limited in patients with milder or early pulmonary arterial hypertension 
who may have a relatively high baseline 6MWD (the ‘ceiling’ effect)78, 79.  In these 
patients PAH treatment may improve pulmonary haemodynamics and functional class, but 
not significantly alter 6MWD80. 
 
In idiopathic PAH, baseline 6MWD is predictive of survival and correlates with WHO 
functional class and haemodynamic parameters81, 82.  It has been demonstrated that after 
long-term epoprostenol therapy, absolute values of 6MWD > 380 m correlated with 
improved survival, whereas change in 6MWD from baseline did not53.  The 6MWT is 
widely used to assess response to PAH treatment, however it is yet to be demonstrated that 
changes in 6MWD after treatment correspond to improved survival.  Recent meta-analysis 
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of PAH therapeutic trials found no relationship between 6MWD changes and clinical 
outcomes83 or survival84.  An analysis of data from a recent clinical trial of the 
phosphodiesterase-5 inhibitor tadalafil has proposed that the minimal important difference 
in the 6MWT for PAH is approximately 33m, i.e. an improvement of 6MWD of +33m was 
associated with an improvement in quality of life measures85. 
 
 
During cardiopulmonary exercise testing, ventilation and gas exchange are continuously 
recorded throughout incremental exercise on a cycle ergometer or treadmill.  
Ventilation/perfusion mismatching and impaired oxygen transport can cause impaired 
exercise tolerance in PAH.   At CPET this results in reduced peak oxygen pulse (VO2/HR), 
reduced peak work rate, peak heart rate and ventilatory efficiency, and reduced oxygen 
uptake at anaerobic threshold and peak exercise.  A peak VO2 < 10.4 ml/min/kg and peak 
systolic blood pressure below 120 mmHg have been shown to be independent predictors of 
poor outcome in idiopathic PAH86.  Due to a lack of standardization and sufficient 
expertise performing CPET, the 6MWT remains, at present, the only Food and Drug 
Administration / European Agency for the Evaluation of Medicinal Products accepted 
exercise endpoint for studies evaluating treatment effects in PAH2.   
 
 
1.5.3  Inert Gas Rebreathing 
 
The inert gas rebreathing (IGR) method allows pulmonary blood flow (PBF) to be 
measured during the rebreathing of a mixture of blood-soluble and blood-insoluble gases87.  
When rebreathing through a respiratory apparatus from a bag prefilled with the gas mixture 
for about 30 seconds, the blood-soluble gas dissolves rapidly in the pulmonary capillary 
blood, and its rate of disappearance from the alveoli is in proportion to the effective 
pulmonary blood flow.  The blood-insoluble gas is not taken up in the pulmonary capillary 
blood, and remains in the alveoli to allow for correction in total alveolar volume during the 
rebreathing manoeuvre.  In the absence of significant intracardiac or intrapulmonary shunts 
then the measured PBF will equal cardiac output.  
 
The recently developed metabolic IGR system called Innocor (Innovision, Odense, 
Germany) has been demonstrated to be a reliable and reproducible way of measuring 
cardiac output in patients with heart failure88, interstitial lung disease89, and pulmonary 
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hypertension90.  The Innocor device is portable, easy to maintain and can be used to 
provide measurements at rest and during exercise.   
 
 
1.5.4  Natriuretic Peptides 
 
Biochemical markers are a commonly used non-invasive tool for assessment and 
monitoring of RV dysfunction in patients with pulmonary hypertension.  Brain natriuretic 
peptide (BNP) induces vasodilatation and natriuresis, and is released from myocardium in 
response to wall stress.  The final step of BNP synthesis consists of a high molecular 
weight precursor, proBNP, cleaved into biologically inactive N-terminal segment (NT-
proBNP) and the proper low molecular weight BNP91.  NT-proBNP has a better stability 
both in circulating blood and after sampling due to its longer half-life.   
 
NT-ProBNP has been shown to be an objective, non-invasive method for identifying right 
ventricular dysfunction in pulmonary hypertension92, 93.  In a heterogenous group of 
patients with chronic precapillary PH, plasma NT-proBNP was used to determine the 
clinical severity of disease and was independently associated with long-term mortality94.  
In patients with systemic sclerosis an elevated NT-proBNP (>395 pg/ml) was associated 
with a very high probability of having PAH, and a 10-fold increase in NT-proBNP on 
therapy was associated with a greater than three-fold increase in mortality in SSc-PAH95.  
Serial BNP/NT-proBNP measurements have been used to track RV function over 12 
months in deteriorating or improving patients with PAH96, and to identify residual PH 
following pulmonary endarterectomy for CTEPH97.   
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1.5.5  Right Heart Catheterisation 
 
Right heart catheterisation remains the gold standard for the diagnosis of pulmonary 
arterial hypertension, and is required to confirm the diagnosis of PAH, to assess the 
haemodynamic severity, to test the vasoreactivity of the pulmonary circulation, and to help 
select the appropriate therapy.  Right heart catheterisation is performed using a Swan-Ganz 
thermodilution catheter, inserted into a central vein and floated through the right heart 
chambers into the pulmonary artery98.  The following variables are measured: right atrial 
pressure, right ventricular pressure, pulmonary artery pressure (systolic, diastolic and 
mean) and pulmonary artery occlusion pressure.  Pulmonary vascular pressures are 
measured at end-expiration when the lungs are at functional residual capacity.  Cardiac 
output (CO) is measured in triplicate by thermodilution or by the Fick method.  Sampling 
of oxygen saturations from different sites can be used to identify any ‘step-up’ or ‘step-
down’ in oxygen saturation to detect and quantify shunting.   
 
Transpulmonary gradient (TPG) and pulmonary vascular resistance (PVR) are derived 
from the following equations: 
 
TPG = mPAP – pulmonary artery occlusion pressure 
PVR = TPG/CO, where 
 
TPG = transpulmonary gradient 
mPAP = mean pulmonary artery pressure 
PVR = pulmonary vascular resistance 
CO = cardiac output 
 
The haemodynamic definitions of pulmonary hypertension are displayed in Table 1.3 
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Table 1.3   Haemodynamic definitions of pulmonary hypertension  
 
Definition Characteristics Clinical Group(s) per Dana 
Point Classification 
Pulmonary hypertension 
(PH) 
Mean PAP ≥ 25mmHg All 
Pre-capillary PH Mean PAP ≥ 25mmHg 
PAWP ≤ 15mmHg 
CO normal or reduced* 
1. Pulmonary arterial 
hypertension 
3. PH due to lung diseases 
4. Chronic thromboembolic PH 
5. PH with unclear and/or 
multifactorial mechanisms 
Post-capillary PH 
 
 
  Passive 
  Reactive 
Mean PAP ≥ 25mmHg 
PAWP > 15mmHg 
CO normal or reduced 
TPG ≤ 12 mmHg 
TPG > 12 mmHg 
2. PH due to left heart disease 
 
All values to be measured at rest 
 
* High CO can be present in cases of hyperkinetic conditions such as systemic-to-
pulmonary shunts (only in the pulmonary circulation), anaemia, hyperthyroidism, etc. 
 
CO = cardiac output; PAP = pulmonary arterial pressure; PH = pulmonary 
hypertension; PAWP = pulmonary artery wedge pressure; TPG = transpulmonary 
pressure gradient (mean PAP – mean PAWP) 
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Accurate recording of PAWP is essential for the diagnosis of PH due to left heart disease, 
particularly PH due to heart failure with preserved ejection fraction (HFpEF). It was 
traditionally felt that a PAWP > 15 mmHg effectively excluded the diagnosis of pre-
capillary PAH, however there is growing recognition of the variability of wedge pressure 
measurements and the need for standardisation of methodology.  A review of PAWP data 
from the REVEAL registry highlighted a number of cases where there was a significant 
difference in PAWP between initial and follow-up RHC99.  When there is a strong clinical 
suspicion of Group 2 PH, but initial PAWP is ≤ 15mmHg, then fluid challenge with 500ml 
saline over 5-10 minutes has been used to “unmask occult pulmonary venous 
hypertension” by showing a disproportionate rise in PAWP100.  In some cases, left heart 
catheterisation may be required for direct assessment of LV end-diastolic pressure.   
 
In PAH, vasoreactivity testing may be performed at the time of diagnostic RHC to identify 
patients who may benefit from long-term therapy with calcium channel blockers (CCBs).  
An acute vasodilator challenge is usually performed with inhaled nitric oxide, although 
intravenous epoprostenol or adenosine have also been used.  A positive acute response is 
defined as a reduction of mPAP ≥ 10 mmHg to reach an absolute value of mPAP ≤ 40 
mmHg with increased or unchanged cardiac output101.  Approximately 10% of idiopathic 
PAH are acute responders and about half of these acute responders are also positive long 
term responders to calcium channel blockers.  The role of vasoreactivity testing in non-
idiopathic PAH (e.g PAH due to connective tissue disease or HIV) is less clear, and it is 
not recommended in PH Groups 2-5.   
 
 
1.5.6  Complications associated with right heart catheterisation  
 
Right heart catheterisation (RHC) is one of the most commonly performed procedures in 
current medical practice, with over 1 million performed in the USA annually102.  The vast 
majority of RHCs are performed without incident, however complications may occur in 
association with central venous access, catheter insertion and catheter manipulation103.  
These include accidental arterial puncture, arteriovenous fistula, air embolism, 
pneumothorax, cardiac arrhythmias, thrombosis and infection.  Pulmonary artery rupture, 
which can occur following eccentric balloon inflation in small distal vessels, is associated 
with a 70% mortality rate but occurs in only 0.031% of procedures104.   
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The potential hazards of performing RHC in patients with pulmonary hypertension have 
been a long-standing concern105.  Early reports had described high rates of serious adverse 
events and fatal complications54, 106.  A recent large multi-centre study addressing this issue 
found a serious adverse event rate of 1.1%107.  The most frequent complications were 
related to venous access (e.g. haematoma, pneumothorax), followed by arrhythmias and 
hypotensive episodes related to vagal reactions or pulmonary vasoreactivity testing.  
Overall procedure related mortality was low at only 0.055% (four deaths in 7218 
procedures), however if RHC frequency could be reduced without reducing standard of 
care this would be an advantage for both patient safety and comfort. 
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1.6  Cardiac Magnetic Resonance Imaging 
 
Cardiac magnetic resonance (CMR) imaging is a well established technique in the 
diagnosis and management of a wide range of cardiovascular diseases.  Advances in CMR 
technology, with improved ECG gating and respiratory suppression, have facilitated rapid 
and robust data acquisition, so that now even very dyspnoeic patients can usually complete 
a CMR scan.  It provides 3-dimensional anatomical measurements of cardiac morphology 
that are unaffected by coexisting conditions e.g. obesity, lung disease, heart rate, posture or 
hydration status.  CMR imaging produces tomographic still images that accurately and 
reproducibly assess right and left ventricular chamber sizes, wall thickness and mass, and 
is used for both morphological and functional assessment.   
 
Steady state free-precession pulse (SSFP) sequences are used to construct a cine image, a 
movie of 15–20 frames, in which the full cardiac cycle can be observed.  The contrast 
between cavity blood and myocardium make planimetry of the interface accurate and 
easily reproducible for assessment of left and right ventricular function108.  Ventricular 
volumes and myocardial mass are typically obtained from a stack of contiguous ‘‘bright 
blood’’ cine CMR 5–10 mm slices covering the left and right ventricles acquired in short-
axis or transverse orientation.  Epicardial and endocardial contours are added during post-
processing on end-diastolic and end-systolic frames, and right and left ventricular volumes 
are calculated as the sum of individual slice volumes109.   Left (LVESV) and right 
ventricular end-systolic volumes (RVESV) are subtracted from the end-diastolic volumes, 
giving stroke volumes.  Ejection fraction represents stroke volume divided by end-diastolic 
volume.  Ventricular mass is the product of myocardial volume and muscle-specific 
density (1.05 g/cm3).  Analysis of cine data to produce ventricular volumes and masses was 
previously very time-consuming, however advances in computerized semi-automated 
myocardial/blood border definition has enabled analysis to become much faster.   
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1.6.1  Accuracy and Variability of Cardiac Magnetic Resonance Imaging 
 
CMR is an accurate, precise and reliable method for measuring cardiac volumes, mass and 
function, in healthy individuals and in a variety of disease states.   
 
In one of the earliest studies using CMR, ECG-gated MR images of the left ventricle were 
compared with X-ray contrast ventriculograms, with excellent correlation observed 
between the imaging modalities110.  In a later study of hypertensive patients, CMR 
estimates of LV mass were within 17.5g (95% confidence interval) of the true LV mass at 
autopsy, and had superior precision and reliability compared with echocardiography111.  
Subsequent work investigating LV dimensions and function have demonstrated that CMR 
has excellent interstudy reproducibility in normal, dilated, and hypertrophic hearts, 
superior to 2-dimensional echocardiography112. 
 
Grouthes et al demonstrated that whilst interstudy reproducibility values are lower for the 
complex-shaped right ventricle than for the left ventricle, CMR remains a reliable method 
for assessing the RV and is a suitable modality for serial RV assessment113.  In a 
repeatability study of 10 PAH patients, manual analysis measures were found to be more 
robust than semiautomated analysis, and repeatability improved if the interventricular 
septum was wholly apportioned to the LV114. 
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1.6.2  Cardiac Magnetic Resonance Assessment of Pulmonary Hypertension 
 
1.6.2.1  Ventricular volumes and function 
 
In patients with pulmonary hypertension right ventricular dilatation results in increased 
CMR RV end-diastolic and end-systolic volumes compared with healthy volunteers115.  
There is reduced RV ejection fraction, lower RV stroke volume and poorer cardiac output 
in PH patients compared with normal individuals116. 
 
CMR imaging has also demonstrated reduced LV end-diastolic volume, LV stroke volume 
and LV peak filling rate in patients with pulmonary hypertension compared with healthy 
controls42, 116.  A low LVEDV is felt to be the result of impaired LV filling, which can be 
due to the combination an elevated PVR limiting RV stroke volume and left ventricular 
septal bowing reducing LV volume in early diastole117, 118.  Gan et al demonstrated that 
leftward interventricular septum curvature correlated with left ventricular filling rate and 
left ventricular end-diastolic volume, concluding that ventricular interaction mediated by 
the interventricular septum impairs left ventricular filling, contributing to decreased stroke 
volume42.  
 
In their study of 64 patients with IPAH assessed with CMR at diagnosis and after 1-year 
follow-up, Van Wolferen et al found that a low stroke volume (≤ 25 ml/m2), high RV end-
diastolic volume (≥ 84 ml/m2) and low LV end-diastolic volume (≤ 40 ml/m2) were strong 
independent predictors of mortality and treatment failure118.  A subsequent CMR study 
from the same group has shown that the minimal important difference (MID) of stroke 
volume after PAH therapy was 10ml, i.e. changes of ≥ 10ml should be considered 
clinically relevant119.   
 
 
1.6.2.2  Ventricular Mass 
 
In pulmonary hypertension, increased afterload results in right ventricular hypertrophy, 
with increased RV mass observed at CMR when compared with healthy controls120, 121.  
There was no difference in LV mass between normal individuals and patients with 
IPAH120, 122.  Saba et al demonstrated that a ventricular mass index ((VMI), the ratio of 
right ventricular mass over left ventricular mass) of >0.6 , had a sensitivity of 84% and 
49 
specificity of 71% for detecting pulmonary hypertension of various aetiologies122.  There 
was a strong correlation between VMI and mPAP (r = 0.81), with VMI having superior 
correlation to mPAP than right ventricular mass alone.  In patients with systemic sclerosis 
undergoing diagnostic assessment, VMI correlated strongly with mPAP, and had 
prognostic value, with two-year survival in patients with VMI <0.7 and ≥ 0.7 of 91% and 
43%, respectively123.  However, in the Van Wolferen study of patients with IPAH, RV 
hypertrophy (as measured by RV mass index) did not appear to be as strongly related to 
mortality as RV dilatation118.   
 
 
1.6.2.3  Interventricular Septal Configuration 
 
It is recognized that abnormal interventricular septal position and motion can occur in the 
setting of right ventricular pressure overload.  In children with a range of congenital heart 
defects, echocardiography has demonstrated a leftward shift and flattening of the 
interventricular septum during systolic contraction, with marked exaggeration of this 
change occurring when RV systolic pressures were >50% of systemic pressure124.  Severe 
left ventricular septal bowing is often considered to be associated with an unfavourable 
prognosis in pulmonary hypertension, and has been associated with an adverse response to 
CCB trial in IPAH125.  Normalisation of septal abnormalities has been observed at 
echocardiography following bilateral lung transplantation for advanced IPAH126, and at 
CMR after pulmonary endartarectomy for CTEPH127.  Using CMR and ventricular 
pressure measurements, Roeleveld et al found that maximal distortion of the normal septal 
shape occurred during right ventricular relaxation, occurring when pressure within the RV 
exceeded that within the LV128.  The degree of septal curvature was proportional to systolic 
PAP, with leftward septal bowing likely to occur when sPAP exceeded 67mmHg.  By 
measuring both RV longitudinal shortening (apex-base distance change) and transverse 
shortening (septum-free wall distance change), it has been observed that declining RV 
function in advanced PAH is likely due to progressive leftward septal displacement with a 
decrease in transverse shortening129.  Contrast-enhanced CMR has also demonstrated 
delayed contrast enhancement, a well-established marker of myocardial abnormalities, 
present within the interventricular septum of PH patients with abnormal septal motion130. 
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1.6.3.  Estimation of pulmonary haemodynamics by cardiac magnetic   
  resonance 
 
There has been sustained interest in using non-invasive CMR as a method for estimating 
pulmonary haemodynamics in a variety of settings, including screening for PH, diagnosis, 
monitoring response to therapy and assessment of clinical deterioration131.   In a group of 
44 patients with PH, five different MRI-based estimators of PAP were compared with 
invasive pressure measurements, with VMI found to show the best correlation with mean 
PAP (r = 0.56, p < 0.001) but not accurate enough to replace right heart catheterisation in 
clinical practice 132.  A computed method that combines a number CMR variables 
(including main pulmonary artery blood flow velocity at peak systole, maximal systolic 
main pulmonary artery cross sectional area) with biophysical parameters (height, weight 
and heart rate) has been proposed to improve the accuracy of CMR to noninvasively 
estimate pulmonary artery pressures133, although there are concerns regarding the 
underlying mathematical methodology134.  A different mathematical model combining 
CMR-derived RV ejection fraction and pulmonary artery average velocity has been used as 
a non-invasive method for estimating PVR, with good correlation observed between 
invasively quantified and CMR-estimated PVR (r = 0.84, p <0.001)135.  In their cohort of 
unselected treatment-naïve patients with suspected PH, Swift et al combined CMR-derived 
mPAP (mPAP = -4.6 + (interventricular septal angle x 0.23) + (ventricular mass index x 
163), with CMR-predicted PAWP from left atrial volumetry and CMR phase-contrast 
cardiac output, to non-invasively calculate PVR136.  Noninvasive CMR- and RHC-derived 
PVR correlated well (r2 = 0.76), with CMR-estimated PVR identifying invasive PVR ≥3 
Wood units (WU) with a high degree of accuracy (area under curve 0.94, p < 0.0001).  
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1.7  Treatment of Pulmonary Arterial Hypertension 
 
1.7.1  General Measures and Supportive Therapy 
 
The following general measures are commonly used in the treatment of pulmonary arterial 
hypertension: 
 
• Exercise – A small study in patients with severe but stable symptomatic pulmonary 
hypertension has demonstrated that exercise and respiratory training could improve 
6MWD and CPET performance, quality of life and NYHA functional class137.  
There are a number of ongoing trials investigating the use of exercise training in 
patients with PAH138, and current guidelines recommend that supervised exercise 
training should be considered in physically deconditioned PAH patients139. 
 
• Oxygen - Acute oxygen therapy can improve pulmonary haemodynamics in 
hypoxic and normoxic patients140.  Patients with resting arterial PaO2 < 8kPa may 
be prescribed oxygen for at least 15 hrs per day.  In-flight oxygen is recommended 
for pulmonary hypertension patients in functional class III and IV141, although the 
utility of hypoxic challenge testing in precapillary pulmonary hypertension remains 
unclear142. 
 
• Anticoagulation - PAH is associated with abnormalities in coagulation and 
fibrinolytic pathways, and impaired platelet function.  Anticoagulation may prevent 
vascular thrombotic lesions and pulmonary embolism106, 143.  Oral anticoagulant 
treatment should be considered in patients with IPAH, heritable PAH, and PAH due 
to use of anorexigens, and may be considered in associated PAH. 
 
• Diuretics - In PAH there is excessive afterload, resulting in right ventricular 
dilatation and right heart failure.  Diuretic therapy, often at high dosages, may 
benefit patients with significant fluid overload. 
 
• Arrhythmia Management - Tachyarrhythmias are poorly tolerated, and often 
manifest with worsening dyspnoea, syncope or right heart failure56, 144.  Digoxin 
has been shown to improve cardiac output acutely in IPAH and may be given to 
slow ventricular rate in patients who develop atrial tachyarrhythmias.   
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• Pregnancy – Despite recent therapeutic advances, pregnancies in patients with 
PAH are associated with serious complications and high mortality rates.  
Consequently, all current guidelines strongly discourage pregnancy and 
recommend an effective method of contraception in women of childbearing age.2 
 
 
1.7.2  Disease-Targeted Therapies for Pulmonary Arterial     
  Hypertension 
 
Acute vasoreactivity testing performed during right heart catheterisation is used to identify 
patients who may benefit from long term therapy with calcium channel blockers (CCB).  
Patients with a positive vasodilator response at RHC (approximately 10% of patients with 
idiopathic PAH) can be commenced on nifedipine (if there is a relative bradycardia) or 
diltiazem (if there is a relative tachycardia).  Relatively high daily CCB dosages are used in 
this setting, 120–240 mg for nifedipine and 240–720 mg for diltiazem.  Only half of the 
positive acute responders are also positive long term responders to calcium channel 
blockers101.  If there is an inadequate clinical response to, or poor tolerance of, CCB 
therapy then additional PAH therapy should be instituted.   
 
Until the 1990s, therapeutic options for pulmonary arterial hypertension were limited to 
supportive measures (oxygen, diuretics, anticoagulation) and lung transplantation.  
However, in the last two decades there have been a number of different classes of disease-
targeted therapies developed to treat PAH, targeting different pathways.  Prostacyclin and 
its analogues target the prostacyclin pathway, endothelin receptor antagonists target the 
endothelin-1 pathway, and phosphodiesterase-5 inhibitors and soluble guanylate cyclase 
activators target the nitric oxide pathway.       
 
In the United Kingdom and Ireland, there are currently nine approved PAH targeted drugs 
with different routes of administration (Table 1.4), although the approval of additional 
drugs is expected in the near future. 
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Table 1.4 Approved PAH therapies in United Kingdom in 2015 
 
Treatment Route of administration 
Epoprostenol Intravenous 
Iloprost Inhaled / Intravenous 
Treprostinil Subcutaneous 
Bosentan Oral 
Ambrisentan Oral 
Macitentan Oral 
Sildenafil Oral 
Tadalafil Oral 
Riociguat Oral 
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1.7.2.1  Prostanoids 
 
Prostacyclin is an arachidonic acid derivative, produced predominantly by endothelial cells 
and acting via the cyclic adenosine monophosphate pathway, which induces potent 
vasodilatation of the pulmonary vascular beds as well as having antithrombotic and 
antiproliferative effects145.  Patients with PAH have been shown to have abnormalities in 
prostacyclin metabolic pathways, with reduced prostacyclin synthase expression in the 
pulmonary arteries146.   
 
Epoprostenol is a synthetic prostacyclin available as a stable freeze-dried preparation for 
intravenous infusion.  It must be dissolved in an alkaline buffer, has a very short half-life 
(3–5 min) and is stable at room temperature for only 8 h.  Therefore, it needs to be 
administered continuously by means of an infusion pump via a tunnelled, cuffed central 
venous catheter.  Treatment with epoprostenol is initiated at a dose of 2–4 ng/kg/min, with 
the dose increasing at a rate limited by side effects (flushing, headache, diarrhoea, jaw 
ache, hypotension). The optimal dose varies between individual patients, usually ranging 
between 20 and 40 ng/kg/min53, 147.  Serious adverse events related to the epoprostenol 
therapy include pump malfunction, local site infection, catheter obstruction, and sepsis.  
Abrupt interruption of the infusion should be avoided as it can lead to a rebound PH with 
symptomatic deterioration and death. 
 
More stable prostacylin analogues such as treprostinil and iloprost with similar 
pharmacodynamic effects are now available for the treatment of PAH.  Treprostinil is a 
tricyclic benzidene analogue of prostacyclin, which is chemically stable and has a longer 
half-life than Epoprostenol.   In the UK it is administered via a continuous subcutaneous 
infusion (although has been used in intravenous, inhaled and oral forms in the USA & 
Canada).  The most common adverse effect of subcutaneous treprostinil is pain at the 
infusion site, leading to discontinuation of therapy or dose limitation dose148.  Treatment 
with subcutaneous treprostinil is initiated at a dose of 1–2 ng/kg/min, with doses increasing 
at a rate limited by side effects (site pain, flushing, headache) to an optimal dose usually 
between 20 and 80 ng/kg/min.  Iloprost is a stable, synthetic analogue of prostacyclin that 
can be administered by the aerosolised route, so is theoretically selective for the pulmonary 
circulation.  Inhaled Iloprost is administered by daily repetitive inhalations (6–9 times per 
day, 2.5 – 5 mg per inhalation) and is usually well tolerated, with flushing and jaw pain 
being the most frequent side effects. 
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1.7.2.2  Endothelin Receptor Antagonists 
 
The endothelin system plays a prominent role in the pathogenesis of PAH, with activation 
of the endothelin system demonstrated in both the plasma and lung tissue of PAH 
patients149, 150.  Endothelin-1 is a potent vasoconstrictor that binds to two distinct receptor 
isoforms in the pulmonary vascular smooth muscle cells, endothelin-A and endothelin-B 
receptors, to regulate cell proliferation and vascular tone.  The activation of endothelin-B 
receptors, present in endothelial cells, leads to the release of nitric oxide and prostacyclin 
that may counterbalance the deleterious effects of endothelin-1.   
 
Bosentan is an oral active dual endothelin-A and endothelin-B receptor antagonist and was 
the first orally active agent to be granted regulatory approval in the treatment of PAH151.  It 
is started at a dose of 62.5 mg twice daily, and is uptitrated to 125 mg twice daily after 4 
weeks.   Liver function tests should be performed monthly in patients receiving Bosentan 
as up to 10% of patients experience elevated hepatic transaminases, however these are 
usually reversible after dose reduction or discontinuation2.   
 
Ambrisentan is a selective endothelin-A receptor antagonist that has been approved for 
patients in WHO class II and III.  It is commenced at 5mg once daily, increasing to 10mg 
once daily if the initial dosage is well tolerated.  Ambrisentan is associated with a lower 
incidence of abnormal liver function tests than Bosentan, and has been used safely in a 
small group of patients who had previously discontinued Bosentan (or Sitaxentan) for this 
reason152.  Monthly liver function testing is still required.  An increased incidence of 
peripheral oedema has been noted with Ambrisentan. 
 
Macitentan is a dual endothelin A/B receptor anatagonist, chemically related to Bosentan, 
which has been recently received approval for use in WHO class II and III PAH in the UK.  
It has been shown to improve morbidity and mortality in a 24-month event-driven study of 
patients with PAH153.    
 
Sitaxentan, an oral endothelin-A receptor antagonist, was withdrawn from use in 2010 due 
to an association with fatal acute hepatic failure154.  
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1.7.2.3  Phosphodiesterase type-5 Inhibitors and Soluble Guanylate Cyclase  
  Activators 
 
The pulmonary vasculature contains substantial amounts of phosphodiesterase type-5 
(PDE-5), a cyclic guanosine monophosphate (cGMP) degrading enzyme.  Endothelium 
dependent vasodilation is mediated by nitric oxide synthase in the pulmonary circulation, 
with endothelium derived nitric oxide (NO) diffusing into pulmonary smooth muscle cells, 
where it stimulates soluble guanylate cyclase to produce cGMP.   Cyclic GMP promotes 
vascular smooth muscle relaxation via protein kinase G.  PDE-5 inhibitors have been 
shown to augment nitric oxide-mediated vasodilatation, and also exert antiproliferative 
effects155-157. 
 
Sildenafil is an orally active, potent and commonly used PDE-5 inhibitor that is effective 
in idiopathic PAH and PH associated with a range of conditions158-160.  It is usually 
commenced at a dose of 20mg tid, but up-titration to 50-80mg tid is frequently performed.  
The most common side effects are headaches, flushing and epistaxis, although it can rarely 
be associated with sensorineural hearing loss161.   
 
Tadalafil is a less commonly used once daily PDE-5 inhibitor, with a similar side-effect 
profile to Sildenafil.   
 
Riociguat is the first in a new class of agents known as soluble guanylate cyclase (sGC) 
activators.  It has a dual mode of action, increasing the sensitivity of soluble guanylate 
cyclase to nitric oxide, and directly stimulating soluble guanylate cyclase independently of 
nitric oxide162.  Riociguat has been shown to improve exercise capacity in PAH, and to 
improve exercise capacity and pulmonary vascular resistance in inoperable or persistent 
(post-endarterectomy) CTEPH163, 164.    
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1.7.2.4  Disease-targeted Therapy in Connective-Tissue Disease Associated  
  Pulmonary Arterial Hypertension 
 
Despite similar baseline clinical and haemodynamic characteristics, outcomes in CTD-
PAH are worse than in IPAH165.  PAH therapies have been widely studied in patients with 
connective tissue disease, although often as a subgroup analysis of clinical trials containing 
patients with PAH of all causes.  Nifedipine was found to produce an acute and sustained 
reduction in pulmonary vascular resistance in a small group of patients with CTD-PAH166.  
In a large study of 111 patients with scleroderma and moderate-to-severe pulmonary 
hypertension, twelve weeks of intravenous Epoprostenol was found to improve exercise 
capacity (placebo-corrected increase in 6MWD of +108m), haemodynamics and functional 
class, although there was no difference in survival167.  Similar symptomatic and 
haemodyanamic improvements were observed with subcutaneous Treprostinil therapy, 
although improvements in 6MWD were more modest (placebo-corrected increase of 
+25m)168.  Patients with SSc-PAH treated with bosentan monotherapy were less likely to 
improve NYHA functional class, and had higher mortality rates than a similar group of 
bosentan-treated IPAH patients169.   In a post-hoc analysis of the SUPER-1 study, 
Sildenafil at a dose of 20mg tid was found to improve exercise capacity, functional class 
and pulmonary vascular resistance in 84 patients with CTD-PAH170.  The magnitude of 
treatment effects in CTD-PAH is often smaller than in IPAH, and this may be due to the 
difficulties associated with performing 6MWT in the CTD group.  Patients with CTD may 
have coexisting interstitial lung disease, left heart disease or musculoskeletal problems, 
which could all limit any potential improvement in 6MWD.   
 
The overall effect of PAH therapy in CTD-PAH has therefore been assessed by meta-
analysis.  In a review of 10 randomized controlled trials, containing patients with CTD-
PAH treated with bosentan, sitaxentan or sildenafil, there was an absence of clinically 
relevant improvement on exercise capacity (as measured by 6MWD) in patients with 
CTD/SSc after 12 to 18 weeks of treatment171.  When examining the impact of modern 
PAH therapy (oral therapies) on IPAH and SSc-PAH, Rubenfire et al found that survival 
rates in their centre of patients with SSc-PAH presenting in the “modern era” did not differ 
from pre-2002, when the sole PH-specific treatment was Epoprostenol.  Patients with SSc-
PAH had a lower probability of treatment with a prostacyclin, and were less likely to be 
taking warfarin, when compared with IPAH patients172.   This finding was in keeping with 
data from the large US-based REVEAL cohort, where patients with CTD-PAH were less 
likely to be on prostacyclin (36.3% vs 46.9%, p < 0.0001) and combination PAH therapy 
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(39.5% vs 45.0%, p = 0.03) than those with IPAH173.  Despite these findings it is still 
generally felt that, in contrast to patients treated historically with basic drugs and 
prostanoids, patients treated in the present day had improved survival associated with a 
lack of deterioration in cardiac haemodynamic function174, 175.  This is supported by data 
from the 2015 UK National Pulmonary Hypertension Audit which demonstrated similar 
survival rates in IPAH and CTD-PAH in the current treatment era 
(http://www.hscic.gov.uk/ph).    
 
The use of immunosuppressant therapy is more common in CTD-PAH than in IPAH, with 
highest rates of use in SLE, MCTD and RA rather than in systemic sclerosis173.  
Combination therapy with glucocorticosteroids and cyclophosphamide may result in 
clinical improvement in patients with PAH associated with SLE or MCTD176.  In patients 
with advanced PAH (i.e. PVR ≥10, already on ≥ 2 PAH therapies), the tyrosine kinase 
inhibitor Imatinib was found to improve exercise capacity and pulmonary haemodynamics, 
but resulted in serious adverse events and drug discontinuations177.  
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1.7.2.5  Use of Pulmonary Arterial Hypertension Therapies in Left Heart   
  Disease 
 
The use of PAH-specific therapies in PH due to left heart disease has not been as 
successful as their use in IPAH.   There are no long-term studies examining the use of 
prostanoids solely in PH-HFpEF, however in the Flolan International Randomized Trial 
(FIRST), long-term intravenous prostacyclin was associated with increased mortality in 
patients with advanced left ventricular failure with or without PH, despite improvements in 
cardiac output and PAWP178.  
 
Long-term use of the endothelin-receptor antagonist Bosentan in patients with PH-HFpEF 
was not associated with improvements in pulmonary haemodynamics, but was associated 
with an increased rate of serious adverse events179.  Some small studies have suggested that 
the phosphodiesterase-5 inhibitor Sildenafil may potentially improve pulmonary 
haemodynamics in patients with heart failure and elevated PAP, without detrimental 
systemic haemodynamic consequences180.   However, in the RELAX study of 216 patients 
with HFpEF (and median PASP of 41mmHg), twenty-four weeks of Sildenafil therapy did 
not cause a significant improvement in exercise capacity or clinical status181. 
 
In a Phase IIb study, the soluble guanylate cyclase activator Riociguat was well tolerated in 
patients with PH caused by left ventricular systolic dysfunction and improved cardiac 
index and pulmonary and systemic vascular resistance, although did not significantly alter 
6MWD182.  In patients with PH-HFpEF, a single acute dose of Riociguat was well 
tolerated, had no significant effect on mPAP, and improved exploratory haemodynamic 
and echocardiographic parameters183.   
 
PAH-specific therapies are expensive (e.g. endothelin receptor antagonist therapy is 
approximately £20,000 per patient per annum), and potentially dangerous, so current 
guidelines do not recommend their use in PH-HFpEF. 
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1.8  Changing Demographics in Pulmonary Arterial Hypertension 
 
There is growing recognition that the demographics of pulmonary arterial hypertension 
have changed from the traditional phenotype of the “young female” observed in early 
registries of primary pulmonary hypertension in the 1980s and 1990s.  In the initial NIH 
(National Institutes of Health) registry published in 1987, the mean age of patients was 36 
yrs, with a female-to-male ratio of 1.7:154.   
 
In the French registry, 674 cases of PAH presenting at seventeen university pulmonary 
vascular centres between October 2002 and October 2003 were prospectively enrolled and 
followed up for three years81.  The mean age of the whole PAH population was 50yrs 
(idiopathic PAH = 52 yrs), with a quarter of cases occurring over the age of 60, and some 
patients diagnosed in their 80s. In the USA-based REVEAL registry, the mean age of 
idiopathic PAH at diagnosis was 50 years, approximately 5% of the patients were 
diagnosed at ≥75 years of age, and many patients had significant comorbidities including 
systemic hypertension (42%), obesity (38%), sleep apnoea (27%), obstructive airway 
disease (23%), thyroid disease (20%), diabetes (14%) and ischaemic cardiovascular event 
(10%)184.  
 
The Pulmonary Hypertension Registry of the United Kingdom and Ireland was the first 
major national study of incident, treatment-naive patients with IPAH, and consisted of 482 
newly diagnosed IPAH patients from 2001 to 2009185.  The median age of the group was 
50 years (IQR, 36–65) and 13.5% (n = 65) of patients were older than 70 years of age at 
the time of diagnosis.  Patients diagnosed at > 50yrs of age had a higher incidence of 
ischaemic heart disease (24% v 1%), systemic hypertension (42% v 11%), atrial fibrillation 
(11% v 0%), diabetes (23% v 5%) and hypothyroidism (16% v 8%) than those diagnosed 
at ≤ 50yrs.  In a comparison of baseline characteristics according to year of diagnosis, 
patients were stratified into three cohorts based on the date of diagnostic RHC (2001-2003, 
2004-2006, and 2007-2009)185.  Patients diagnosed in the latest cohort (2007-2009) were 
older (52 v 45 yrs), had higher BMI (29.8 v 28.1) and more comorbidities than those 
diagnosed in the earliest cohort (2001-2003). 
 
These registry findings demonstrate that IPAH is being increasingly diagnosed in older 
patients, who often have coexisting cardiovascular disease or other comorbities.  Using 
data from the multi-centre COMPERA (Comparative, Prospective Registry of Newly 
Initiated Therapies for Pulmonary Hypertension) registry, Hoeper et al compared 
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demographics, clinical characteristics, haemodynamics, treatment patterns and outcomes of 
younger (18–65 years) and elderly (>65 years) patients with newly diagnosed IPAH186.  
The median (IQR) age at diagnosis for the whole patient population was 71 (16) years, 
with a mean age of 65 years. Younger patients (n=209; median age, 54 [16] years) showed 
a female-to-male ratio of 2.3:1 whereas the gender ratio in elderly patients (n=378; median 
age, 75 [8] years) was only 1.2:1.  At baseline RHC, there was no difference in right atrial 
pressure or cardiac index between the groups, however PAWP was higher (10 v 9 mmHg, 
p <0.001) and mPAP (41 v 50 mmHg, p < 0.001) and PVR (8.3 v 12.0 Wood units) were 
lower in the older patient population.   Compared with younger patients, elderly patients 
were less likely to receive combination PAH therapy, less likely to reach current treatment 
targets, and had lower survival rates.   
 
Whilst it is clear that IPAH is now being diagnosed more frequently in older people, it 
remains a rare condition, and pulmonary hypertension in this age group is usually the result 
of underlying left heart or lung disease.  Pulmonary artery systolic pressure measured by 
echocardiography increases with age, with increasing PASP associated with higher 
mortality in patients with and without cardiopulmonary disease187.   
 
Pugh et al investigated the underlying cause of pulmonary hypertension in 246 elderly 
(>65yr) patients who had been referred for diagnostic assessment between 1995 and 2011, 
of which 202 had PH188.  PAH (WHO group 1) was diagnosed in 36 patients (15%), of 
which only 4 patients had idiopathic PAH.  PH owing to left -sided heart disease (WHO 
group 2) was the most common type of PH in the cohort (70 patients, 28%), most of these 
patients had no significant valvular heart disease and a left ventricular ejection fraction of 
greater than 50%, and therefore diagnosed as PH-HFpEF.   Comorbid conditions were 
common throughout the study population, with cardiovascular and metabolic diseases seen 
most commonly in patients with WHO group 2 PH.  It is worth noting that the “WHO 
group 2 PH” cohort in this study contained patients with an initial normal PAWP, but who 
had an increase in PAWP > 7 mmHg to > 15 mmHg after IV fluid challenge.  By contrast, 
patients with evidence for Group 2 disease with PH that was believed to be “out of 
proportion” (i.e. transpulmonary gradient ≥ 15 mm Hg) were classified as “other/mixed 
PH”.   
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1.9  Left Ventricular Diastolic Dysfunction and Heart Failure with   
  Preserved Ejection Fraction 
 
Left ventricular diastolic dysfunction is common within the general population, with 
community-based echocardiography studies reporting that in patients aged over 45yrs 
20.8% had mild diastolic dysfunction, 6.6% had moderate diastolic dysfunction and 0.7% 
had severe diastolic dysfunction189.  The prevalence of diastolic dysfunction increased with 
age, was equally common in men and women, and was more common in patients with 
known cardiovascular disease (including LV systolic dysfunction) or diabetes.  LV systolic 
dysfunction was less common than diastolic dysfunction, with only 6.0% having an LV 
ejection fraction of ≤ 50% and 2.0% ≤ 40%, and 5.6% of the study population had 
moderate or severe diastolic dysfunction with a normal ejection fraction.  Diastolic 
dysfunction was predictive of all-cause mortality even after controlling for age, sex and LV 
ejection fraction.   
 
Heart failure with preserved ejection fraction (HFpEF) describes the entity of clinical heart 
failure in the setting of a left ventricular ejection fraction of more than 50 percent, and is 
felt to be primarily the result of left ventricular diastolic dysfunction190, 191.  HFpEF is 
currently observed in approximately 50% of heart failure patients, with a prevalence rising 
by 1% per year compared with heart failure due to reduced ejection fraction (HFrEF)192, 193.   
Patients with HFpEF are more likely to be older and female and to have a history of 
hypertension and atrial fibrillation than those with HFrEF194. Outcomes in HFpEF are 
similar to that seen in HFrEF (1year mortality: HFpEF 22% v HFrEF 26 %), even after 
adjusting for age, sex and comorbidites.   
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1.9.1  Pulmonary Hypertension in Heart Failure with Preserved Ejection   
  Fraction 
 
Pulmonary hypertension is frequently associated with left heart disease, with increased 
left-sided filling pressure causing a ‘passive’ increase in pulmonary artery pressure (PAP), 
which can eventually lead to pulmonary vasoconstriction and remodelling of the small-
resistance pulmonary arteries195.  The most recent World Health Organization 
classification identified four different categories: PH secondary to left ventricular systolic 
dysfunction, PH resulting from left ventricular diastolic dysfunction, PH due to left-sided 
valvular disease, and PH associated with congenital/acquired left heart inflow/outflow 
obstruction and congenital cardiomyopathies5.  The most common type of left heart disease 
that causes PH is HFpEF (PH-HFpEF).   
 
PH-HFpEF is usually defined as mean PAP > 25 mm Hg in the presence of pulmonary 
artery wedge pressure (PAWP) > 15 mm Hg, signs and symptoms of heart failure, left 
ventricular ejection fraction > 50%, and absence of significant left-sided valvular heart 
disease196.  It has been proposed that PH due to left heart disease, including PH-HFpEF, 
can be further categorized depending on the presence or absence of a “precapillary” or 
intrinsic pulmonary vascular component.  In isolated post-capillary PH-HFpEF the 
transpulmonary gradient (TPG) and PVR are usually within normal limits (TPG < 12 - 15 
mmHg and PVR < 2.5 - 3 Wood units).  In combined post- and precapillary PH or “mixed 
PH” the superimposed precapillary component increases the PAP disproportionate to the 
left-sided filling pressure, resulting in an increased TPG or PVR (TPG ≥ 12 - 15 mm Hg 
and PVR ≥ 2.5 - 3 Wood units)197.  However, there are concerns that TPG and PVR do not 
truly represent intrinsic pulmonary arteriolar remodelling, and that the diastolic pulmonary 
gradient (DPG: diastolic PAP - PAWP) should be used instead198.  A new proposed 
categorisation based on DPG would therefore be: isolated postcapillary (mean PAP > 25 
mm Hg, PAWP > 15mm Hg, and DPG < 7 mm Hg) and combined postcapillary and 
precapillary PH (mean PAP > 25 mm Hg, PAWP > 15 mm Hg, and DPG ≥ 7 mmHg)199. 
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1.9.2  Prevalence of Pulmonary Hypertension in Heart Failure with Preserved  
  Ejection Fraction 
 
The prevalence of pulmonary hypertension among the overall HFpEF population varies 
depending on the haemodynamic threshold used to define PH, the diagnostic modality 
(echocardiography or RHC) used, and the patient group studied.  In a retrospective analysis 
of patients hospitalized with HFpEF between 1999 and 2001, “moderate” pulmonary 
hypertension at echocardiography (mean RVSP of 47 ± 17 mm Hg) was observed in 272 of 
the 619 patients200.  In their retrospective review of cardiac catheterisation data from 455 
patients with HFpEF from 1996 to 2007, Leung et al found that 239 patients (52.5%) had 
PH as defined by an mPAP of >25mmHg201.  In a study investigating baseline 
haemodynamics and response to vasodilator therapy in HFpEF and HFrEF, both groups 
had elevated mPAP (41 vs 40 mm Hg, p = 0.50) and PASP was higher in HFpEF than 
HFrEF (64 vs 59 mm Hg, p = 0.02)202.   
 
In a community-based study, Lam et al found that 83% of patients with HFpEF had 
pulmonary hypertension compared with only 8% of a control group of hypertensive 
individuals without heart failure, and that the PASP strongly predicted mortality in 
HFpEF203.  However, in this study the cutoff to define PH was low (a PASP of >35mmHg 
at echocardiography), especially given that normal PASP increases with age204.  Even after 
adjusting for PAWP, PASP was still higher in the HFpEF group than in the hypertensive 
controls, suggesting that a pre-capillary component was contributing to greater PH in 
HFpEF.  In 548 subjects with HFpEF and a variable degree of PH and RV dysfunction, 
followed for up to ten years, a worse prognosis was observed for patients with PASP above 
the median (>47 mm Hg) and RV systolic dysfunction205.  RV systolic dysfunction was a 
significant predictor of mortality even after adjustment for age and PASP.   
 
In a clinical trial setting,  only 36% of patients with HFpEF (left ventricular ejection 
fraction ≥45%) enrolled in the Treatment of Preserved Cardiac Function Heart Failure with 
an Aldosterone Antagonist (TOPCAT) study had a baseline tricuspid regurgitant jet 
velocity > 2.9 m/s (equivalent to a PASP > 35mmHg) at echocardiography206.  TR jet 
velocity was significantly related to the E/E′ ratio, and an elevated TR velocity in the 
absence of elevated E/E′ was uncommon, occurring on only 5% of participants.  After a 
median follow-up of 2.9 years, a higher pulmonary artery pressure was predictive of the 
composite outcome heart failure hospitalization, cardiovascular death, or aborted cardiac 
arrest207.  In the RELAX trial, investigating the effect of Sildenafil in 216 stable outpatients 
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with HFpEF (ejection fraction ≥ 50%), the median PASP for the entire study population at 
baseline was 41mmHg181.   
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1.9.3  Pathophysiology and Pathogenesis of Pulmonary Hypertension in   
  Heart Failure with Preserved Ejection Fraction 
 
HFpEF is a heterogeneous syndrome, with a range of phenotypes and pathophysiologies, 
which result in increased left ventricular filling pressures and the clinical picture of heart 
failure208.  In HFpEF there is normal systolic LV function but impaired diastolic LV 
function, consisting of prolonged relaxation, slow filling and increased diastolic 
stiffness191, 209.  Invasive studies have demonstrated abnormalities in active relaxation and 
passive stiffness of the LV in patients with HFpEF210.   
 
LV diastolic dysfunction usually results from increased myocardial stiffness, either within 
the extracellular matrix or the cardiomyocytes.  Stiffness of the extracellular matrix can be 
the result of a number of collagen abnormalities, including excessive synthesis and 
impaired degradation of collagen type 1211, and decreased matrix degradation due to 
downregulation of matrix metalloproteinases (MMPs) and upregulation of tissue inhibitors 
of matrix metalloproteinases (TIMPs)212.   Intrinsic cardiomyocyte stiffness also 
contributes to diastolic LV dysfunction in HFpEF213, 214.  Abnormal slowing of LV 
relaxation, which can result in a reduction in LV stroke volume particularly at high heart 
rates, is also prominent in HFpEF and may be associated with a myocardial energy 
deficit215.  It is also recognised that there are other contributors to disease pathophysiology 
in HFpEF, including potential LV myocardial contractile dysfunction216, impaired 
ventricular–vascular coupling217, 218, chronotropic incompetence219 and abnormal exercise-
induced and flow mediated vasodilation191.   
 
Increased LV filling pressures, irrespective of LV systolic function, lead to pulmonary 
venous hypertension and postcapillary PH220.  The histological changes that are observed 
in postcapillary PH include enlarged and thickened pulmonary veins, pulmonary capillary 
dilatation, interstitial oedema, alveolar haemorrhage, and lymphatic vessel and lymph node 
enlargement221.  Additional abnormalities of the pulmonary vasculature observed in 
“mixed / pre-capillary and post-capillary” PH-HFpEF include thickening of the alveolar-
capillary membrane and remodelling of the small pulmonary arteries, with luminal 
occulusion, medial hypertrophy, and intimal and adventitial fibrosis195.  The 
angioproliferative plexiform lesions typical of PAH are rare in PH-HFpEF.  In pathological 
specimens from patients with PH due to left heart disease, Gerges et al demonstrated a 
direct correlation between TPG / DPG and the degree of smooth muscle proliferation in 
resistance pulmonary arteries, and that patients with combined mixed PH-HFpEF with a 
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DPG > 7 mmHg had an increased proportion of small pulmonary arteries with medial 
hypertrophy, intimal fibrosis, adventitial fibrosis, and luminal occlusion compared with 
those with a DPG of < 7 mmHg222. 
 
Most patients with HFpEF who develop PH will have isolated postcapillary PH, with only 
a small minority developing combined precapillary and postcapillary PH.  Proposed risk 
factors for developing the “precapillary” pulmonary arterial vasoconstriction and 
remodelling include increasing age203 and female gender223, 224, whilst atrial arrhythmias, 
obesity and chronic obstructive pulmonary disease are associated with an overall increased 
risk for developing PH in HFpEF201.   
 
As pulmonary artery pressure increases in HFpEF there is a progressive increase in RV 
afterload, which can eventually result in RV failure.  Right ventricular dysfunction is less 
common in HFpEF than in HFrEF225, however estimates of prevalence vary widely (from 
as low as 4% 206 to as high as 33% 226 of patients with HFpEF).  Increased pulmonary 
artery pressure and RV dysfunction are associated with increased mortality in HFpEF.  
Kjaergaard et al demonstrated that patients with HFpEF and a PASP at echocardiography 
of > 39 mmHg had an increased mortality compared with those with PASP of < 39 
mmHg227.  In HFpEF, RV dysfunction is associated with an additional increased risk of 
adverse outcomes beyond the risk conferred by PH alone, with an RV Fractional Area 
Change of < 35% equating to a 2.4-fold increase in mortality compared with patients 
without RV dysfunction, independent of systolic PAP226.  Similarly, increasing RV 
hypertrophy is also associated with higher mortality in HFpEF228.     
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1.10  Hypotheses and Aims of Thesis 
 
The overall aim of this thesis was to determine if cardiac magnetic resonance imaging 
could be used to help address three important contemporary issues in the diagnosis and 
determination of outcome in pulmonary hypertension.   
 
These are: 
  
(1)  Is there a non-invasive way to distinguish idiopathic pulmonary arterial hypertension 
(rare) from pulmonary hypertension due to heart failure with preserved ejection fraction 
(common)? 
 
(2) Do disease-targeted PAH therapies improve right ventricular function? 
 
(3) Does impaired cardiac function explain why survival is worse in connective-tissue 
disease associated PAH than in idiopathic PAH? 
 
 
To answer these questions, three separate, but related studies were performed; see Chapters 
3, 4 and 5.  The hypothesis of each study is explained below. 
 
Chapter 3.  ‘Left atrial volume by CMR distinguishes IPAH from PH-HFpEF’.  HFpEF 
due to left ventricular diastolic dysfunction is common within the general population, and 
is often associated with PH192, 193, 203.  Meanwhile, the average age at diagnosis of IPAH 
has increased over recent decades, with registry data now suggesting a mean age of 50 
years81, 185.  Distinguishing between IPAH and PH-HFpEF can therefore be difficult on 
clinical grounds57, and invasive RHC is currently performed by PH centres to achieve this2.  
Left atrial enlargement, a marker of LV diastolic dysfunction, is commonly observed in 
PH-HFpEF but less so in PAH57, 229.  The principal hypothesis of this study was that left 
atrial volume measured using CMR imaging would be able to distinguish IPAH from PH-
HFpEF. 
 
 
Chapter 4.   ‘Changes in RV function measured by CMR imaging in patients receiving 
PAH–targeted therapy’.  Right ventricular function is an important predictor of survival in 
PAH1, 230, 231.  The last 2 decades have seen the introduction of several treatments targeting 
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the pathophysiological mechanisms of PAH, however their approval is largely based on 
improved haemodynamic variables at RHC, or improved exercise capacity measured with 
6MWT2, 232.  The principal hypothesis of this study was that direct assessment of RV 
function using CMR would be an appropriate way of determining response to therapy and 
monitoring disease progression in PAH. 
 
 
Chapter 5.   ‘Prognostic value of cardiac dysfunction in IPAH and CTD-PAH’.  Despite 
similar baseline clinical and haemodynamic characteristics, outcomes in CTD-PAH are 
worse than in IPAH, with increased mortality and poorer response to disease-targeted PAH 
therapy165, 171, 233, 234.  The principal hypothesis of this study was that right and left sided 
cardiac dysfunction could influence prognosis and explain the survival difference between 
these two conditions. 
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Chapter 2 
 
Materials and Methods 
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2.1   Patient Recruitment 
 
The patients involved in the studies in this thesis were recruited during their diagnostic 
assessment for suspected pulmonary hypertension at the Western Infirmary, Glasgow UK 
(pre-August 2008) or the Golden Jubilee National Hospital, Clydebank, UK (post-August 
2008).  The clinical studies conducted in this thesis were reviewed and approved by the 
West Glasgow Research Ethics Committee. The patient consent form and information 
sheet are shown in Appendix 1.  Patients were also recruited into the EURO-MR study 
from PH centres in: Amsterdam, Netherlands; Graz, Austria; Rome, Italy.   
 
All patients had either been assessed first in the out-patient pulmonary vascular clinic and 
offered diagnostic admission for further assessment, or admitted directly for assessment 
following faxed or telephone referral from other hospitals within Scotland.  All referrals 
were vetted by a Consultant from the Scottish Pulmonary Vascular Unit (Professor Andrew 
Peacock, Dr Martin Johnson), 
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2.2   Routine Diagnostic Assessment 
 
2.2.1   Non-invasive Assessment 
 
During the diagnostic admission, all patients underwent a series of investigations as part of 
the recommended diagnostic algorithm for PH 2.  These included routine blood tests, 
arterial blood gas analysis, 12-lead electrocardiogram, chest radiograph, transthoracic 
echocardiogram, lung function and six-minute walk tests, ventilation/perfusion (V/Q) scan, 
High Resolution CT scan and a CT Pulmonary Angiogram (CTPA).  The CTPA was not 
performed if the examination had been performed recently at the referring hospital, or if 
the patient had significant renal dysfunction.  These investigations were performed at 
either the Western Infirmary and Gartnavel General Hospital, or the Golden Jubilee 
National Hospital.   
 
The 6-minute walk test was performed in accordance with current guidelines76.  
 
Assessment of functional class was made in accordance with WHO guidelines    
(Appendix 2) 
 
2.2.2   Right heart catheterisation 
 
Right heart catheterisation was performed on the Thursday of the diagnostic admission in 
the cardiac catheterisation lab of the Golden Jubilee National Hospital (or Western 
Infirmary if pre-August 2008).  For patients on regular diuretics or calcium channel 
blockers, these were stopped the day before.  An 8F introducer sheath was inserted in the 
right internal jugular vein under ultrasound guidance, either on the Wednesday afternoon, 
or at the time of cardiac catheterisation.  Right heart catheterisation was performed using a 
7F triple-channel thermodilution Swan Ganz catheter (Baxter Healthcare, Irvine, 
California, USA).  Pre-medication or sedation was not routinely used. The external 
pressure transducer was zeroed at the mid-thoracic line with the patient in the supine 
position, halfway between the anterior sternum and the bed surface, representing the level 
of the left atrium. Measurements were recorded with the patient in a supine position, at 
rest, breathing room air (unless supplemental oxygen was already in use prior to the 
procedure).  All pressure measurements were determined at the end of normal expiration.  
These included mean right atrial pressure (RAP), right ventricular pressure and systolic 
and diastolic pulmonary artery pressures (PAP). Mean PAP was determined as the area 
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under the PAP trace.  Pulmonary artery wedge pressure (PAWP) was recorded with the 
catheter in the wedge position and the balloon inflated.  Cardiac output (CO) was 
determined in triplicate by the thermodilution technique, allowing the determination of 
pulmonary vascular resistance (PVR) by the following: (mean PAP - PAWP)/CO.  Cardiac 
Index was determined as CO / body surface area.   
 
If the right heart catheterisation suggested pulmonary arterial hypertension, then 
pulmonary vasoreactivity testing was performed. Patients inhaled a mixture of nitric oxide 
(dose 10-20 parts per million) and oxygen for 5 minutes, and pulmonary haemodynamic 
measurements were repeated.  A positive acute response was defined as a reduction of 
mean PAP ≥10 mmHg to reach an absolute value of mean PAP <40 mmHg with an 
increased or unchanged CO.   
 
The V/Q scan and CTPA had been reviewed by our specialist thoracic radiologist (Dr Mike 
Sproule, Gartnavel General Hospital) prior to right heart catheterisation, and if there was 
suspicion of chronic thromboembolic disease then pulmonary angiography was also 
performed.   
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2.2.3   Cardiovascular Magnetic Resonance Imaging 
 
The CMR scans in this thesis were performed at the Western Infirmary or the Golden 
Jubilee National Hospital.  Before August 2008 the scans were performed at the Western 
Infirmary by Ms Tracy Steedman, Cardiac MR Radiographer, and one of the previous 
SPVU clinical research fellows (Dr Kevin Blyth, Dr Lindsey McLure).  After August 2008 
scans were performed at the Golden Jubilee National Hospital by Ms Rosemary 
Woodward, Mr Andrew Saul or Mrs Carolyn Clark, Cardiac MR Radiographers.  At both 
sites, scans were performed on a 1.5 T Siemens Sonata whole body MR scanner.   
 
2.2.3.1  Patient preparation and positioning 
 
Prior to entering the CMR scanning room, the patient was asked to complete and sign a 
safety questionnaire to ensure there was no contraindication to performing CMR. After 
changing into a hospital gown, the patient was asked to lie supine on the CMR examination 
table, which had been remotely removed from inside the magnet bore.  Three-lead ECG 
monitoring pads were connected, and the phased array chest coil placed on the patient’s 
chest and secured with a Velcro strap.  Protective ear-defenders were fitted and an 
emergency buzzer supplied.  The centre of the chest coil, approximating the position of the 
heart, was defined by a laser pointer attached to the magnets inner circumference at the 12 
o’clock position.  This reference point was obtained to allow the patient to be moved 
within the bore of the magnet, to the point where their heart was at the centre of the main 
magnetic field.   Once the patient was inside the bore of the magnet, the scanning room 
door was sealed and the staff performing the scan returned to the control room. 
Microphone and headphone function, allowing direct communication between patient and 
the CMR operator, was verified before image acquisition commenced.   
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2.2.3.2  CMR Image acquisition 
  
A standard CMR core imaging protocol was followed in all subjects.  Steady state 
procession sequences (True FISP) were used to generate the initial axial scout images in 
the coronal, transverse and sagittal planes, allowing the heart to be localised within the 
thoracic cavity, and were used for planning subsequent cine images (Figure 2.1).   
 
Figure 2.1   CMR scout images in the coronal, transverse and sagittal planes 
 
  
Coronal Scout Image    Transverse Scout Image  
 
Sagittal Scout Image 
 
Typical axial scout images used to localise the heart within the thoracic cavity during CMR 
scanning of a patient with PH.  Note the low definition images of these preliminary fast 
imaging with steady state procession (TrueFISP) scout images. 
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Vertical- and horizontal-long axis (VLA and HLA) cines (Figures 2.2 and 2.3) were 
planned and acquired based on the initial scout images.   
 
Figure 2.2   Image 1 of a vertical long axis cine 
 
 
Image 1 of a vertical long axis fast imaging with steady state precession (TrueFISP) cine 
acquired in a patient with PH.  
 
Figure 2.3  Image 1 of a horizontal long axis cine 
 
 
Image 1 of a horizontal long axis fast imaging with steady state precession (TrueFISP) cine 
acquired in a patient with IPAH.  Note the right ventricular and right atrial enlargement, 
and the right ventricular hypertrophy. 
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A series of short axis (SA) cines was then planned on image one of the HLA cine, 
intersecting the atrioventricular valve roots on this view. The SA imaging plane was then 
propagated towards the cardiac apex, covering both ventricles with 8-mm SA imaging 
slices, separated by a 2-mm inter-slice gap (Figure 2.4).   
 
 
Figure 2.4   Horizontal long axis cine with planned short axis imaging slices 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A horizontal long axis fast imaging with steady state precession (TrueFISP) cine acquired 
in a patient with PH due to left heart disease.  This image was used to plan the first of a 
series of short axis (SA) cines, intersecting the atrioventricular valve roots. The SA 
imaging plane was then propagated apically, covering both ventricles with 8-mm SA 
imaging slices (red lines), separated by a 2-mm inter-slice gap.  
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A traditional left ventricle (LV) short axis cine stack was used for the acquisition of both 
RV and LV images (Figure 2.5).  This stack of short axis images was used for the 
measurement of ventricular volume and mass using manual planimetry, at end-diastole and 
end-systole. 
 
Figure 2.5   Basal, middle and apical short-axis cine images at end-systole and end- 
  diastole 
    
Basal (End-Diastole)    Basal (End Systole) 
 
   
Middle (End-Diastole)   Middle (End Systole) 
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Apical (End-Diastole)   Apical (End Systole) 
 
End-diastolic and end-systolic images from short axis cines acquired in a patient with 
IPAH. A stack of these images were acquired covering both ventricles from base to apex.  
Note the right ventricular dilatation, right ventricular hypertrophy, bowing of the 
interventricular septum at end-systole, and the presence of a pericardial effusion
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Imaging parameters, which were standardised for all subjects, included: TR/TE/flip 
angle/voxel size/FoV = 3.14ms/1.6 ms/60°/2.2 x 1.3 x 8.0 mm/340 mm.  Whenever 
possible, retrospective ECG-gating was used.  This involves continuous data collection and 
the assignment of the collected data to appropriate points in the cardiac cycle 
retrospectively. Although this means that a mean cardiac cycle must be interpolated, 
because of natural variation in R-R interval, it ensures complete coverage of the cardiac 
cycle. 
 
2.2.3.3  Common problems encountered during CMR imaging 
 
The most common problem was that some patients could not hold their breath long enough 
to accommodate a complete pulse sequence. This was most commonly observed in patients 
who were already oxygen-dependent at the time of diagnostic assessment.  In extreme 
cases imaging was performed with the patient breathing freely.  However, in most the TR 
of the sequences could be shortened by altering the flip angle and/or reducing the phase 
oversampling used as standard in the imaging sequences. 
 
Other problems encountered include claustrophobia, and difficulties obtaining a 
satisfactory supine position within the scanner, particularly in very obese or kyphotic 
patients.   
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2.2.3.4  Data Storage 
 
On completion of each CMR scan, the images were saved to the hard-drive of the 
scanner, and backed up onto a compact disc (CD).  Individual CDs were coded by 
number and stored in a locked office until data analysis.  
 
 
2.2.3.5  Analysis of Cardiovascular Magnetic Resonance Images 
 
All CMR images in this thesis were analysed on a satellite workstation attached to the 
main MR scanner using the Argus analysis software (Siemens, Erlangen, Germany). 
Individual CDs, which corresponded to individual patients undergoing diagnostic 
assessment, were retrieved and analysed prior to right heart catheterisation. CMR scans 
performed prior to August 2008 were analysed in a similar fashion by previous SPVU 
research fellows (Dr Kevin Blyth, Dr Lindsey McLure).   
 
The standard technique of manual planimetry was used for analysing the CMR images.  
After loading the patient CD, the Argus programme automatically identified the images 
within each SA cine loop that had the largest and smallest blood volumes and defined these 
as end-diastole and end-systole respectively.  The end-diastolic image was usually the first 
image acquired after R wave deflection.  Using a cursor the epicardial and endocardial 
borders of the end-diastolic and end-systolic images at each slice position within the SA 
stack were manually defined.  Trabeculations and papillary muscles were included in the 
analyses.  An example of planimetric analysis of the right ventricle is displayed in Figure 
2.6, and of the left ventricle in Figure 2.7.   
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Figure 2.6  An example of planimetry analysis of RV volumes and mass using  
  the Argus analysis software.   
 
 
 
Each row of short axis images represents a loop of cine images acquired during one cardiac 
cycle at consecutive slice positions, beginning at the base of the heart, moving apically to 
cover both ventricles.  The first images within each row (or slice position) were acquired 
immediately after R-wave deflection.  They are defined by the Argus software as the end-
diastolic images (indicated by the yellow ED at the top of the left-hand column) and have 
the greatest total ventricular blood volume.  The end-systolic images were defined 
automatically by the Argus software as the column of images with the smallest total 
ventricular blood volume, however this was also verified visually.  A trackball mouse and 
cursor was used to define the endocardial (in red) and epicardial (in green) surfaces of the 
RV at end-diastole, and the endocardial surface only at end-systole (in red).  This allowed 
calculation of RV end-diastolic and end-systolic volumes and RV mass. 
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Figure 2.7   Planimetric analysis of a left ventricular short axis image in a   
 patient without PH 
 
 
 
 
An example of planimetric analysis of the left ventricle is displayed on a short axis image 
from a patient who did not have pulmonary hypertension at RHC.  A trackball mouse and 
cursor was again used to define the endocardial (in red) and epicardial (in green) surfaces 
of the LV. 
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The individual slice areas were multiplied by slice thickness (8mm) plus the inter-slice gap 
(2mm), Simpson’s rule was applied, and the Argus software automatically calculated 
RVEDV, RVESV, LVEDV and LV end-systolic volume (LVESV).  Stroke volumes for 
the RV and LV were determined as (RV/LV) EDV-ESV.  Right and left ventricular 
ejection fractions were determined as a percentage (%) as: 
((RV or LV) SV/EDV) x 100).   
 
In keeping with current CMR practice, RV and LV mass (RVM and LVM) were 
determined as the product of the difference between the end-diastolic and end-systolic 
volume for each ventricle and the density of cardiac muscle (1.05 g/cm3). RV mass was 
determined as RV free wall mass, with the Interventricular Septum (IVS) considered part 
of the LV.  Ventricular Mass Index (VMI) was determined as RVM/LVM, as previously 
shown122.  Throughout this thesis, all ventricular volumes are corrected for Body Surface 
Area (BSA) and reported as indexed measurements: (RVEDV Index (RVEDVI), RVSV 
Index, (RVSVI), LVEDV Index (LVEDVI) and LVSV Index (LVSVI)). 
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2.2.3.6  Measurement of Atrial volumes 
 
The biplane area length method was used to measure left atrial volume (LAV)235.  The 
vertical and horizontal long axis cines were used to obtain images of the left atrium at 
maximal filling (Figure 2.8.).  The atrial lengths and areas were measured from both views 
using the Argus image measurement tools. The left atrial endocardial area was manually 
traced to exclude the atrial appendage and pulmonary veins.  The long-axis length of the 
left atrium was defined as the distance from the central of the mitral annulus to the 
posterior atrial wall.   LAV was calculated using the equation: 
 
Left Atrial Volume (LAV) 
 = (0.848 x area4chamber x area2chamber)/[(length4ch + length2ch)/2] 
 
LAV was corrected for body surface area (LAV/BSA).   
 
Right atrial volume (RAV) was determined using the horizontal long axis cine image of the 
right atrium at maximal filling, using the monoplane area-length formula: 
  
 Right Atrial Volume (RAV) = 0.848 x (area4ch)2 / length4ch 
86 
Figure 2.8   Vertical and horizontal long axis cine images used for calculating atrial  
  volumes 
  
The red shading is the left atrial area, the blue shading is the right atrial area, and the white 
arrows are the atrial lengths.   
 
Modified from Whitlock et al.  Comparison of left and right atrial volume by 
echocardiography versus cardiac magnetic resonance imaging using the area-length 
method. American Journal of Cardiology. 2010;106:1345-1350  
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2.3   Diagnosis and Commencement of PAH Treatment 
 
2.3.1  Multi-Disciplinary Team Meeting 
 
A multi-disciplinary team meeting (MDTM) was held on the Thursday afternoon of the 
diagnostic admission.  In attendance were: The Pulmonary Vascular Research Fellow and 
Consultant, Consultant Radiologist, Consultant Cardiologist, Pulmonary Vascular Clinical 
Nurse Specialist, Clinical Trials Nurse.  For each patient undergoing assessment the 
relevant clinical history, examination findings, imaging, non-invasive investigations and 
pulmonary haemodynamics were reviewed.  A diagnosis was then made in accordance 
with current PH guidelines2, and agreed by the MDTM.   
 
2.3.2  Starting PAH-specific Therapy 
 
If a diagnosis of PAH was made then the patient was offered PAH-specific therapy, in 
accordance with the current clinical guidelines2 
 
If parenteral prostanoid treatment was being commenced then the patient was transferred to 
the Respiratory Unit (Wards 6C/7C) at Gartnavel General Hospital.  Oral PAH therapy 
(PDE-5 Inhibitor, Endothelin Receptor Antagonist, Calcium Channel Blocker) was either 
commenced at the end of the diagnostic admission, or as an outpatient within 7 days of 
right heart catheterisation.   
 
Continuous intravenous Epoprostenol was initially administered via a 2F peripherally 
inserted central catheter (PICC), before switching to a permanent hickmann line.  The 
starting dose was typically 2ng/kg/min and was gradually uptitrated over a two-week 
period, dependent on patient tolerance and side-effects such as hypotension.  
 
Inhaled Iloprost was administered via the I-neb Adaptive Aerosol Delivery (AAD) System.  
The starting dose was 2.5mcg per inhalation, with target of 6 – 9 inhalations per day.   
 
The typical starting doses of oral PAH therapies were: Sildenafil 20mg tid, Ambrisentan 
5mg od, Bosentan 62.5mg bd.   
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Patients receiving PAH-specific therapy in the context of a clinical trial were commenced 
on treatment in accordance with the relevant study protocol.   
 
2.3.3  Follow-up after commencing PAH therapy 
 
2.3.3.1  Out-patient Clinic 
 
If disease-targeted PAH therapy was commenced following the diagnostic admission, then 
the patient was reviewed in the outpatient clinic after approximately 3-4 months, 6 months, 
9 months and 12 months of treatment.  Patients recruited into clinical trials were followed 
up as per the individual study protocol.  Out-patient clinic visits were at Gartnavel General 
Hospital (prior to August 2008) or the Golden Jubilee National Hospital (from August 
2008 onwards) 
 
2.3.3.2  Assessment at Out-patient follow-up visits 
 
Follow-up assessment involved clinical examination, documentation of NYHA functional 
class, and a repeat six-minute walk test was performed.  Liver Function Tests and Full 
Blood Count were performed for patients receiving endothelin receptor antagonists, and 
where possible NT-ProBNP was performed at each visit.   
 
2.3.3.3  Repeat Cardiac Magnetic Resonance Imaging 
 
Patients recruited into the EURO-MR study underwent a repeat CMR scan after 
approximately 3-4 months of treatment, and again after approximately 12 months of 
treatment.  The CMR protocol for these repeat scans was identical to the baseline CMR.  
Analysis of follow-up CMR images was performed immediately, and without knowledge 
of the follow-up 6MWT result and NYHA functional class.   
 
 
2.3.3.4  Changes to PAH Therapy 
 
At each out-patient visit the effectiveness of the PAH therapy that had been commenced at 
the diagnostic admission was assessed.   
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PAH therapy was then: continued at the current dose; continued at an increased dose (e.g. 
Sildenafil increased to 50mg tid); switched to a different class of drug (e.g. Sildenafil 
switched to Bosentan); or another drug was added to the initial therapy (e.g. Nebulized 
Iloprost added to Sildenafil).  All changes to PAH therapy were discussed with a 
Consultant within the Scottish Pulmonary Vascular Unit.   
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2.4   Survival analysis 
 
2.4.1  Cox Proportional Hazards Analysis 
 
Cox proportional hazards model with right censoring was used to identify predictors of all-
cause mortality. Survival time was calculated from the date of diagnostic RHC to censor 
date or date of death. Patients were censored at the time of data cut-off, lung 
transplantation or last clinical contact if lost to follow-up.  
 
Univariate analysis was first performed to identify predictors of mortality from candidate 
variables. These variables were tested for collinearity using Pearson or Spearman 
correlation coefficients depending on data distribution. Variables with p value less than a 
predefined level in the univariate analysis or those considered clinically relevant based on 
previous studies were analysed in a multivariate Cox proportional model using a backward 
selection procedure. Highly correlated variables (r > 0.7) were not included.  To avoid 
over-fitting, one covariate was included in the final model for approximately every ten 
deaths. A p value <0.05 by likelihood ratio test was defined as statistically significant. 
 
 
2.4.2  Kaplan Meier Analysis  
 
Kaplan Meier analysis was used to estimate survival rates using all-cause mortality as the 
end-point. Log-rank test was used for group comparison. Survival time was calculated 
from the date of diagnostic RHC to censor date or date of death. Patients were censored at 
the time of data cut-off, lung transplantation or last clinical contact if lost to follow-up. 
Results were presented as Kaplan Meier survival curves and the number of subjects at risk 
at regular time intervals. A p value <0.05 was defined as statistically significant. 
 
 
2.4.3  Receiver Operating Characteristics Analysis 
 
Receiver-operating characteristics (ROC) analysis was used to determine the 
discriminatory power and optimal threshold of a continuous variable in predicting all-cause 
mortality at a defined time point. A ROC curve was constructed by plotting sensitivity (y 
axis) against 1-specificity (x axis). The optimal threshold was identified from the curve by 
locating the point closest to the coordinate y=1 (100% sensitivity), x=0 (100% specificity). 
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The discriminatory power of a predictor variable was determined by calculating the area 
under the ROC curve (AUC). An AUC of 0.5 indicated that the variable had no 
discriminatory power whereas an AUC of 1 indicated that the variable had perfect 
discriminatory power. 
 
 
Additional statistical methodology pertaining to each study in this thesis is described 
separately, within the relevant chapters. 
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Chapter 3 
 
Left Atrial Volume by Cardiac Magnetic Resonance 
Distinguishes Idiopathic Pulmonary Arterial Hypertension 
From Pulmonary Hypertension due to Heart Failure with 
Preserved Ejection Fraction 
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3.1   Introduction 
 
3.1.1  Current methods for distinguishing IPAH from PH-HFpEF 
 
As discussed in earlier chapters, current guidelines on the classification, diagnosis and 
management of pulmonary hypertension emphasise the importance of distinguishing IPAH 
from PH-HFpEF2, 4, 236.  It can be difficult to distinguish IPAH from PH-HFpEF on clinical 
grounds, particularly in older patients with significant medical comorbidities.  Typically, 
compared with IPAH, patients with PH-HFpEF are older, more often female, and more 
frequently have other cardiovascular comorbidities including hypertension, diabetes, 
obesity, and coronary artery disease57.   In their cross-sectional study that included 522 
patients with PAH and 100 patients with PH-HFpEF, Thenappan et al demonstrated that a 
model consisting of ten clinical characteristics (Age, WHO functional class, hypertension, 
obesity, diabetes mellitus, coronary artery disease, serum creatinine, diuretic use, beta-
blocker use, and ACE inhibitors / Angiotensin Receptor Blocker use) could distinguish 
between the two conditions with an area under the ROC curve of 0.9257.  
 
 
Echocardiographic abnormalities typically observed in PH-HFpEF but not in PAH include 
left ventricular hypertrophy, grade II or grade III diastolic dysfunction, left atrial 
enlargement, and less frequent midsystolic notching pattern on the RV outflow tract 
Doppler signal195.  Robbins et al found that left atrial dilatation on echocardiography was 
present in 77% of patients with pulmonary venous hypertension but only 10% of patients 
with pulmonary arterial hypertension229.  Similarly, Thenappan et al noted 
echocardiographic left atrial enlargement in 64% of their PH-HFpEF group and only 18% 
of the PAH group, however the addition of echocardiographic predictors (left ventricular 
posterior wall thickness, left atrial enlargement, and right atrial enlargement) to the model 
described above did not provide any significant incremental value over baseline clinical 
characteristics alone57. 
 
Right heart catheterisation is the definitive diagnostic technique for distinguishing IPAH 
from PH-HFpEF.  At RHC, patients with PH-HFpEF typically have only a moderate 
increase in PAP and PVR, and higher cardiac output and aortic systolic pressures than 
IPAH patients.  The key measurement that distinguishes the two conditions is the PAWP, 
with a PAWP of ≤ 15mmHg excluding a diagnosis of PH-HFpEF2.  It is therefore essential 
that PAWP is measured accurately, ideally manually at end-expiration, rather than relying 
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on digitized results237.  PAWP correlates closely with, although is generally slightly higher 
than, the mean left atrial pressure238.  If an accurate wedge pressure measurement cannot 
be obtained, then left ventricular end-diastolic pressure (LVEDP) should be measured 
using left heart catheterisation196.  However, discrepancies between PAWP and LVEDP 
measurements are not uncommon, with some groups proposing that up to 50% of patients 
diagnosed with PAH based on a normal PAWP would be diagnosed with Group 2 PH if 
LVEDP measurements were used239.    
 
When the clinical picture is in keeping with PH-HFpEF but the initial PAWP is normal 
(e.g. if patients are fasting and/or over-diuresed) then additional provocative measures such 
as fluid challenge or exercise may be performed during cardiac catheterisation.  In a study 
of 207 patients with an initial haemodynamic profile of PAH at RHC, a 500ml infusion of 
normal saline over 5-10 minutes resulted in 46 patients (22.2%) developing a PAWP of 
>15mmHg and being reclassified as “occult pulmonary venous hypertension”100.  It is 
worth noting that:  PAWP also significantly increased after fluid challenge in the “PAH” 
group (from 9 ± 3mmHg to 11 ± 4 mmHg, p < 0.001)100,  PAWP has been reported to 
increase after acute saline loading in normal individuals240, and that there is no firm 
consensus on the volume of saline, rate of infusion, and the magnitude of increase in 
PAWP required for differentiating PH-HFpEF from PAH196.  
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3.1.2  The Structure and Function of the Left Atrium 
 
The left atrium is a thin-walled structure located in the inflow path from the pulmonary 
veins to the left ventricle (LV).  Its anterior wall lies behind the transverse pericardial 
sinus, and its posterior wall is located close to the tracheal bifurcation and the oesophagus, 
and receives the pulmonary veins241.   It consists of (a) a main body with smooth walls, 
embryologically developed from the outgrowth of the pulmonary veins and (b) a 
trabeculated finger-like appendage.   
 
 
The mechanical function of the left atrium can be defined by three phases of volume 
variation during the cardiac cycle.  During ventricular systole the LA collects blood 
coming from the pulmonary veins, the “reservoir phase”.  In this phase LV contraction and 
LA relaxation results in movement of the mitral annulus towards the cardiac apex, with an 
overall increase in LA volume242.  Atrial compliance allows chamber volume to increase 
during the reservoir phase, but preserving filling pressures within normal limits.  At the 
end of ventricular systole, a reduction in atrial compliance leads to an increase in LA 
pressure, and in early diastole the high early diastolic atrial–ventricular pressure gradient 
results in blood stored in LA during the reservoir phase being driven into LV.  Following 
this, direct flow of blood from the pulmonary vein through the atrium into the left ventricle 
occurs, the “conduit phase”.  Finally there is a “contractile phase” during late diastole, 
when the LA muscle contracts in order to increase left ventricular stroke volume by 
approximately 20%241.  In early-stage LV filling impairment there is augmentation of LA 
reservoir and pump functions, however at end-stage ventricular dysfunction the limits of 
atrial preload reserve have been reached and therefore conduit of blood through the atrium 
will take precedence243.  
 
A normal “compliant” left atrium can prevent elevations in LVEDP from resulting in 
damage to the pulmonary vasculature.  By contrast, if the left atrium is stiff then post 
capillary PH can occur even in the setting of normal LVEDP244.   Left atrial enlargement is 
not felt to be part of the normal ageing process, and maximum and minimum LA volumes 
do not differ between younger and older study populations245, 246.  Similarly, the impact of 
gender on LA volume is largely accounted for by the differences in body surface area 
between men and women247, 248.   
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In PH-HFpEF there is preserved LV systolic function, i.e. normal LV ejection fraction, but 
impaired diastolic function with abnormal LV relaxation and increased LV filling 
pressure249.    Sustained elevations of LV filling pressures can result in enlargement of the 
thin-walled left atrium, allowing left atrial volume to be used as a marker of the severity 
and chronicity of diastolic dysfunction206, 250-253.  Left atrial volume is higher in patients 
with HFpEF than in asymptomatic hypertensive patients or healthy controls254.  In patients 
with HFpEF, LAVI correlates with NT-pro-BNP levels in the setting of an elevated E/E' 
(early transmitral inflow to diastolic velocity of the mitral annulus) ratio at 
echocardiography255.   
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3.1.3  Assessment of Left Atrial Size 
 
Under normal conditions, the left atrium may have a spherical or ellipsoid shape, however 
with even mild chamber distortion it enlarges asymmetrically due to the presence of 
surrounding structures and eccentrically directed mitral regurgitation jets.  Therefore, LA 
volume is preferred over linear dimensions such as diameter or area, since it allows more 
accurate measurement of the asymmetric remodelling of the atrial chamber256. 
 
There are a number of methods that can be used to determine left atrial volume with CMR.  
The most precise method is the multiple slice method (MSM) or Simpson’s method, which 
involves time-consuming manual tracings of left atrial area on each cross-sectional image, 
and has been found to very closely relate to postmortal assessment of true LA size257.  The 
biplane area-length method (ALM) is a much simpler method of assessing LAV.  It uses 
the formula:  LAV = (0.848 x area4ch x area2ch)/[(length4ch + length2ch)/2], where 4ch and 
2ch is the 4-chamber and 2-chamber view respectively, and is usually then indexed to body 
surface area258.  The ALM has been found to correlate closely with the MSM, with no 
significant difference in intraobserver and interobserver variability between the 
techniques259-262.  A third method, the prolate ellipse technique, consistently 
underestimates LAV compared with the other two methods263.     
 
In their study of 85 patients and 18 controls, Whitlock et al demonstrated that atrial 
volumes estimated using the area-length method were significantly smaller when measured 
using echocardiography than when measured using CMR (LA volume 35 ± 20 vs 49 ± 30 
ml/m2, p <0.001)258.  In patients with permanent atrial fibrillation (AF), CMR by the area-
length method can be used to assess left atrial size with excellent levels of intra-observer 
and inter-observer agreement235, superior to the reproducibility seen with 2D-transthoracic 
echocardiography264.  In AF, left atrial volume measured by ALM at CMR has been found 
to have superior correlation to CMR-MSM than LAV measured by ALM at 
echocardiography265.   
 
In a small study investigating the influence of CMR field strength on left atrial volumes 
and function, there was no significant difference in LAV in healthy volunteers between 
CMR at 1.5 Tesla and 3 Tesla266.  Similarly, there was no difference in left atrial volume 
measured at end-diastole using prospective ECG triggering or retrospective gated 
sequences267.   
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There have been a number of studies performed to establish a normal reference range for 
left atrial volumes for healthy individuals with no history of cardiovascular disease.  The 
most recent update from the American Society of Echocardiography and the European 
Association of Cardiovascular Imaging (2015) has recommended that the upper normal 
limit for 2D echocardiographic LA volume is 34 ml/m2 for both genders268, whilst the 
normal value using CMR is estimated to be 40 ml/m2 248. 
 
The experiment in this chapter tested the hypothesis that left atrial volume measured using 
CMR imaging would be able to distinguish IPAH from PH-HFpEF, and might be 
considered a non-invasive alternative to right heart catheterisation. 
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3.2   Methods 
 
3.2.1  Patients 
 
Consecutive treatment-naïve patients with a suspected new diagnosis of pulmonary 
hypertension were admitted for diagnostic assessment between January 2009 and March 
2011 as described in Chapter 2.2.  Patients underwent CMR imaging followed by RHC 
within 72 hours.   
 
Patients with clear evidence of an underlying cause of pulmonary hypertension such as 
chronic thromboembolic disease, connective-tissue disease, left ventricular systolic 
dysfunction, or significant (≥moderate) mitral or aortic valvular disease on 
echocardiography were excluded.  In 58 patients the diagnostic issue that remained was 
whether the patient had IPAH or PH-HFpEF.   
 
3.2.2   CMR Image Acquisition 
 
CMR image acquisition was performed as described in Methods Section 2.2.3 
 
3.2.3  CMR Image Analysis 
 
CMR image analysis was performed as described in Methods Sections 2.2.3.5 and 2.2.3.6.   
 
3.2.4  Statistical Analysis 
 
A retrospective analysis of 40 CMR scans performed in our unit between 2005 and 2008 
had shown that left atrial volume was higher in patients diagnosed with PH-HFpEF than 
those with IPAH (IPAH 20 ± 8 ml/m2, PH-HFpEF 62 ± 15 ml/m2, mean difference 41.8 
ml/m2).  A power calculation based on mean values and standard deviations from this 
analysis, aiming for a power of 90% and assuming a Type 1 error of 0.05, had suggested 
that only 4 patients in each group were needed to demonstrate significant differences in left 
atrial volume if present.  
 
For all variables, normal Gaussian distribution was verified using histograms and 
Kolmogorov-Smirnov tests.  For demographic, CMR, and haemodynamic variables mean 
values ± one standard deviation (±SD) were calculated.  Categorical variables are 
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presented as number (%).  Student’s t-test was used to compare the mean values between 
the groups.  The Chi-squared test was used to compare categorical variables.  Correlations 
between normally distributed CMR and haemodynamic variables were tested by Pearson’s 
method.  ROC analysis was used to determine the respective AUC for non-invasive 
variables that could be used to distinguish IPAH from PH-HFpEF.  Optimal thresholds 
were identified by selecting the data point closest to the coordinate y=1 (100% sensitivity), 
x=0 (100% specificity) on the ROC curves.  No adjustment was made to P-values to 
account for multiple testing.  A p value < 0.05 was defined as statistically significant. 
 
All calculations were performed using GRAPHPAD Prism (Version 5.00; GraphPad 
Software Inc, La Jolla, CA, USA).   
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3.3   Results 
 
3.3.1   Clinical characteristics 
 
Clinical characteristics for the study population are displayed in Table 3.1. 
 
Table 3.1 Clinical characteristics 
 IPAH 
(n = 37) 
PH-HFpEF 
(n = 21) 
P-value 
Age (years) 60 (± 15) 71 (± 12) 0.004 
Sex (♀; ♂) 19 ; 18 14 ; 7  
Functional Class (II; III; IV) 9 ; 26 ; 2 8 ; 13 ; 0  
Body Surface Area (m2) 1.79 (± 0.21) 1.84 (± 0.28) 0.40 
Diabetes Mellitus, n (%) 7 (19) 9 (43) 0.0029† 
Atrial Fibrillation, n (%) 1 (3) 16 (76) < 0.0001† 
Systolic BP (mmHg) 127 (± 24) 161 (± 26) < 0.0001 
Diastolic BP (mmHg) 79 (± 12) 81 (± 13) 0.49 
Mean BP (mmHg) 97 (± 13) 111 (± 14) 0.0004 
Resting Heart Rate (bpm) 76 (± 14) 75 (± 18) 0.87 
6MWD (m) 261 (± 144) 251 (± 100) 0.80 
Serum Creatinine (µmol/L) 94 (± 31) 115 (± 44) 0.03 
 
IPAH, idiopathic pulmonary arterial hypertension; PH-HFpEF, pulmonary hypertension 
associated with heart failure with preserved ejection fraction: 6MWD, six-minute walk 
distance 
 
Data presented as mean (±SD) otherwise specified 
† - using the Chi-squared test for categorical variables 
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The IPAH group was younger, had a higher proportion of males, and had lower systemic 
blood pressure than the PH-HFpEF group.  There was a higher incidence of diabetes 
mellitus and atrial fibrillation in the PH-HFpEF group.  There was no significant difference 
between the groups in body surface area, resting heart rate or distance achieved on the six-
minute walk test.  The PH-HFpEF group had higher serum creatinine than the IPAH group 
(115 ± 44 vs 94 ± 31 µmol/L, p = 0.03).  
 
At echocardiography, the IPAH group had a significantly lower left atrial area than the PH-
HFpEF group (14 ± 4 vs 25 ± 5 cm2, p <0.0001), however left atrial area could not be 
assessed in 10 of the 58 study patients (17%) due to poor image quality.  Other 
echocardiographic measurements of left ventricular diastolic function (E/A ratio, E/E' 
ratio) were not routinely performed during the diagnostic assessment.   
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3.3.2   Pulmonary haemodynamics 
 
Invasive measurements obtained in the IPAH and PH-HFpEF groups at right heart 
catheterisation are shown in Table 3.2.  The IPAH group had lower PAWP, lower cardiac 
output and higher PVR than the PH-HFpEF group.  There was, however, no significant 
difference in systolic or mean PAP between the groups. 
 
 
Table 3.2 Pulmonary haemodynamics at right heart catheterisation 
 
 IPAH 
(n = 37) 
PH-HFpEF 
(n = 21) 
P-value 
Systolic PAP (mmHg) 80 (± 14) 77 (± 13) 0.51 
Diastolic PAP (mmHg) 30 (± 8) 24 (± 8) 0.008 
Mean PAP (mmHg) 48 (± 9) 44 (± 9) 0.17 
PAWP (mmHg) 7 (± 4) 23 (± 6) <0.0001 
Cardiac Output (L/min) 3.7 (± 1.4) 4.6 (± 1.3) 0.03 
PVR (Wood Units) 12.5 (± 5.5) 5.0 (± 2.2) <0.0001 
RAP (mmHg) 8 (± 6) 14 (± 5) 0.0007 
 
IPAH, idiopathic pulmonary arterial hypertension; PH-HFpEF, pulmonary hypertension 
associated with heart failure with preserved ejection fraction; PAP, pulmonary artery 
pressure; PAWP, pulmonary artery wedge pressure; DPAP, diastolic pulmonary artery 
pressure: PVR, pulmonary artery pressure; RAP, right atrial pressure. 
 
Data presented as mean (±SD) otherwise specified 
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3.3.3  Cardiac magnetic resonance imaging 
 
Ventricular dimensions, systolic function and atrial volumes for the groups are presented in 
Table 3.3.   
 
Table 3.3  CMR Results in patients with IPAH and PH-HFpEF 
 
 IPAH 
(n = 37) 
PH-HFpEF 
(n = 21) 
P-value 
Right Ventricle    
EDV Index (ml/m2) 88 (± 25) 72 (± 26) 0.023 
Stroke Volume Index (ml/m2) 26 (± 9) 31 (± 11) 0.04 
Ejection Fraction (%) 31 (± 13) 45 (± 11) 0.0001 
Mass (g/m2) 58 (± 13) 45 (± 15) 0.002 
Left Ventricle    
EDV Index (ml/m2) 42 (± 13) 60 (± 22) 0.0002 
Stroke Volume Index (ml/m2) 26 (± 9) 36 (± 13) 0.002 
Ejection Fraction (%) 64 (± 14) 63 (± 16) 0.82 
Mass (g/m2) 49 (± 9) 62 (± 21) 0.002 
Atrial Analysis    
Right Atrial Volume (ml/m2) 62 (± 27) 61 (± 43) 0.93 
Left Atrial Volume (ml/m2) 24 (± 9) 67 (± 20) <0.0001 
 
IPAH, idiopathic pulmonary arterial hypertension; PH-HFpEF, pulmonary hypertension 
associated with heart failure with preserved ejection fraction; EDV,  
end-diastolic volume. 
 
Data presented as mean (±SD) otherwise specified  
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In IPAH the right ventricle was more dilated and hypertrophied (increased RVEDV and 
RV mass) than in PH-HFpEF, but had poorer systolic function (reduced RVEF and RV 
stroke volume).  In IPAH the left ventricle was poorly filled (reduced LVEDV and LV 
stroke volume).   Left ventricular systolic function was found to be well preserved in both 
groups.   
 
Right atrial volume was increased in both IPAH and PH-HFpEF (62 ± 27 vs 61 ± 43 
ml/m2, p = 0.93).  Left atrial volume was significantly lower in IPAH than in PH-HFpEF 
(24 ± 9 vs 67 ± 20 ml/m2, p<0.0001) (Figure 3.1.).  
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Figure 3.1 Left atrial volume in IPAH versus PH-HFpEF  
 
IPA
H
PH
-H
Fp
EF
0
20
40
60
80
100
120 p < 0.0001
Le
ft 
A
tr
ia
l V
ol
um
e 
(m
l/m
2 )
 
 
 
Left Atrial Volume (LAV) calculated from cardiac magnetic resonance was significantly 
lower in idiopathic pulmonary arterial hypertension (IPAH) than in pulmonary 
hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). 
- - - - - - - - - represents a LAV threshold of 43ml/m2 
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When the PH-HFpEF group was stratified by the median PVR, there was no difference in 
left atrial volume between patients with PH-HFpEF and supramedian PVR (PVR ≥ 5.0) 
and inframedian PVR (PVR < 5.0) (63 ± 18 vs 73 ± 22 ml/m2, p = 0.27).  Similarly, when 
the PH-HFpEF group was stratified by the diastolic pulmonary gradient (DPG), 17 patients 
had “isolated postcapillary hypertension” (i.e. mean PAP > 25 mm Hg, PAWP > 15mm 
Hg, and DPG < 7 mm Hg) and 4 of 21 had “combined postcapillary and precapillary PH” 
(i.e. mean PAP > 25 mm Hg, PAWP > 15 mm Hg, and DPG ≥ 7 mmHg), however there 
was no difference in LAV between these groups (68 ± 21 vs 64 ± 22 ml/m2, p = 0.69).   
 
There was strong correlation between left atrial volume at CMR and PAWP measured at 
right heart catheterisation (r = 0.71, p < 0.0001) (Figure 3.2). 
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Figure 3.2   Correlation between PAWP measured at right heart  catheterisation  
  and left atrial volume at CMR 
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Correlation between PAWP obtained at right heart catheterisation and LAV measured 
using CMR, in 37 patients diagnosed with IPAH and 21 with PH-HFpEF.  LAV correlated 
strongly with PAWP.   
 
PAWP, pulmonary artery wedge pressure; LAV, left atrial volume; IPAH, idiopathic 
pulmonary arterial hypertension; PH-HFpEF, pulmonary hypertension due to heart failure 
with preserved ejection fraction 
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An additional twenty-three patients underwent CMR assessment who did not have 
pulmonary hypertension at right heart catheterisation (i.e. mPAP < 25 mmHg).  LAV for 
this group was 49 ± 33 ml/m2 (Figure 3.3.) 
 
 
Figure 3.3   Left atrial volume in IPAH, PH-HFpEF and patients with no PH 
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IPAH, idiopathic pulmonary arterial hypertension; PH-HF-pEF, pulmonary hypertension 
due to heart failure with preserved ejection fraction; PH, pulmonary hypertension 
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3.3.4  ROC Analysis 
 
Receiver operating characteristic (ROC) analysis was performed on the non-invasive 
variables which could potentially distinguish IPAH from PH-HFpEF.  These included age, 
systolic BP, serum creatinine, RV ejection fraction, and left atrial volume (Table 3.4).   
 
Table 3.4  ROC Analysis of non-invasive variables to distinguish IPAH from   
  PH-HFpEF 
Variable Criterion* AUC P Value 
Serum Creatinine (µmol/L) < 96 0.685 0.020 
Age (yrs) < 62 0.734 0.003 
RV Ejection Fraction (%) < 38 0.801 0.0002 
Systolic BP (mmHg) < 132 0.839 <0.0001 
CMR Left Atrial Volume 
(ml/m2) 
< 43 0.990 <0.0001 
 
AUC, area under the curve; ROC, receiver operating characteristic curve; IPAH, idiopathic 
pulmonary arterial hypertension; PH-HFpEF, pulmonary hypertension associated with 
heart failure with preserved ejection fraction; BP, blood pressure; RV, right ventricle. 
 
* The criterion value presented had the optimal balanced sensitivity and specificity for 
distinguishing IPAH from PH-HFpEF 
 
 
Left atrial volume was found to be the most sensitive and most specific single variable, 
with an area under the ROC curve of 0.990 (Figure 3.4).  Using a threshold LAV of less 
than 43 ml/m2, IPAH could be distinguished from PH-HFpEF with 97% sensitivity and 
100% specificity. 
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Figure 3.4 ROC curve of left atrial volume for distinguishing IPAH from  
  PH-HFpEF 
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Receiver operating characteristic (ROC) curve demonstrating a left atrial volume threshold 
of less than 43ml/m2 is a highly sensitive and specific way to distinguish idiopathic 
pulmonary arterial hypertension (IPAH) from pulmonary hypertension associated with 
heart failure with preserved ejection fraction (PH-HFpEF). 
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3.4   Discussion 
 
This chapter has identified that CMR-derived left atrial volume is a sensitive and specific 
way to distinguish IPAH from PH-HFpEF.  At present, IPAH is distinguished from PH-
HFpEF by demonstration of a PAWP of ≤ 15 mmHg at right heart catheterisation, however 
a left atrial volume threshold of < 43 ml/m2 at CMR could be considered as a simple, non-
invasive alternative.  Left atrial volume at CMR appears to correlate closely with invasive 
PAWP, and in the setting of preserved LV systolic function an elevated LAV will reflect 
LV diastolic dysfunction.   
 
Historically IPAH was considered to be a disease that predominately affected young 
females, however recent epidemiological studies have demonstrated that patients of any 
age can be affected, and there is growing awareness of the prevalence of IPAH in the 
elderly population81, 184, 269.  Traditionally, patients with PH-HFpEF were managed solely 
in the general cardiology clinic rather than at a specialist tertiary PH centre.  However, PH 
centres are now spending an increasing amount of time and resources distinguishing IPAH 
from PH-HFpEF270.  The importance of distinguishing IPAH from PH-HFpEF has 
increased over the last two decades following the growth in therapeutic options now 
available for IPAH.  These new therapies have been shown to improve symptoms, increase 
exercise capacity, delay time to clinical worsening, and in the case of intravenous 
prostacyclin, improve survival in IPAH53, 151, 271, 272.  However, PAH-specific therapies are 
very expensive, and are not effective but instead may be potentially harmful in PH-HFpEF.   
 
 
The current study has demonstrated that a single non-invasive variable, CMR-derived left 
atrial volume, can be used to distinguish accurately IPAH from PH-HFpEF.  This is in 
contrast to other published models that have used a combination of clinical, biochemical, 
haemodynamic and imaging criteria to distinguish between these conditions57, 273.   It is 
worth noting that in the study by Thenappan et al the majority of patients in the PAH 
group did not have idiopathic PAH, but instead had PAH associated with connective-tissue 
disease, congenital heart disease or portal hypertension57.  In clinical practice, the most 
important diagnostic uncertainty is distinguishing IPAH from PH-HFpEF. 
 
Left atrial size is already an established marker of cardiovascular disease.  Increased left 
atrial size at echocardiography predicts adverse cardiovascular events274, 275, with left atrial 
volume being a superior predictor to area or diameter276.  Increased LAV at CMR was 
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associated with poorer survival in patients with end-stage renal disease and left ventricular 
hypertrophy277.  Similarly, LAV was higher in patients with stage 3 and 4 chronic kidney 
disease than in those with normal renal function, and in these patients an increased LAV 
was predictive of adverse cardiac events278.  Abnormalities in left atrial structure and 
function, including an elevated LAV, have been shown to precede development of heart 
failure symptoms in a group of patients previously free of clinical cardiovascular 
diseases279.  LAV predicts heart failure hospitalization and mortality with similar statistical 
power as LV ejection fraction in adults with coronary artery disease280.  LAV at CMR was 
the main determinant of outcome following pulmonary vein isolation plus linear lesion 
ablation for paroxysmal-persistent atrial fibrillation281.   
 
Patients with IPAH were found to have a lower LAV than is reported for healthy 
controls258.  The left heart is poorly filled in IPAH as impaired right ventricular systolic 
function, reduced RV stroke volume and progressive luminal obliteration of small 
pulmonary arteries results in a reduced volume of blood reaching the left atrium.  Indeed, it 
has been shown that a low LV end-diastolic volume, a marker of poor LV filling, is 
associated with increased mortality in IPAH118.   
 
In this study CMR was used as the main imaging modality to assess left atrial size rather 
than echocardiography or CT.  Whilst this may limit the applicability of the current results 
to specialist centres with CMR facilities, it has been demonstrated previously that 
echocardiography significantly underestimates CMR-derived LAV, in both healthy 
subjects and patients with cardiovascular disease258.  This is thought to be the result of 
poorer endocardial definition and less accurate delineation of pulmonary veins and atrial 
appendages 282.  CMR is already considered the ‘gold standard’ for evaluating the right 
ventricle in pulmonary hypertension, providing valuable information about right 
ventricular morphology and function109.  Left atrial volume assessment was performed by a 
single operator, however this technique has been shown to have low inter-observer and 
intra-observer variability. Echocardiographic assessment of left atrial size could potentially 
be useful in distinguishing IPAH from PH-HFpEF in non-specialist centres, however it 
should be noted that this could not be performed in 17% of patients in the current study.  
The findings of the current study suggest that LAV measured with CMR may be a useful 
method for distinguishing IPAH from PH-HFpEF, however given the small number of 
patients it not possible to assess the added value of CMR over clinical and 
echocardiographic data.   
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In the current study a prospective methodology (i.e. using previously established CMR cut-
offs to establish diagnosis and then confirming these using RHC) was not used.  This was 
due to the absence of an established ‘normal’ range for CMR left atrial volume in IPAH, 
and the relatively small number of patients in our retrospective pre-2008 analysis.  It is also 
important to acknowledge that in the current study the precise diagnosis was not fully 
established to current standards, with no standardized protocol for the use of fluid 
challenge or exercise during RHC, and no patients subsequently underwent measurement 
of LVEDP.  The importance of fully establishing diagnosis was highlighted in the recent 
AMBITION study investigating ERA and PDE-5 combination therapy versus 
monotherapy, where approximately 60% of the first 100 patients recruited to the study had 
a “left heart” profile (older age, AF, hypertension, diabetes) despite a PAWP <15mmHg283.  
This recognition of the high prevalence of risk factors for LV diastolic dysfunction resulted 
in a change to the eligibility criteria for the study, with the exclusion of patients with three 
or more risk factors for LV diastolic dysfunction, and a tightening of haemodynamic entry 
requirements.   
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3.5    Conclusions 
 
One of the most important diagnostic challenges for a pulmonary vascular centre is to 
distinguish IPAH from PH-HFpEF, particularly since the emergence of PAH-specific 
therapies.  This study has demonstrated that a single, noninvasive, CMR-derived variable, 
LAV of <43 ml/m2, can distinguish these two conditions with high sensitivity and 
specificity.  At present, a normal PAWP measured at RHC is currently used to distinguish 
IPAH from PH-HFpEF.  LAV measured by CMR correlates closely with PAWP, and 
future studies may help determine if it could be a suitable non-invasive alternative to 
cardiac catheterisation.    
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Chapter 4 
 
Changes in Right Ventricular Function Measured by 
Cardiac Magnetic Resonance Imaging in Patients Receiving 
Pulmonary Arterial Hypertension–Targeted Therapy 
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4.1   Introduction 
 
In Chapter 3 it was shown that left atrial volume measured by CMR could be used to 
distinguish idiopathic PAH from PH due to HFpEF, and therefore identify which patients 
would be suitable to receive disease-targeted PAH therapy.  In PAH, increased pressure in 
the pulmonary arteries overloads the right ventricle (RV), causing hypertrophy and 
eventually RV failure23, 284, 285.  Most measures that are known to predict survival in PH 
relate directly to RV function (right atrial pressure, cardiac index, TAPSE) or correlate 
with measures related to RV function (e.g. exercise capacity and functional class)1, 69, 230, 
231.  However, whilst the past two decades have seen the introduction of several treatments 
targeting the pathophysiological mechanisms of PAH, these agents have been approved 
largely based on improved haemodynamic variables or exercise capacity.  Consequently, 
disease progression and treatment efficacy have typically been assessed using 6MWD or 
RHC (in non-UK centres).  Recent interest in the RV and its response to change in 
afterload has raised the possibility that direct assessment of RV function may be a more 
appropriate way of determining response to therapy and monitoring disease progression38, 
286.
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4.1.1  Disease targeted PAH therapy and exercise capacity  
 
The 6MWT has been used as a primary outcome measure in many clinical trials of PAH 
therapy due to its simplicity, low cost and reproducibility.  In the pivotal trials of PAH 
monotherapy, absolute improvements in 6MWD have ranged from -10m to +108m, but 
have usually been around 30m to 45m (Table 4.1).  Clinical trials investigating the use of 
combination PAH therapy have noted less impressive improvements in placebo-adjusted 
6MWD, despite improvements in pulmonary haemodynamics and rates of clinical 
worsening287.  In the EARLY (Endothelin Antagonist tRial in mildLY symptomatic 
pulmonary arterial hypertension) trial, six months of bosentan treatment in WHO FC II 
patients had no significant effect on 6MWD despite reducing PVR and improving 
TTCW79.  A similar result has been demonstrated in patients with well preserved 6MWD 
(>450m) at diagnosis, in that disease targeted therapy improved functional class and 
cardiac index but 6MWD remained unchanged80.   
 
Pooled data from 10 randomized trials of PAH therapy (including 2404 patients) was used 
to investigate whether changes in 6MWD after 12 weeks of treatment could predict the 
relationship between treatment assignment (active vs placebo) and occurrence of a 
predefined clinical event (death, transplantation, hospitalization for worsening PAH, need 
for additional PAH therapy).  Whilst Delta 6MWD did meet the criteria for being a 
mediator of this relationship, the association was weak (22.1% of the treatment effect) and 
a large proportion of the treatment effect was not explained by changes in 6MWD288.  
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Table 4.1   Change in 6MWD in key PAH therapy trials 
 
Author Year Pts Active Drug Study 
Period 
Other 
Therapy 
Aetiology ∆6MWD 
Rubin289 1990 
 
23 Epoprostenol 
v  Controls 
8wks  IPAH +45m 
Barst271 1996 81 Epoprostenol 
v Controls 
12wks  IPAH +47m 
Badesch167 2000 111 Epoprostenol 
v Controls 
12wks  APAH +108m 
Channick151 2001 32 Bosentan v 
Placebo 
12wks  84% IPAH 
16% APAH 
+76m 
Simmoneau148 2002 470 Treprostinil v 
Placebo 
12wks  58% IPAH 
42% IPAH 
+16m 
Olschewski290 2002 203 Iloprost v 
Placebo 
12wks  50%  IPAH 
22% APAH 
28%  CTEPH 
+36m 
Rubin291 2002 213 Bosentan v 
Placebo 
16wks  70% IPAH 
30% APAH 
+44m 
Humbert292 2004 33 Bosentan vs 
Placebo 
16wks EPO IPAH 82% 
APAH 18% 
Epo & Bos 
+68m  
Epo & 
Placebo  
 +74m 
Galie272 2005 278 Sildenafil v 
Placebo 
12wks  IPAH 64% 
APAH 30% 
 
+45m 
Wilkins293 2005 26 Bosentan vs 
Sildenafil 
16wks  IPAH 88% 
APAH 12% 
Both 
increased 
by +59m 
McLaughlin294 2006 67 Inhaled 
Iloprost vs 
Placebo 
12wks EPO IPAH 55% 
APAH 45% 
+26m 
Hoeper295 2006 40 Inhaled 
Iloprost vs 
Placebo 
12wks Oral 
Bosentan 
IPAH -10m 
Galie296 2008 394 Ambrisentan 
vs Placebo 
12wks  IPAH 64% 
APAH 32% 
+45m 
Galie79 2008 185 Bosentan vs 
Placebo 
24wks  IPAH 61% 
APAH 35% 
+19m 
Simmoneau287 2008 267 Sildenafil vs 
Placebo 
16wks EPO IPAH 79% 
APAH 21% 
+29m 
 
EPO, epoprostenol; IPAH, idiopathic pulmonary arterial hypertension; APAH, associated 
pulmonary arterial hypertension; CTEPH, chronic thromboembolic pulmonary 
hypertension 
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4.1.2  Disease targeted PAH therapy and Survival 
 
Epoprostenol is the only treatment that has been shown to improve survival in IPAH in a 
randomised controlled trial271.  In this landmark study 81 IPAH patients in functional class 
III and IV were randomised to intravenous epoprostenol plus conventional therapy or 
conventional therapy alone. After 12 weeks, the epoprostenol treated group had improved 
quality of life scores, improved functional class, increased 6MWD and improved 
haemodynamic parameters compared with the conventional group. Eight patients died 
during the 12 weeks study period, all of whom had been in the conventional therapy group.  
Based on this result intravenous epoprostenol is recommended as the first-line therapy for 
WHO FC IV PAH patients, and is used as a “rescue” therapy in the deteriorating patient232.  
However, subsequent randomised placebo-controlled trials using mortality as an endpoint 
could no longer ethically be performed.   
 
The impact of disease-targeted PAH therapy on survival has been investigated by means of 
meta-analysis.  The meta-analysis of the 3 epoprostenol randomised controlled trials 
showed a relative risk reduction in mortality of 68-70%167, 271, 289.   In their meta-analysis 
of 23 randomised controlled trials of all classes of PAH therapy involving 3199 patients, 
Galie et al demonstrated that treatment with disease targeted therapies (after an average 
treatment period of 14.3 weeks) improved survival in PAH, with 43% reduction in 
mortality and 61% reduction in hospital stays297.   
 
Improved survival of PAH in the disease-targeted therapy era has also been demonstrated 
by comparing survival in the current era with that of historical controls.  The NIH 
(National Institute of Health) registry was a multicentre, prospective registry from the pre-
treatment era where 194 patients in the United States with the diagnosis of primary 
pulmonary hypertension were enrolled from between 1981 and 1985 and followed through 
to 198854.   The median survival was 2.8 years after diagnosis, with estimated 1-, 3- and 5- 
year survival rates were 68%, 48% and 34% respectively1.  The recent REVEAL (Registry 
to Evaluate Early and Long-term PAH Disease Management) registry from the United 
States has demonstrated improved 1-, 3- and 5-year survival rates of 91%, 74% and 65% in 
the 1166 patients with idiopathic and heritable PAH298.  Whilst the NIH and REVEAL 
registries included both incident and prevalent patients, in the UK study of a purely 
incident, treatment-naive cohort of idiopathic, heritable, and anorexigen-associated PAH, 
patients diagnosed in 2001-2003 were more likely to have a shorter survival time 
compared with patients diagnosed in 2007–2009 (p =0.019)185.  Survival in PAH 
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associated with systemic sclerosis has also improved in the disease-targeted therapy era, 
with one- and three- year survival rates now of 78 and 47%, compared with one year 
survival of 45% in a historical cohort299, 300.   
 
The experiment in this chapter tested the hypothesis that direct assessment of RV function 
using CMR would be an appropriate way of determining response to therapy and 
monitoring disease progression in PAH. 
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4.2   Methods 
 
4.2.1  Patients 
 
As part of the EU Framework 6 “Pulmotension” initiative, the prospective, longitudinal 
European Magnetic Resonance Imaging Study in PAH (EURO-MR) study was conducted 
in 4 European centres: Scottish Pulmonary Vascular Unit, Glasgow, United Kingdom; 
Medical University Graz, Graz, Austria; Sapienza University of Rome, Rome, Italy; and 
Department of Pulmonary Medicine, VU University Medical Center, Amsterdam, The 
Netherlands. 
 
Between June 2003 and May 2010, patients with suspected PH were referred to their local 
PH centre for evaluation.  Patients underwent clinical assessment, including New York 
Heart Association (NYHA) FC, RHC, 6MWD, and CMR, as described in Chapter 2.2 
 
PH was diagnosed and classified according to current guidelines2 and, if appropriate, 
disease-targeted therapy was initiated4.  The initial therapy used was left to the discretion 
of the local PH physician. The 12-month follow-up evaluation assessment included 6MWD 
and CMR.  Patients from the Glasgow centre also had a planned assessment (6MWD and 
CMR) after 4 months of treatment. 
 
Patients in World Health Organization (WHO) group 1, WHO group 3, or WHO group 4, 
if ineligible for surgery, were included in the study.  
 
Patients excluded from the analysis included: 
• those unable to attend or who declined follow-up evaluation 
• those who were not commenced on disease-targeted therapy after initial 
evaluation 
• those with no evidence of PH at RHC  
• those with PH associated with left heart disease (WHO group 2) 
• those previously treated with disease-targeted therapy. 
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4.2.2   CMR Assessment 
 
CMR was performed locally using a 1.5-T MRI scanner (Sonata Magnetom, Siemens; 
Erlangen, Germany) using the protocol described in Chapter 2.2.3. Individual scans from 
Graz, Rome and Amsterdam were coded by number and transferred to Glasgow for 
analysis.  All scans were read in a blinded fashion by one of three observers (Dr Kevin 
Blyth, Dr Lindsey McLure, Dr Stephen Crawley) on a single MR work station using Argus 
analysis software.   
 
Reproducibility and reliability of the CMR analysis were assessed by calculating the 
interobserver and intraobserver variability (presented as the mean bias and the 95% limits 
of agreement between two estimations) for the LV and RV measurements. In these 
retrospective calculations, 24 and 10 Glasgow CMR examinations were randomly selected 
to determine interobserver variability and intraobserver variability, respectively. For 
interobserver variability, CMR images were analysed by one observer (K.G.B or L.McL) 
and then reanalysed by another observer (S.F.C) who was blinded to the initial results.  For 
intraobserver variability, scans were reanalyzed by the same observer, blinded to the initial 
results. 
 
 
4.2.3   Statistical Analysis 
 
For all variables, a normal distribution was verified using histograms and  Kolmogorov–
Smirnov tests.  For demographic, haemodynamic, and CMR variables, mean ± SD were 
calculated.  For the entire cohort, comparison between baseline and 12-month follow-up 
was performed using the paired t test.  A repeated measure 1-way ANOVA was used to 
compare the mean values in the smaller Glasgow subgroup.  Variability analyses were 
compared using Bland–Altman analysis and t tests.  The correlation between the change in 
CMRI variables and 6MWD as determined by Pearson correlation was also conducted.  A 
p value < 0.05 was defined as statistically significant. 
 
All calculations were performed using GRAPHPAD Prism (Version 5.00; GraphPad 
Software Inc; La Jolla, CA). 
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4.3   Results 
 
4.3.1  Clinical characteristics 
 
91 patients underwent assessment at baseline and after 12 months of disease-targeted 
therapy (Glasgow: 35; Amsterdam: 26; Rome: 17; and Graz: 13).  Baseline characteristics 
for the entire cohort and by study centre are summarized in Table 4.2.  The majority of 
patients were in WHO group 1, with idiopathic PAH and CTD-PAH the most common 
types.  There were twice as many female patients as male patients, and the mean age at 
diagnosis was fifty-two years.  Patients from the Glasgow subgroup had the poorest NYHA 
functional class and lowest 6MWD, with patients from the Rome subgroup having the best 
FC and 6MWD.   
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Table 4.2   Clinical characteristics for the study cohort 
 
 
Total Cohort 
(n=91) 
Glasgow  
(n=35) 
Amsterdam 
(n=26) 
Rome  
(n=17) 
Graz  
(n=13) 
Age, yrs 52 ± 16 53 ± 16 46 ± 15 51 ± 15 61 ± 12 
♀ : ♂ 60 : 31 23 : 12 21 : 5 11 : 6 5 : 8 
Body surface 
area, m2 1.82 ± 0.23 1.80 ± 0.24 1.86 ± 0.25 1.78 ± 0.19 1.82 ± 0.22 
Causes of PH, n (%) 
WHO group 1  
IPAH   42 (46.2) 16 (45.7) 10 (38.5) 12 (70.6) 4 (30.8) 
PAH-CTD   15 (16.5) 5 (14.3) 7 (26.9) 1 (5.9) 2 (15.4) 
PAH-CHD   4 (4.4) 1 (2.9) 2 (7.7) 0 1 (7.7) 
Porto-
pulmonary   4 (4.4) 2 (5.7) 0 0 2 (15.4) 
Other  ‡ 6 (6.6) 0 4 (15.4) 1 (5.9) 1 (7.7) 
WHO group 3  
PH because 
of hypoxic 
lung disease   5 (5.5) 3 (8.6) 0 1 (5.9) 1 (7.7) 
WHO group 4  
CTEPH   15 (16.5) 8 (22.9) 3 (11.5) 2 (11.8) 2 (15.4) 
 
NYHA functional class, n (%) 
I  2 (2.2) 0 0 0 2 (15.4) 
II  37 (40.7) 11 (31.4) 12 (46.2) 11 (64.7) 3 (23.1) 
III  48 (52.7) 23 (65.7) 13 (50.0) 6 (35.9) 6 (46.2) 
IV  4 (4.4) 1 (2.9) 1 (3.8) 0 2 (15.4) 
Baseline 
6MWD, m 381 ± 127 316 ± 89 441 ± 140 461 ± 105 362 ± 126 
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6MWD indicates 6-minute walk distance; CTEPH, chronic thromboembolic pulmonary 
hypertension; IPAH, idiopathic PAH; NYHA, New York Heart Association; PAH, 
pulmonary arterial hypertension; PAH-CHD, PAH associated with congenital heart 
disease; PAH-CTD, PAH associated with connective tissue disease; PAP, pulmonary 
artery pressure; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; and 
WHO, World Health Organization 
 
‡ PAH associated with HIV infection (n=1), heritable PAH (n=3), and drug and toxin-
induced PAH (n=2). 
 
All data expressed as mean ± SD.   
 
 
 
Baseline characteristics for the Group 1 PAH subgroup (n = 71) were: 
Age (49 ±15yrs), 52 Female and 19 Male, Body Surface Area (1.80 ± 0.24 m2).   
 
Within this subgroup most patients were in NYHA functional class II or III  
(Fc I = 2pts; Fc II = 26pts;  Fc III = 41pts; Fc IV = 2pts) 
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4.3.2  Pulmonary Haemodynamics 
 
Baseline right heart catheterisation data for the study group is displayed in Table 4.3.  
These demonstrate significant pulmonary hypertension at the onset of disease-targeted 
therapy, with elevated mPAP and PVR and reduced cardiac index.  Patients from the 
Glasgow subgroup had the most severe pulmonary haemodynamics, with those from the 
Graz subgroup having the least severe.  
 
Table 4.3   Baseline pulmonary haemodynamics for the study cohort 
 
Baseline 
haemodynamics, 
mean ± SD 
Total cohort 
(n = 91) 
Glasgow 
(n = 35) 
Amsterdam 
(n = 26) 
Rome 
(n = 17) 
Graz 
(n = 13) 
Mean PAP, mmHg 46 ± 15 47 ± 14 49 ± 16 44 ± 16 38 ± 10 
PVR, Wood Units 10.0 ± 6.3 11.2 ± 5.3 10.6 ± 8.2 9.4 ± 5.9 6.3 ± 3.4 
Cardiac Index, 
L/min/m2 2.4 ± 0.9 2.1 ± 0.5 2.7 ± 1.0 2.3 ± 0.6 2.9 ± 1.2 
 
 
Pulmonary haemodynamics for the PAH subgroup (n = 71) were mean PAP (46 ± 15 
mmHg), PVR (10.0 ± 6.7 Wood Units) and Cardiac Index (2.5 ± 0.9 L/min/m2).  
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4.3.3  Pulmonary Arterial Hypertension Therapy and Clinical Outcome 
 
Medical therapy initiated at baseline within each centre is displayed in Table 4.4.  
Endothelin receptor antagonist monotherapy was the most frequently used treatment, with 
phosphodiesterase type-5 inhibitor the next most commonly used therapy.  Upfront 
combination therapy was not used in the Glasgow centre, but was used in three patients in 
each of the other three centres.   
 
Table 4.4   Initial PAH therapy for study patients 
 
Initial medication, n (%) 
Total 
(n = 91) 
Glasgow 
(n = 35) 
Amsterdam 
(n = 26) 
Rome 
(n = 17) 
Graz 
(n = 13) 
Endothelin receptor 
antagonist 43 (47.3) 16 (45.7) 17 (65.4) 7 (41.2) 3 (23.1) 
Phosphodiesterase 
 type-5 inhibitor 23 (25.3) 16 (45.7) 1 (3.8) 4 (23.5) 2 (15.4) 
Combination therapy 9 (9.9) 0 3 (11.5) 3 (17.6) 3 (23.1) 
Calcium channel blocker 5 (5.5) 1 (2.9) 0 3 (17.6) 1 (7.7) 
Prostanoid 5 (5.5) 1 (2.9) 3 (11.5) 0 1 (7.7) 
Unknown 6 (6.6) 1 (2.9) 2 (7.7) 0 3 (23.1) 
 
 
Within the Group 1 PAH subgroup (n = 71), the initial treatment was endothelin receptor 
anatagonist (34 pts), phosphodiesterase type-5 inhibitor (16 pts), combination therapy (8 
pts), calcium channel blocker (4 pts), prostanoid (5 pts) and unknown in four patients.   
 
There was a significant increase in 6MWD after 12 months of disease-targeted therapy 
(381 ± 127 m at baseline, 443 ± 124 m at month 12; p<0.0001).  
 
At the 12-month follow-up, 5, 46, 36, and 4 patients were in NYHA FC I, II, III, and IV, 
respectively. Functional class had improved in 21 patients, was unchanged in 63 patients, 
and deteriorated in 7 patients. 
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4.3.4   CMR Assessment 
 
CMR characteristics at baseline and after 12 months of disease-targeted therapy in the 
whole group (n=91) are displayed in Table 4.5.  As expected, at baseline there was right 
ventricular dilatation (increased RVEDVI) and hypertrophy (increased RV mass index and 
VMI), impaired right ventricular systolic function with low stroke volume index and poor 
filling of the left ventricle (low LVEDVI).  Left ventricular systolic function was normal.   
 
Table 4.5.   CMR Results for the whole study cohort 
 
CMR Variable 
Baseline  
(n = 91) 
12 months  
(n = 91) Mean Change P Value 
Right ventricle 
EDV index, ml/m2 84 ± 26 86 ± 29 3 ± 19 0.22 
Stroke volume index, ml/m2 31 ± 8 36 ± 9 5 ± 11 <0.0001 
Cardiac index, L/min/m2 2.29 ± 0.63 2.62 ± 0.66 0.33 ± 0.72 <0.0001 
Ejection fraction, % 41 ± 16 45 ± 15 5 ± 11 <0.0001 
Mass index, g/m2 52 ± 21 52 ± 19 0.4 ± 10.1 0.68 
Left ventricle 
EDV index, ml/m2 48 ± 13 53 ± 14 4 ± 12 0.0015 
Stroke volume index, ml/m2 32 ± 10 37 ± 10 4 ± 11 0.0002 
Cardiac index, L/min/m2 2.36 ± 0.63 2.66 ± 0.67 0.30 ± 0.68 <0.0001 
Ejection fraction, % 67 ± 12 70 ± 10 4 ± 10 0.0007 
Mass index, g/m2 50 ± 12 52 ± 13 1 ± 7 0.11 
Ventricular mass index 1.04 ± 0.37 1.03 ± 0.36 −0.01 ± 0.2 0.97 
 
All data expressed as mean ± SD.  EDV, end-diastolic volume. 
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After 12 months of therapy, there were significant increases in right ventricular function, 
whether measured by RV ejection fraction (40.5 ± 16.0% at baseline, 45.2 ± 14.7% at 
month 12; p<0.0001) or RV stroke volume index (31.0 ± 8.4 ml/m2 at baseline, 35.9 ± 9.3 
ml/m2 at month 12; p<0.0001). Significant improvements were also noted in LVEDV 
index (48.4 ± 12.9 ml/m2 at baseline, 52.5 ± 14.1 ml/m2 at month 12; p=0.0015) and LV 
ejection fraction (66.7 ± 11.7% at baseline, 70.3 ± 9.8% at month 12; P=0.0007).  Overall, 
there was no improvement or deterioration in the degree of RV dilatation (RVEDV index) 
or RV hypertrophy (ventricular mass index). 
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4.3.4.1  CMR Assessment in Group 1 Pulmonary Arterial Hypertension 
 
CMR characteristics at baseline and after 12 months of disease-targeted therapy in the 
WHO Group 1 PAH group (n=71) are displayed in Table 4.6.  Improvements in RV 
ejection fraction and stroke volume index, LV end-diastolic volume index and LV ejection 
fraction were again observed.   
 
Table 4.6.   CMR Results in Group 1 PAH Only 
 
CMR Variable 
Baseline 
(n=71) 
12 months 
(n=71) 
Mean 
Change P Value 
Right ventricle 
EDV index, ml/m2 83 ± 27 84 ± 27 1 ± 17 0.58 
Stroke volume index, 
ml/m2 31 ± 9 36 ± 9 4 ± 10 0.0006 
Cardiac index, 
L/min/m2 2.35 ± 0.65 2.63 ± 0.65 0.29 ± 0.68 0.0008 
Ejection fraction, % 41 ± 16 46 ± 14 5 ± 13 0.0016 
Mass index, g/m2 51 ± 21 51 ± 20 -0.2 ± 9 0.82 
Left ventricle 
EDV index, ml/m2 48 ± 13 52 ± 15 4 ± 12 0.0034 
Stroke volume index, 
ml/m2 32 ± 10 37 ± 11 4 ± 11 0.0011 
Cardiac index, 
L/min/m2 2.39 ± 0.63 2.68 ± 0.68 0.29 ± 0.66 0.0004 
Ejection fraction, % 68 ± 11 71 ± 10 3 ± 9 0.0037 
Mass index, g/m2 50 ± 13 51 ± 13 1 ± 6 0.17 
Ventricular mass index 1.05 ± 0.38 1.03 ± 0.38 −0.02 ± 0.2 0.85 
 
All data expressed as mean ± SD.  EDV, end-diastolic volume. 
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4.3.4.2  CMR Assessment by PH Treatment  
 
Patients were stratified by initial PAH therapy, with CMR characteristics at baseline and 
after 12 months of endothelin receptor antagonist (Table 4.7) or phosphodiesterase type-5 
inhibitor (Table 4.8) therapy are displayed below.   
 
 
Table 4.7.  CMR Results for patients receiving Endothelin Receptor Antagonist as 
initial therapy 
 
CMR Variable 
Baseline  
(n = 43) 
12 months  
(n = 43) Mean Change P Value 
Right ventricle 
EDV index, ml/m2 80 ± 26 83 ± 29 2.7 ± 18.9 0.36 
Stroke volume index, ml/m2 32 ± 7 37 ± 10 5.4 ± 9.8 0.001 
Cardiac index, L/min/m2 2.3 ± 0.6 2.7 ± 0.7 0.4 ± 0.7 0.0018 
Ejection fraction, % 43 ± 15 48 ± 14 4.9 ± 10.2 0.0035 
Mass index, g/m2 50 ± 25 49 ± 21 -1.1 ± 11.6 0.53 
Left ventricle 
EDV index, mL/m2 48 ± 12 53 ± 15 4.7 ± 10.2 0.0043 
Stroke volume index, mL/m2 32 ± 10 37 ± 10 4.7 ± 8.6 0.0002 
Cardiac index, L/min/m2 2.3 ± 0.5 2.7 ± 0.6 0.34 ± 0.53 0.0001 
Ejection fraction, % 68 ± 9 72 ± 8 3.4 ± 7.9 0.0067 
Mass index, g/m2 50 ± 11 51 ± 12 0.9 ± 6.5 0.73 
 
All data expressed as mean ± SD.  EDV, end-diastolic volume. 
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Table 4.8.  CMR Results for patients receiving Phosphodiesterase type-5 Inhibitor  
as initial therapy 
 
CMR Variable 
Baseline 
(n=23) 
12 months 
(n=23) 
Mean 
Change P Value 
Right ventricle 
EDV index, ml/m2 89 ± 28 96 ± 31 6.4 ± 16.7 0.08 
Stroke volume index, ml/m2 27 ± 9 35 ± 5 7.1 ± 8.8 0.0008 
Cardiac index, L/min/m2 2.1 ± 0.6 2.6 ± 0.6 0.5 ± 0.6 0.0007 
Ejection fraction, % 35 ± 17 41 ± 16 6.2 ± 10.1 0.0077 
Mass index, g/m2 55 ± 19 58 ± 21 3.4 ± 9.4 0.10 
Left ventricle 
EDV index, ml/m2 45 ± 12 52 ± 9 7.0 ± 9.4 0.0017 
Stroke volume index, ml/m2 28 ± 11 36 ± 8 7.8 ± 9.0 0.0004 
Cardiac index, L/min/m2 2.1 ± 0.7 2.7 ± 0.7 0.6 ± 0.7 0.0008 
Ejection fraction, % 61 ± 15 69 ± 11 7.7 ± 12.6 0.0079 
Mass index, g/m2 48 ± 8 51 ± 10 3.3 ± 8.5 0.08 
 
All data expressed as mean ± SD.  EDV, end-diastolic volume. 
 
Treatment with endothelin receptor antagonist therapy and phosphodiesterase type-5 
therapy were both associated with improvements in right ventricular ejection fraction and 
stroke volume index, as well as improvements in left ventricular end-diastolic volume and 
ejection fraction.  Neither therapy was associated with changes in the extent of right 
ventricular dilatation and hypertrophy.  Direct comparison of the effectiveness of the two 
treatments was not performed.   
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4.3.4.3  CMR Assessment in the Glasgow subgroup  
 
An additional clinical and CMR assessment was performed after 4 months of disease-
targeted therapy in 27 of the 35 patients from Glasgow.  CMR data for these patients are 
presented in Table 4.9 
 
Table 4.9.   CMR Results at baseline, 4 and 12 months for the Glasgow subgroup 
 
 Baseline 4/12 Change 
(0 to 4/12) 
12/12 Change 
(0 to 12/12) 
P value 
Right 
Ventricle 
      
EDV Index, 
ml/m2 
88 ± 24 88± 24 -1 ± 13 90 ± 27 2 ± 19 0.61 
SV Index, 
ml/m2 
27 ± 8 35± 11 7 ± 9 36 ± 8 9 ± 9 <0.0001 
Cardiac Index 2.00 ± 
0.41 
2.43 ± 
0.7 
0.43 ± 
0.67 
2.58 ± 
0.51 
0.59 ± 
0.68 
0.0002 
Ejection 
Fraction, (%) 
34 ± 17 42± 15 8 ± 9 43 ± 15 9 ± 11 <0.0001 
Mass Index, 
g/m2 
60 ± 22 57± 22 -3 ± 8 58 ± 21 -2 ± 13 0.28 
Left  
Ventricle 
      
EDV Index, 
ml/m2 
45 ± 11 54± 15 8 ± 11 53 ± 13 8 ± 10 <0.0001 
SV Index, 
ml/m2 
28 ± 9 37± 10 9 ± 8 37 ± 10 9 ± 9 <0.0001 
Cardiac Index 2.04 ± 
0.48 
2.58 ± 
0.68 
0.54 ± 
0.61 
2.62 ± 
0.59 
0.58 ± 
0.64 
<0.0001 
Ejection 
Fraction (%) 
61 ± 13 69 ± 7 7 ± 11 69 ± 11 8 ± 11 0.0004 
Mass Index, 
g/m2 
52 ± 9 53 ± 6 1 ± 6 54 ± 11 2 ± 8 0.47 
VMI 1.2 ± 0.4 1.1 ± 
0.4 
-0.1 ± 
0.2 
1.1 ± 
0.4 
-0.1 ± 0.3 0.16 
 
All data are expressed as mean ± SD.  P-value refers to comparison from 1-way ANOVA. 
CMR indicates cardiac MRI; EDV, end-diastolic volume; SV, stroke volume; VMI, 
ventricular mass index 
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Within this subgroup, 6MWD increased throughout the study, and there were early 
improvements in RV ejection fraction and stroke volume index after four months of 
treatment, that were preserved at 12 months (Figure 4.1 A-C).  There was no overall 
improvement or deterioration in RV hypertrophy or RV dilatation.   
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Figure 4.1   Changes in 6MWD, RV ejection fraction and RV stroke volume index  
  after four and twelve months of disease-targeted PAH therapy  
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Change in 6-minute walk distance (6MWD; A); right ventricular (RV) ejection fraction 
(B); and RV stroke volume index (C) after 4 months and 12 months of disease-targeted 
therapy in the Glasgow cohort.  Improvements occurred after 4 months of treatment and 
were preserved at 12 months.   
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4.3.4.4  Association of CMR Variables With 6MWD 
 
Significant correlations were observed between change in 6MWD and change in RV 
ejection fraction (r = 0.28, p = 0.01), and between change in 6MWD and % change in LV 
end-diastolic volume (r = 0.26, p = 0.02), although correlation coefficients were low 
(Figure 4.2).  There was no significant correlation between change in 6MWD and changes 
in right ventricular stroke volume (p = 0.054) or cardiac output (p = 0.08).   
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Figure 4.2 Correlation between changes in CMR variables and ∆6MWD  
 
 
 
 
 
 
Pearson correlation between the absolute change in right ventricular ejection fraction 
(RVEF; A); and the % change in left ventricular end-diastolic volume (LVEDV; B) with 
change in 6MWD, for the whole study cohort.  
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4.3.4.5   Interobserver and Intraobserver variability of CMR variables 
 
Analysis of interobserver variability in a subgroup of 24 patients from the Glasgow centre 
demonstrated lower interobserver variability for left ventricular measurements than for 
those in the right ventricle. (Table 4.10)   
 
Table 4.10   Inter-observer variability of CMR measurements 
 
 Mean Bias 95% Limits of 
Agreement 
LV ejection fraction (%) -1.7 -16.2 to 12.3 
LV end-diastolic volume 
(ml) 
1.2 -17.4 to 19.7 
LV stroke volume (ml) -0.3 -14.3 to 13.6 
LV mass (g) -8.2 -42.8 to 26.5 
   
RV ejection fraction (%) 0.8 -9.4 to 11.0 
RV end-diastolic 
volume (ml) 
-11.6 -45.0 to 22.0 
RV stroke volume (ml) -4.2 -15.0 to 6.6 
RV mass (g) 13.7 -14.0 to 41.3 
 
Note that measures of end-diastolic volume, stroke volume and mass are not indexed 
for body surface index. LV, left ventricular; RV, right ventricular. 
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Intra-observer variability data was assessed in 10 patients at the Glasgow centre selected at 
random. Scans were reanalysed blinded to the initial results.  Intra-observer variability was 
low for volume measurements (EDV, stroke volume, and EF) but higher for mass 
measurements. (Table 4.11) 
 
Table 4.11 Intra-observer variability of CMR measurements 
 
 Mean Bias 95% Limits of 
Agreement 
LV ejection fraction (%) -1.2 -6.5 to 4.2 
LV end-diastolic volume 
(ml) 
-0.2 -3.6 to 3.3 
LV stroke volume (ml) -1.3 -6.5 to 3.8 
LV mass (g) -5.4 -15.0 to 4.1 
   
RV ejection fraction (%) -0.8 -6.7 to 5.0 
RV end-diastolic 
volume (ml) 
-0.1 -12.2 to 12.4 
RV stroke volume (ml) -1.2 -7.0 to 4.5 
RV mass (g) 6.7 -13.3 to 26.6 
 
Note that measures of end-diastolic volume, stroke volume and mass are not indexed 
for body surface index. LV, left ventricular; RV, right ventricular. 
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4.4   Discussion 
 
The current study prospectively assessed the use of CMR before and during PAH disease-
targeted therapy.  It has demonstrated that both left-sided and right-sided variables should 
be included when assessing cardiac function in patients with precapillary PH.  Stroke 
volume index, cardiac index, and ejection fraction were associated with response when 
measured in either the left or the right heart, and LVEDV index was also associated with 
therapeutic response.  In the past, it has been suggested that the initial benefits achieved 
with some disease-targeted therapies are not maintained during long-term treatment301; 
however, the data from the Glasgow subgroup demonstrates that the improvement in stroke 
volume index, cardiac index, and ejection fraction at four months was still present at 
twelve months. 
 
The results of the current study support the data from prior trials studying changes in 
CMR-derived RV variables during treatment for PH.  There has been only one major 
clinical trial of PAH therapy that has used right ventricular function as a pre-specified 
primary or secondary endpoint.  In the Sildenafil versus endothelin receptor antagonist for 
pulmonary hypertension (SERAPH) study, 26 patients with IPAH or CTD-PAH and WHO 
Fc III, were randomized to sildenafil (50 mg twice daily for 4 weeks, then 50 mg three 
times daily) or bosentan (62.5 mg twice daily for 4 weeks, then 125 mg twice daily) over 
16 weeks.  Patients on sildenafil who completed the protocol revealed a significant 
reduction in RV mass (as measured by CMR) (p = 0.015) compared with baseline, whereas 
there was no reduction observed in the Bosentan treated patients293.  Retrospective review 
of twelve patients from the Ambrisentan in Pulmonary Arterial Hypertension: A Phase 3, 
Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy Study (ARIES-1) 
clinical trial and extension phase reported that two years of ambrisentan therapy resulted in 
an increased right ventricular ejection fraction at CMR, but no improvement in RV end-
diastolic volume index or RV mass302.   
 
 
Some single-centre studies have prospectively examined the effect of PAH therapy on right 
ventricular structure and function.   Twelve months of intravenous Epoprostenol was found 
to improve right ventricular stroke volume at CMR in a small cohort of eleven patients, 
although there was neither progression nor regression of RV hypertrophy and dilatation115.  
In fifteen patients with PAH already receiving bosentan, the addition of Sildenafil for three 
months resulted in right ventricular reverse remodelling, with a decrease in the RV 
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dilatation and hypertrophy that had progressed whilst on bosentan monotherapy303.  
Similarly, in twenty patients with PAH who were clinically worsening despite prostanoid 
therapy, the addition of Sildenafil resulted in a reduction in right ventricular end-diastolic 
diameter at echocardiography304.  
 
Lee et al used non-invasive IGR haemodynamic measurements (stroke volume and 
pulmonary blood flow) to detect a treatment response in patients with precapillary PH 
receiving de novo or modified disease-targeted therapy, and found that these measurements 
may be more responsive to change than 6MWD in fitter patients305.  Serial measurement of 
B-type natriuretic peptide (BNP) was performed in approximately 50% of the patients 
enrolled in the aforementioned ARIES-1 study of ambrisentan therapy296.  In the placebo 
group BNP concentrations increased slightly from baseline, whereas active treatment was 
associated with a reduction in BNP in 30% of patients in the 5mg/day group and 45% of 
patients in the 10mg/day group.  NT-ProBNP measurement was performed in 136 of the 
185 patients in the EARLY study of bosentan therapy in NYHA FC II patients, with a 
reduction in NT-ProBNP observed in the bosentan group compared with the placebo group 
(mean treatment effect -471 ng/L, p = 0.0003) that corresponded to the improvements 
observed in pulmonary haemodynamics79.   
 
The prognostic significance of changes in RV function after PAH therapy have also been 
investigated.  In sixteen patients with PAH evaluated at baseline and after 12 months of 
bosentan, treatment resulted in improvements in cardiac index, pulmonary vascular 
resistance, and 6MWD, with a trend toward improvement in RV stroke volume (70 +/- 27 
to 81 +/- 30 ml; p = 0.08), but no change in RV ejection fraction (RVEF) or RV end-
diastolic volume.  However, 6MWD improved more in patients in whom RVEF increased 
compared with those with stable or decreased RVEF (+98m vs -37m; p = 0.01)306.   A large 
cohort of 76 newly diagnosed PAH patients were evaluated at baseline and after 12 months 
of therapy (34% endothelin antagonists, 13% PDE-5 inhibitor, 11% prostacyclin, 41% 
combination therapy)307.  Overall, despite improvements in PVR and cardiac index, PAH 
therapy did not improve 6MWD (421m v 425m; p = 0.73), or CMR measurements of right 
ventricular structure and function.  However, at survival analysis RVEF measured at 
baseline was a better predictor of mortality than PVR, and that changes in RVEF after 12 
months predicted long-term outcome, whereas changes in PVR did not.  In 25% of patients 
with a reduced PVR after treatment, there was deterioration in RV function and this was 
associated with a poor prognosis.  Further analysis of the same cohort of patients was 
performed to identify the minimal important difference (MID) in stroke volume at CMR 
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that would constitute a clinically significant change.  A 10ml change in stroke volume 
following PAH therapy was found to be clinically relevant, and changes in stroke volume 
correlated with changes in 6MWD119.   
 
The multi-centre nature of the current study provided the opportunity to study the 
consistency of the CMR findings in several subanalyses.  Although the number of patients 
in each centre was small and the analysis was not powered for comparison, at the majority 
of centres, there was a trend toward improvement or at least no deterioration in the CMR 
variables significantly associated with therapeutic response in the main analysis.  
Similarly, when stratified for initial PAH therapy the same variables were identified, and 
despite the small study size, statistical significance was achieved. These findings support 
the wider applicability of CMR for the follow-up patients with PH on disease-targeted 
therapy. 
 
In this analysis, identification of patients suitable for therapy, and initial therapy used, was 
at the discretion of the responsible physician, although all units will have followed 
recognized national and international guidelines2, 236.  This suggests that the results 
obtained reflect real clinical practice, and that the findings are likely to be pertinent for 
other treatment centres, and may also provide insight into different treating practices. 
However, differences between treatments cannot be determined because the study was not 
designed to collect data on changes in therapy during the study duration.  The consistency 
of the findings when stratified by baseline PAH-specific therapy suggests that although 
acting via different pathways, the net effect of these treatments on pulmonary vasculature 
and RV function may be similar. 
 
Whilst it is well established that RV function is associated with outcome in PAH, some left 
heart variables are known to better correlate with overall cardiac function than RV 
function.  LV end-diastolic volume is more closely related to stroke volume than 
RVEDV42, and data from echocardiography studies have demonstrated that diastolic 
eccentricity index, which include LV size, is closely associated with outcome in PAH72.  
Several groups have also demonstrated that poor LV output in PH is related to poor filling 
of the LV117.  This underfilling of the LV, a consequence of poor filling on the left side 
because of prolonged RV contraction time41, contributes to decreased SV42.  For this 
reason, it is likely that LVEDV may be a particularly important variable because it reflects 
both SV and increased RV contraction time, and highlights the importance of LV volume 
measurements in patients with PH.   
145 
There are several limitations of the current study.  It is not possible to provide information 
on patients who underwent initial CMR but were then unable to attend for subsequent 
CMR imaging due to patient preference, geographical limitations, illness or death, and 
clearly this could lead to a ‘survivor’ bias within the results obtained.  Similarly, the 
overall PH population from which the study cohort was drawn could not be determined in 
detail, so it is not possible to assess if there was any bias in study entry. In this study a 
heterogeneous population of patients with PH were enrolled, and, unlike previous studies, 
it was not restricted to patients with PAH. Although disease-specific therapy is only 
recommended in management guidelines for PAH2, in clinical practice, these treatments 
are also often used in WHO groups 3, 4, and 5.  The multi-centre nature of the study meant 
that it was not possible to obtain information on changes to PAH therapy that may have 
occurred during the study period.  It would have been valuable to determine the 
relationship between the CMR variables and patient outcome, however outcome data were 
not collected in this study, and retrospective analysis was therefore not feasible.  Another 
limitation of the current study is that inter-observer and intra-observer reproducibility were 
assessed via reanalysis of the same pre-derived images, rather than an alternative method 
such as ‘test-retest’, potentially leading to an overestimation of CMR reproducibility.   
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4.5   Conclusions 
 
The study in this chapter has demonstrated that disease-targeted PAH therapy improves 
right ventricular function, as measured by CMR.  Improvement in RV function occurs 
early, within 4 months of treatment, and is preserved at 12 months.  On-treatment changes 
in CMR variables from the left and right sides of the heart reflect changes in functional 
class and exercise capacity, and the robust and non-invasive nature of CMR imaging 
means that it has potential to be a useful indicator of therapeutic response in future trials of 
PH therapy.   
 
147 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
 
Prognostic value of cardiac dysfunction  
in IPAH and CTD-PAH 
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5.1   Introduction 
 
In Chapter 4 it was shown that direct measurement of right ventricular function with CMR 
could be use to assess the benefit of disease-targeted therapy in patients with PAH, 
including PAH due to connective tissue disease (CTD-PAH).  PAH is a well recognized 
complication of connective tissue diseases, most commonly systemic sclerosis (SSc)299.   
Estimates of SSc-PAH prevalence range from 10% to 12% depending on the diagnostic 
modality used308, 309.  Following the development of angiotensin-converting enzyme 
therapy to treat renal crises, PAH is now one of the leading causes of morbidity and 
mortality in SSc310.  Therefore, patients with SSc typically undergo annual screening for 
pulmonary hypertension with transthoracic echocardiogram, and are referred for diagnostic 
RHC if they have an elevated TR jet velocity / PASP estimate or unexplained dyspnoea311.  
In the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma 
(PHAROS) cohort study, 251 “at-risk” SSc patients were prospectively followed for 2.5 
+/- 1.2 years (“at risk” = echo SPAP >40 mmHg, TLCO <55% predicted, or % FVC : 
%TLCO > 1.6)312.  A low TLCO, high FVC:TLCO, and entry echo SPAP > 40 mmHg  
were strongly associated with future pulmonary hypertension at cardiac catheterisation, 
however of the 35 new PH patients, 22 had PAH, 10 had pulmonary venous hypertension, 
and 3 had pulmonary hypertension due to interstitial lung disease (WHO group 3).  The 
symptoms associated with SSc-PAH are similar to those observed in IPAH (dyspnoea, 
fatigue, syncope, and chest pain), however patients may have minimal or no dyspnoea at 
diagnosis313, and can instead attribute their deteriorating functional status to their 
longstanding SSc.  This can be further complicated by the high prevalence of coexisting 
musculoskeletal involvement314, which can also limit the utility of the 6MWT and 
cardiopulmonary exercise test during diagnostic assessment315.  As discussed in Section 
1.7.2.4, PAH therapies have been extensively studied in patients with connective tissue 
disease, usually as a subgroup analysis of clinical trials containing patients with PAH of all 
causes.  Treatment effects on exercise capacity and survival tend to be more modest in 
CTD-PAH compared with IPAH171, 172.   
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5.1.1  Pathogenesis of SSc-PAH 
 
As in idiopathic PAH, the pathogenesis of SSc-PAH is characterized by progressive 
remodelling of small or medium sized pulmonary arteries.  Within the endothelium there is 
an imbalance between antiproliferative mediators (e.g. prostacyclin and nitric oxide) and 
vasoactive proliferative mediators (endothelin-1 and thromboxane A2), with resultant 
pulmonary artery vasoconstriction and cellular proliferation311.  Subsequent ischaemic 
reperfusion injury within the pulmonary vasculature can promote further cytokine release, 
fibrosis and intraluminal microthrombosis316.  There is also evidence of a higher frequency 
of obstructive vascular lesions in pulmonary veins/preseptal venules in CTD-PAH than in 
IPAH317.  The presence of autoantibodies and autoimmune dysregulation are also 
important in SSc-PAH318, 319.  A recent study has suggested that endothelin-1 receptor type 
A and angiotensin II type-1 receptor antibodies are common in SSc, can contribute to 
pathological vascular remodelling, and are associated with increased mortality320.  
Antiendothelial cell autoantibodies and antifibroblast autoantibodies may also contribute to 
endothelial cell apopotosis, fibroblast proliferation and collagen synthesis in SSc-PAH321, 
322.  In addition to pulmonary vascular abnormalities, SSc can also exert a primary 
inflammatory effect on the heart, with subsequent myocardial fibrosis and impaired 
microcirculatory function323.    
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5.1.2  PAH in Other Connective Tissue Diseases 
 
Whilst pulmonary arterial hypertension occurring in the setting of an underlying 
connective-tissue disease (CTD-PAH) is most frequently observed in patients with 
systemic sclerosis (SSc-PAH), it can also be found in mixed connective tissue disease 
(MCTD), systemic lupus erythematosus (SLE), dermatomyositis/polymyositis (DM/PM), 
rheumatoid arthritis (RA), undifferentiated connective tissue disease (UCTD) and 
Sjogren’s syndrome.  In a recent registry of all incident cases of CTD-PAH diagnosed in 
the UK between 2001 and 2006, 74% of patients had underlying systemic sclerosis299.  
Compared with SSc-PAH, higher survival rates were observed in PAH associated with 
SLE, and associated with DM/PM.  These findings have been supported by data from the 
REVEAL registry which have demonstrated that systemic sclerosis accounts for 62% (399 
out of 641) of CTD-PAH patients, and that SSc-PAH is a unique phenotype with the 
highest BNP levels, lowest DLCO, and poorest survival of all CTD-PAH subgroups173.  
Survival in PAH associated with RA is felt to be comparable to survival in IPAH324.   
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5.1.3  Survival differences between IPAH and CTD-PAH 
 
It is well recognized that despite similar baseline demographics and often less severe 
pulmonary haemodynamics, survival is worse in CTD-PAH, particularly SSc-PAH, than in 
IPAH165, 173, 233, 234.  The recent UK registries of incident, treatment-naïve cases of CTD-
PAH and IPAH has demonstrated one-, two-, and three-year survival rates of 78%, 58%, 
and 47% in SSc-PAH299, compared with 93%, 84%, and 73% in IPAH185.   At baseline 
right heart catheterisation, patients with IPAH had higher mPAP (54 mmHg v 42 mmHg), 
higher PVR (12.8 Wood Units v 8.9 Wood Units) and lower cardiac index (2.1 L/min/m2 v 
2.43 L/min/m2) than those with SSc-PAH.  There was no difference in WHO functional 
class distribution between the groups, however the SSc-PAH cohort were older (64 yrs v 
50yrs), more female (82% v 70%), and had poorer baseline 6MWD (231m v 292m) than 
the IPAH cohort.   
 
Similar findings have been observed in the REVEAL registry of new and previously 
diagnosed PAH patients, which included 1251 patients with IPAH and 641 patients with 
CTD-PAH, of which 399 had SSc-PAH.  One year survival rates were significantly lower 
in CTD-PAH than in IPAH (86% v 93%, p < 0.0001), and lower still in the SSc-PAH 
subgroup (82% at 1 year)173.   Haemodynamics at the time of diagnostic RHC were less 
severe in CTD-PAH (mPAP 45 mmHg, PVR 9.8 WU, Cardiac Index 2.5 L/min/m2) than in 
IPAH (mPAP 53 mmHg, PVR 12.5 WU, Cardiac Index 2.3 L/min/m2).  As before, WHO 
functional class distribution was the same in both groups, however the CTD-PAH cohort 
were older (57 yrs v 50yrs), more female (90% v 79%), and had poorer baseline 6MWD 
(301m v 329m) and higher NT-ProBNP (2313 v 1263 pg/ml) than the IPAH cohort.  It 
should be noted that the time interval between diagnostic RHC and enrolment was 41.1 ± 
44.1 months in the IPAH group and 27.2 ± 29.9 months in the CTD-PAH group. 
 
  
Therefore, the reason for the poorer survival observed in CTD-PAH, particularly SSc-
PAH, remains unclear.  In the UK registry described earlier, Condliffe et al found that age, 
sex, mixed venous oxygen saturation, and WHO functional class were all independent 
predictors of survival in isolated SSc-PAH299.  Similarly, in the REVEAL registry patients 
with SSc-PAH who were at a particularly high risk of death included elderly men and 
those with low baseline systolic blood pressure or 6MWD, or markedly elevated RAP or 
PVR325.  Lefevre et al further investigated the prognostic factors for survival in SSc-PAH 
via a meta-analysis of 22 studies including 2244 patients326.  They reported that age, male 
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sex, DLCO, pericardial effusion, and many of the prognostic factors typically observed in 
IPAH (including 6MWD, right atrial pressure, and cardiac index) were also prognostic 
factors in SSc-PAH.   
 
 
The importance of left ventricular dysfunction in determining survival in the two 
conditions has been investigated less frequently.  In their 2006 study, Fisher et al reported 
that although patients with SSc-PAH had a higher prevalence of LV morphologic and 
functional abnormalities than was seen in IPAH, the presence of left heart disease was not 
associated with increased mortality233.  However, in the recent meta-analyses and registry-
based studies investigating predictors of survival in CTD-PAH and SSc-PAH, the role of 
left ventricular dysfunction, particularly diastolic dysfunction, has not been explicitly 
explored325, 326.  The experiment in this chapter tested the hypothesis that right and left 
sided cardiac dysfunction could influence prognosis in CTD-PAH, and explain the survival 
difference between idiopathic and connective-tissue disease associated PAH.  
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5.2   Methods 
 
5.2.1   Patients 
 
Patients with a new suspected diagnosis of pulmonary hypertension were admitted for 
diagnostic assessment to the Scottish Pulmonary Vascular Unit in Glasgow, UK between 
December 2003 and July 2011.  Patients underwent clinical assessment including New 
York Heart Association (NYHA) functional class (FC), right heart catheterisation (RHC), 
six-minute walk distance (6MWD) and CMR.  CMR imaging was performed within 72 
hours of RHC.  At the time of assessment, no patient had received any specific pulmonary 
hypertension treatment (other than anticoagulation with warfarin). 
 
Following RHC, PH was diagnosed and classified according to current guidelines and, if 
appropriate, disease-targeted therapy was initiated2 .  IPAH was diagnosed when PAH was 
present (i.e. mPAP > 25mmHg, PAWP ≤ 15mmHg, PVR ≥ 3 mmHg/L/min) but no 
underlying cause for the PAH could be identified.  CTD-PAH was diagnosed when PAH 
was present in the setting of connective-tissue disease, as agreed by the MDTM.  The 
underlying connective tissue disease was categorized through review of clinical notes and 
MDT documentation.    Patients with evidence of interstitial lung disease on computed 
tomography scan, as reported by Consultant Radiologist, and impaired spirometry (Forced 
Vital Capacity (FVC) <70% predicted) were excluded from the study.  Survival was 
determined on 31st December 2011, using the computerized SCI-Store system if required.  
Date of diagnosis was taken as the date of the diagnostic right heart catheter. 
 
 
5.2.2   CMR Image Acquisition 
 
CMR image acquisition was performed as described in Methods Section 2.2.3 
 
5.2.3  CMR Image Analysis 
 
CMR image analysis was performed as described in Methods Sections 2.2.3.5 and 2.2.3.6.   
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5.2.4  Statistical analysis 
 
For all variables, normal Gaussian distribution was verified using histograms and 
Kolmogorov-Smirnov tests.  For demographic, CMR, and haemodynamic variables mean 
values ± one standard deviation (±SD) were calculated.  Student’s t-test or Mann-Whitney 
test was used to compare values between the groups.  Discrete data were compared using 
the Chi-squared test.  Survival from date of diagnosis was assessed using the Cox 
regression and Kaplan–Meier methods, with comparisons performed by log-rank test.  
Correlations between normally distributed CMR and haemodynamic variables were tested 
by Pearson’s method.  Post-hoc analysis was carried out by stratifying patients into high 
and low RV function using the median baseline RVSVI, and into normal or abnormal LV 
systolic function using an LVEF threshold of 60%. 
 
Statistical analysis was performed using Statview version 5.0.1 (SAS Institute, 
Cary, NC, USA) and GRAPHPAD Prism (Version 5.00; GraphPad Software Inc, La Jolla, 
CA, USA) 
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5.3   Results 
 
5.3.1  Baseline Characteristics 
 
Between December 2003 and July 2011 138 patients fulfilled the criteria for pulmonary 
arterial hypertension and underwent diagnostic assessment with CMR and right heart 
catheterisation.  Of these 74 were diagnosed with IPAH and 38 were diagnosed with CTD-
PAH.  The remaining 26 had portopulmonary hypertension or PH due to congenital heart 
disease.  In the CTD-PAH group the underlying connective-tissue disease was: systemic 
sclerosis (21 patients), rheumatoid arthritis (5 patients), systemic lupus erythematosus (4 
patients), mixed connective tissue disease (2 patients), dermatomyositis (1 patient), 
unknown (5 patients). 
 
 
Baseline demographics, clinical data and lung function are presented in Table 5.1. There 
was no significant difference in age, NYHA functional class, lung function or 6MWD 
between the two groups.  There were a higher proportion of females in the CTD-PAH 
group.   
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Table 5.1 Baseline characteristics of the study groups 
 
 IPAH 
(n = 74) 
CTD-PAH 
(n = 38) 
P Value 
Age (years) 58 (± 17) 60 (± 14) 0.42 
Sex (♀; ♂) 43 : 31 33 : 5  
NYHA Fc, no (%) 
I / II 
III 
IV 
 
14 (18.9) 
53 (71.6) 
7 (9.5) 
 
9 (23.7) 
25 (65.8) 
4 (10.5) 
0.81† 
Body Surface Area (m2) 1.77 (± 0.23) 1.68 (± 0.26) 0.07 
Resting Heart Rate (bpm) 78 (± 14) 81 (± 17) 0.28 
6MWD (m) 256 (± 132) 214 (± 128) 0.11 
Echo TRPG (mmHg) 70 (± 18) 66 (± 28) 0.32 
FEV1 (% predicted) 85 (± 17) 86 (± 23) 0.96 
FVC (% predicted) 103 (± 19) 99 (± 26) 0.39 
TLCO (% predicted) 43 (± 22) 41 (± 19) 0.79 
 
IPAH, idiopathic pulmonary arterial hypertension; CTD-PAH, connective tissue disease 
associated pulmonary arterial hypertension; NYHA, New York Heart Association; bpm, 
beats per minute; 6MWD, six minute walk distance; TRPG, tricuspid regurgitation 
pressure gradient; FEV1, forced expiratory volume in 1s; FVC, forced vital capacity; 
TLCO, transfer factor for the lung for carbon monoxide 
 
Data presented as mean (±SD) otherwise specified 
 
Student t-test or Mann-Whitney Rank Sum Test as appropriate 
 
† - using the Chi-squared test for categorical variables 
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5.3.2  CMR Analysis 
 
CMR results for the two groups are presented in Table 5.2.  Both groups had significant 
right ventricular dilatation and RV hypertrophy, and poor RV systolic function.   Both 
groups also had impaired left ventricular filling (reduced LVEDV) but well preserved left 
ventricular ejection fraction.  Patients with IPAH had greater right ventricular hypertrophy 
than those with CTD-PAH (VMI 1.16 v 0.99, p = 0.03).  Left atrial volume was lower in 
IPAH than CTD-PAH (23 vs 33 ml/m2, p<0.0001). 
 
Table 5.2 Baseline CMR results for the study groups 
 
 IPAH 
(n = 74) 
CTD-PAH 
(n = 38) 
P Value 
Right Ventricle    
EDV Index (ml/m2) 85 (± 24) 80 (± 21) 0.27 
Stroke Volume Index (ml/m2) 27 (± 9) 27 (± 8) 0.96 
Ejection Fraction (%) 34 (± 13) 37 (± 17) 0.27 
Mass (g/m2) 57 (± 20) 49 (± 16) 0.04 
 
Left Ventricle    
EDV Index (ml/m2) 45 (± 14) 45 (± 14) 0.85 
Stroke Volume Index (ml/m2) 28 (± 9) 29 (± 10) 0.68 
Ejection Fraction (%) 63 (± 13) 64 (± 13) 0.60 
Mass (g/m2) 50 (± 12) 52 (± 12) 0.38 
Ventricular Mass Index 1.16 (± 0.36) 0.99 (± 0.33) 0.03  
    
Left Atrial Volume (ml/m2) 23 (± 11) 33 (± 11) <0.0001 
 
IPAH, idiopathic pulmonary arterial hypertension; CTD-PAH, connective tissue disease 
associated pulmonary arterial hypertension; EDV, end-diastolic volume 
 
Data presented as mean (±SD) otherwise specified 
 
Student t-test or Mann-Whitney Rank Sum Test as appropriate
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5.3.3   Pulmonary Haemodynamics 
 
Baseline haemodynamics for the study groups are presented in Table 5.3.  In IPAH there 
was higher mPAP (50 v 43mmHg, p = 0.01) and higher PVR (12.3 v 10.3 Wood Units, p = 
0.07) than in CTD-PAH.  There was no difference in cardiac index, PAWP or right atrial 
pressure between the groups.   
 
 
Table 5.3  Baseline haemodynamics for the study groups 
 
 IPAH 
(n = 74) 
CTD-PAH 
(n = 38) 
P value 
Mean PAP (mmHg) 50 (± 14) 43 (± 12) 0.01 
PAWP (mmHg) 8 (± 4) 7 (± 5) 0.58 
Cardiac Index 
(L/min/m2) 
2.1 (± 0.6) 2.3 (± 0.7) 0.14 
PVR (Wood Units) 12.3 (± 5.4) 10.3 (± 5.4) 0.07 
 
RAP (mmHg) 8 (± 6) 9 (± 10) 0.42 
 
 
IPAH, idiopathic pulmonary arterial hypertension; CTD-PAH, connective tissue disease 
associated pulmonary arterial hypertension; PAP, pulmonary artery pressure; PAWP, 
pulmonary artery wedge pressure; PVR, pulmonary artery pressure; RAP, right atrial 
pressure. 
 
Data presented as mean (±SD) 
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5.3.4  PAH Treatment 
 
Initial therapy in both groups was in accordance with ERS guidelines and there was no 
difference in the distribution of initial therapies between the IPAH and CTD-PAH groups 
(p = 0.38, Chi-squared test).  In IPAH this was Prostanoid (4 patients), 
Phosophodiesterase-5 Inhibitor (36 patients), Endothelin Receptor Antagonist (31 
patients), Calcium Channel Blocker (3 patients).  In CTD-PAH this was Prostanoid (1 
patient), Phosophodiesterase-5 Inhibitor (13 patients), Endothelin Receptor Antagonist (22 
patients), Other (2 patients).  PDE-5 or ERA monotherapy was used in 67/74 (91%) of 
IPAH and 35/38 (92%) of CTD-PAH patients. 
 
 
5.3.5  Survival Analysis 
 
During a median follow-up period of 22 months (IQR: 9 to 53 months) 17 CTD-PAH and 
18 IPAH patients died.  Survival was greater in IPAH than in CTD-PAH (Log-Rank test – 
p = 0.03) (Figure 5.1).  Survival rate in IPAH was 83% at 1yr, 76% at 2yrs and 74% at 
3yrs, and in CTD-PAH was 75% at 1yr, 53% at 2yrs and 53% at 3yrs. 
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Figure 5.1 Kaplan Meier survival estimates of the study cohort stratified by   
  diagnosis 
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Survival was better in IPAH than in CTD-PAH (p = 0.03).   
 
IPAH, idiopathic pulmonary arterial hypertension; CTD-PAH, connective-tissue disease 
associated pulmonary arterial hypertension 
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5.3.5.1  Predictors of Survival at Univariate Analysis 
 
Univariate analysis was performed on the entire cohort to identify clinical, haemodynamic 
and CMR predictors of survival and the results are presented in Table 5.4.  Age, functional 
class, the presence of connective-tissue disease (vs idiopathic PAH), TLCO, PVR, Cardiac 
Index, RAP, stroke volume (RV and LV), right ventricular ejection fraction and left 
ventricular end-diastolic volume were all predictors of survival. 
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Table 5.4 Univariate Cox proportional hazards analysis 
 
Variable Hazard Ratio 95% C.I. P Value 
Age, yrs 1.0446 1.018 - 1.074 0.001 
 
6MWD, (m) 0.991 0.988 - 0.994 <0.0001 
Functional Class 3.637 1.877 - 7.048 0.0001 
 
FEV1 (% pred) 1.002 0.983 - 1.021 0.86 
FVC (% pred) 1.008 0.992 - 1.025 0.34 
TLCO (%) 0.951 0.927 - 0.976 0.0001 
Disease 
(CTD-PAH) 
2.047 1.053 - 3.976 0.035 
    
mPAP, mmHg 1.003 0.981 - 1.025 0.80 
Cardiac Index, 
L/min/m2 
0.313 0.156 - 0.630 0.001 
PVR, Wood Units 1.068 1.011 - 1.128 0.02 
RAP, mmHg 1.097 1.047 - 1.149 <0.0001 
    
RV EDVI, ml/m2 1.000 0.985 - 1.014 0.97 
RV SVI, ml/m2 0.919 0.875 - 0.964 0.0005 
RV EF, % 0.964 0.939 - 0.990 0.007 
RV Mass, g/m2 0.996 0.979 - 1.013 0.64 
LV EDVI, ml/m2 0.936 0.906 - 0.968 <0.0001 
LV SVI, ml/m2 0.923 0.887 - 0.959 <0.0001 
LV EF, % 0.987 0.961 - 1.013 0.32 
LV Mass g/m2 0.984 0.969 - 0.996 0.04 
VMI 1.890 0.789 - 4.526 0.15 
LAV, ml/m2 1.008 0.980 - 1.037 0.58 
 
CTD-PAH, connective tissue disease associated pulmonary arterial hypertension; 6MWD. 
six minute walk distance; FEV, forced expiratory volume in 1s; FVC, forced vital capacity; 
TLCO, transfer factor for the lung for carbon monoxide; mPAP, mean pulmonary artery 
pressure; PVR, pulmonary vascular resistance; RAP, right atrial pressure; RV, right 
ventricle; EDVI, end-diastolic volume index; SVI, stroke volume index; EF, ejection 
fraction; VMI, ventricular mass index; LAV, left atrial volume 
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5.3.5.2  Predictors of Survival at Multivariate Analysis 
 
At multivariate analysis right ventricular stroke volume index remained an independent 
predictor of survival after correction for age, TLCO and the presence of connective-tissue 
disease (vs idiopathic PAH) (Table 5.5).  The model was limited to four variables due to 
the total number of events (35) during the follow-up period.   
 
Table 5.5   Multivariate mortality predictors 
 
Variable Hazard Ratio 95% C.I. P Value 
 
 
Age, yrs 1.044 1.008-1.082 0.02 
 
TLCO (%) 0.968 0.939-0.998 0.04 
Disease 
(CTD-PAH) 
 
2.624 1.263-5.449 0.01 
RV SVI, ml/m2 0.927 0.880-0.977 0.005 
 
TLCO, transfer factor for the lung for carbon monoxide; CTD-PAH, connective tissue 
disease associated pulmonary arterial hypertension; RVSVI, right ventricular stroke 
volume index 
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5.3.5.3  Survival by Disease and Baseline Right Ventricular Function 
 
The study groups were stratified by disease and by baseline right ventricular function, 
either supramedian RV stroke volume index (≥26 ml/m2) or inframedian RV stroke volume 
index (<26 ml/m2).  Kaplan-Meier analysis was performed and the results presented in 
Figure 5.2.  In IPAH, survival was better with higher RVSVI than with lower RVSVI (p = 
0.004).  Similarly, in CTD-PAH survival was better with higher RVSVI than with lower 
RVSVI (p = 0.005).  Impaired right ventricular function at baseline, as measured by 
RVSVI, was associated with increased mortality in both IPAH and CTD-PAH. 
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Figure 5.2  Kaplan Meier survival estimates of the study cohort stratified by   
  diagnosis and RV stroke volume index 
0 20 40 60 80 100
0
20
40
60
80
100
CTDPH RVSVI ≥ 26 (n = 19)
CTDPH RVSVI < 26 (n = 19)
IPAH RVSVI ≥ 26 (n = 37)
IPAH RVSVI < 26 (n = 37)
Time (months)
Pe
rc
en
t s
ur
vi
va
l
 
 
Poorer right ventricular function (inframedian RVSVI) at baseline was associated with 
impaired survival in both IPAH and CTD-PAH.   
 
IPAH, idiopathic pulmonary arterial hypertension; CTD-PAH, connective-tissue disease 
associated pulmonary arterial hypertension; RVSVI, right ventricular stroke volume index 
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5.3.5.4  Survival by Disease and Baseline Left Ventricular Function 
 
To investigate the importance of left ventricular function on survival, the study groups 
were also stratified by disease and by left ventricular systolic function, into normal LV 
ejection fraction (> 60%) or reduced LV ejection fraction (< 60%) (Figure 5.3).   
 
Using this threshold, there was impaired LV systolic function in twenty-three out of the 
seventy-four (31%) IPAH patients, and in thirteen out of the thirty-eight (34%)  CTD-PAH 
patients.  In IPAH there was no difference in survival between patients with normal and 
reduced LV function (p = 0.65), however in CTD-PAH there was a trend towards poorer 
survival with reduced LV function which approached but did not fully reach statistical 
significance (p = 0.09).  
 
The only measurement of left ventricular diastolic function available for the whole study 
group was CMR-derived left atrial volume (LAV), however when used alone it did not 
predict survival.   
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Figure 5.3  Kaplan Meier survival estimates of the study cohort stratified by   
  diagnosis and LV ejection fraction 
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Survival rates of patients stratified according to disease, and into normal or reduced LV 
ejection fraction (LVEF).  An LVEF < 60% was not associated with reduced survival in 
IPAH (p = 0.65), but there was a trend towards reduced survival in CTD-PAH (p = 0.09).   
 
IPAH, idiopathic pulmonary arterial hypertension; CTD-PAH, connective-tissue disease 
associated pulmonary arterial hypertension 
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5.3.5.5  Relationship between Right Ventricular Filling and Left Atrial Volume 
 
Linear regression analysis was performed to investigate whether the relationship between 
right ventricular filling (as measured by RVSVI) and left atrial volume was the same in 
IPAH as in CTD-PAH (Figure 5.4).  With increasing RVSVI, left atrial volume increased 
more in CTD-PAH than in IPAH (p = 0.035 for the hypothesis of the slopes of the graph 
being equal).  For a given RV stroke volume index, left atrial volume was higher in CTD-
PAH than in IPAH.    
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Figure 5.4  Linear regression analysis of RV stroke volume index versus left   
  atrial volume in IPAH and CTD-PAH 
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Relationship between left atrial volume (LAV) and right ventricular stroke volume 
index (RVSVI) is different in CTD-PAH (r = 0.58) than in IPAH (r = 0.20) 
 
IPAH: idiopathic pulmonary arterial hypertension; CTD-PAH, connective tissue 
disease-associated pulmonary arterial hypertension 
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5.3.5.6 Relationship between right ventricular hypertrophy and pulmonary vascular 
resistance 
 
Linear regression analysis was performed to investigate whether the relationship between 
right ventricular hypertrophy and pulmonary vascular resistance was the same in IPAH as 
in CTD-PAH (Figure 5.5).  There was no difference between IPAH and CTD-PAH in the 
relationship between VMI and PVR (p = 0.66 for the hypothesis of the slopes being equal), 
and no difference in the relationship between RV mass index alone and PVR between the 
two disease states (p = 0.75 for the hypothesis of the slopes being equal).   
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Figure 5.5 Linear regression analysis of PVR versus right ventricular    
  hypertrophy in IPAH and CTD-PAH 
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Ventricular mass index (VMI) (A) and right ventricular mass index (B) versus pulmonary 
vascular resistance (PVR) stratified by diagnosis.   
 
IPAH: idiopathic pulmonary arterial hypertension; CTD-PAH connective tissue disease 
associated pulmonary arterial hypertension 
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5.4   Discussion 
 
The current study investigated survival differences between IPAH and CTD-PAH, with 
particular focus on the prognostic importance of right ventricular and left ventricular 
function.  It has demonstrated that despite similar baseline demographics, lung function, 
haemodynamics, and PAH therapy, survival in CTD-PAH is much worse than in IPAH.  
Poor right ventricular function at baseline is associated with increased mortality in both 
conditions, but left ventricular function may also have some prognostic significance in 
CTD-PAH.   
 
The findings of the current study support the recent interest in the hypothesis that right 
ventricular abnormalities may contribute to the poorer survival in CTD-PAH.  Right 
ventricular dysfunction is common in CTD-PAH, with 37% of patients in the REVEAL 
registry having mild/moderate RV systolic dysfunction at echocardiography and 19% 
having severe RV systolic dysfunction173, although these were actually lower rates than 
those observed in the IPAH group (mild/moderate 47%, severe 24%).  At multivariate 
analysis, specific components of right ventricular dysfunction (RHC-derived stroke volume 
index and pulmonary arterial capacitance) have been found to contribute to increased 
mortality in SSc-PAH327.   
 
Overbeek et al compared the relationship between mean RV pressure and stroke volume in 
SSc-PAH and IPAH, and demonstrated that patients with SSc-PAH had lower stroke 
volumes for any given mean RV pressure, suggesting impaired RV contractility in SSc-
PAH328.  Tedford et al also used pressure-volume loops to demonstrate that RV 
dysfunction is worse in SSc-PAH compared with IPAH at similar afterload, proposing that 
it may be due to problems with intrinsic RV systolic function rather than enhanced 
pulmonary vascular resistive and pulsatile loading329.   
 
In a study comparing CMR-derived RV Mass and VMI with RHC-derived PVR, patients 
with SSc-PAH were found to have significantly less RV hypertrophy with increasing PVR 
than patients with IPAH330.  The conclusion from Kelemen et al was that this difference in 
adaptive hypertrophy could explain decreased contractility and poorer survival in SSc-
PAH.   By contrast, in the current study there was no difference in the relationship of right 
ventricular hypertrophy to pulmonary vascular resistance between the two disease states of 
IPAH and CTD-PAH.  The reason for these differing results is unclear but may relate to 
the use of PAH-specific therapy at the time of cardiac catheterisation and CMR.  The 
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population in the current study was entirely treatment-naïve, whereas in the Kelemen 
group 100% of the IPAH patients but only 37% of the SSc-PAH patients were on PAH-
specific medications.   
 
There are two potential mechanisms by which PAH therapy could have affected the 
observed relationships between RV mass and PVR.  Firstly, PAH-specific medications 
could have lead to a reduction in RV hypertrophy in certain patients unrelated to changes 
in PVR.  Earlier investigations have shown that short-term use of PDE-5 inhibitors but not 
endothelin antagonists can reduce RV mass293, 303.  Secondly, despite PAH therapy, RV 
mass may have remained fixed, but treatment has resulted in a reduction in PVR, and 
therefore a change in the relationship between RV hypertrophy and RV load.  Longer-term 
studies of PAH therapy, have not demonstrated a sustained change in RV mass after 
treatment 115, 118, 302, 331.  The current findings suggest the relationship between RV 
hypertrophy and RV load is similar between the disease states of IPAH and CTD-PAH at 
baseline, but may be modified by the use of PAH-specific therapies, with subsequent 
maladaptive hypertrophy and poorer outcome occurring in patients with underlying 
connective-tissue disease. 
 
Whilst the majority of the patients diagnosed with IPAH and CTD-PAH in this study had 
normal left ventricular systolic function (mean LVEF of 63% in IPAH and 64% in CTD-
PAH), about a third of patients in each group had an LVEF at CMR of <60%.  A reduced 
LVEF was not of prognostic significance in IPAH, but was possibly associated with 
impaired survival in CTD-PAH, although this did not fully reach statistical significance.  
The reason for this prognostic difference may relate to differences in the likely aetiology of 
reduced LV function between the conditions.   
 
In idiopathic PAH, impairment of LV function at the time of diagnosis is likely to be 
secondary to right ventricular abnormalities and ventricular interdependence, such as 
abnormal septal motion with impaired LV filling41, 42.  The normal anatomic spiral 
arrangement of the interventricular septum results in a twisting action that contributes to 
the forceful ejection of blood from both ventricles during systole, and therefore abnormal 
septal motion from elevated RV pressure can reduce ejection fraction from both the LV 
and RV332, 333.  Echocardiography with speckle tracking has shown that RV dyssynchrony 
is significantly associated with LV dyssynchrony and reduced LV ejection fraction in 
patients with pulmonary hypertension334.  CMR has also been used to demonstrate reduced 
LV longitudinal and circumferential contractility in PAH335, reduced LV ejection fraction 
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in the setting of emphysema and right ventricular hypertrophy336, and delayed contrast 
enhancement in the interventricular septum of patients with PH130.   Even with normal LV 
size and normal conventional measures of LV systolic function, patients with PAH have 
been found to have reduced LV free wall systolic strain, and this was associated with 
delayed relaxation mitral inflow Doppler pattern and increased mortality337.  It is 
reasonable to expect these left-sided abnormalities to improve as RV function improves 
following the commencement of PAH-specific therapy, and the recent longitudinal EURO-
MR study demonstrated a small but statistically significant increase in LV ejection fraction 
after twelve months of PAH treatment331.    
 
In CTD-PAH, particularly when related to systemic sclerosis, impaired LV function at 
baseline may also relate to direct effects of the underlying connective-tissue disease on the 
left heart338, and these abnormalities may not resolve despite improvements in RV function 
after PAH therapy.  It is well recognized that patients with systemic sclerosis have a high 
prevalence of left-sided cardiac abnormalities.  In a small CMR study of 52 patients with 
systemic sclerosis, Hachulla et al demonstrated that 75% of the study cohort had at least 
one CMR abnormality339, including thinning of LV myocardium, impaired LV or RV 
ejection fractions, a pericardial effusion or LV diastolic dysfunction (35% of patients).   
Pericardial effusions occurred more frequently in CTD-PAH than in IPAH, but may be a 
manifestation of inflammatory serositis in some patients173.   
 
 
In a large multicentre French study in which echocardiography was used to prospectively 
screen 570 patients with SSc for PAH, LV systolic dysfunction was rare (1.4%) but LV 
hypertrophy (22.6%) and LV diastolic dysfunction (17.7%) were common338.  The 
presence of left ventricular diastolic dysfunction at echocardiography has been associated 
with increased mortality in systemic sclerosis340, 341.  Left ventricular abnormalities in 
systemic sclerosis, particularly diastolic dysfunction, may predate clinical symptoms by 
several years342.  Post-mortem studies have demonstrated cardiac involvement in 70% of 
scleroderma patients compared with 37% of age and sex matched controls, however this 
was often clinically silent343.  In their recent retrospective review, Fox et al found that 
11/29 scleroderma patients with mPAP >25 mmHg and PAWP ≤ 15 mmHg were 
unmasked as having “occult pulmonary venous hypertension” by measurement of LV end-
diastolic pressure (LVEDP) ± fluid challenge344.  However, they were not able to 
determine if these patients had (Group 2) pulmonary venous hypertension, or had genuine 
PAH and concomitant diastolic dysfunction. 
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In the current study, left atrial volume was found to be higher in CTD-PAH than in IPAH, 
supporting the hypothesis that there may be coexisting LV diastolic dysfunction in CTD-
PAH.    In addition, patients with CTD-PAH had a higher LAV for a given RV stroke 
volume index than those with IPAH.  In LV diastolic dysfunction there is abnormal LV 
relaxation and increased LV filling pressure249,     which can result in enlargement of the 
thin-walled left atrium, allowing left atrial volume to be used as a marker of the severity 
and chronicity of diastolic dysfunction206, 250-253.  When used as a single variable, a 
decreased LAV was not found to be associated with better survival, however this might 
relate to the fact that a low LAV can also be the result of impaired filling from a failing 
right ventricle.   
 
One of the main novel findings from this chapter is that RV function appears to have a 
similar impact on prognosis in CTD-PAH as seen in IPAH.  Patients with CTD-PAH and 
poor RV function at baseline have very poor survival, supporting the hypothesis that RV 
failure is the major determinant of outcome in CTD-PAH.  It is not clear from the current 
data whether this is in part due to a global cardiomyopathy, but the increased LA size 
observed in CTD-PAH and the potential significant impact of LV function raise this 
possibility.  CMR has identified a subpopulation at an exceptionally high risk of death, and 
future work may include using CMR data to guide disease-targeted therapy in these 
patients.   
 
There are some limitations of the current study that should be identified.  CMR rather than 
echocardiography was used as the main imaging modality, and it is not possible to include 
E/e′ (early transmitral filling (E) to early diastolic mitral annular velocity (e′)) data or other 
measurements of left ventricular diastolic function345.  Using an LVEF threshold of 60% 
may have stratified some patients with “low-normal” LV function into the “reduced LV 
systolic function group”, although the threshold was applied to both IPAH and CTD-PAH 
cohorts.  The retrospective nature of the current study meant it was not possible to use data 
from the more advanced CMR techniques that are helping to substantially develop our 
knowledge of left heart disease in connective-tissue disease.  These include late 
gadolinium enhancement, tissue phase mapping and more detailed LV dynamic 
assessment346, 347.    
 
In the current study all-cause mortality was examined, rather than specifically death from 
right heart failure, however survival rates in both IPAH and CTD-PAH were similar to 
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those observed in the recent large UK registries185, 299.  The observed mortality rates and 
fairly small sample size meant it was not possible to include more than 3 or 4 variables in 
the multivariate analysis, and the duration of followup was smaller than in typical survival 
studies.  By including patients with PAH due to connective-tissue diseases other than 
systemic sclerosis, there was heterogeneity within the CTD-PAH group that would not 
observed if investigating SSc-PAH alone.  In a small minority of patients it was not 
possible to determine the exact underlying connective-tissue disease, however the 
diagnosis of CTD-PAH was ascribed at a contemporaneous MDT.  The intention was to 
exclude patients with underlying lung disease from the study, however given that observed 
TLCO was significantly lower in both IPAH and CTD-PAH than is commonly seen in 
these cohorts185, 299, it raises the possibility that some patients with lung disease were 
included in the final analysis.  Information was available on the initial PAH therapy 
commenced at diagnosis, but not on subsequent changes to the PAH treatment regime 
during the follow-up period.   
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5.5   Conclusions 
 
In this chapter it has been shown that survival is worse in CTD-PAH than in IPAH, despite 
similar baseline characteristics, lung function, pulmonary haemodynamics and initial PAH 
therapy.  Poor right ventricular function at baseline was associated with markedly reduced 
survival in CTD-PAH, supporting the hypothesis that RV function is the main determinant 
of outcome in this condition.  Reduced left ventricular systolic function was associated 
with poorer survival in CTD-PAH but not in IPAH, and patients with CTD-PAH had 
higher LAV raising the possibility of LV diastolic dysfunction in this group.  Left heart 
disease may contribute to the poorer survival observed in CTD-PAH, possibly as part of a 
global cardiomyopathy, so the diagnostic assessment of CTD-PAH should include close 
interrogation of left ventricular function. 
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Chapter 6 
 
Major Findings and Conclusions  
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6.  Major Findings and Conclusions 
 
The work in this thesis was undertaken to evaluate the role of cardiac magnetic resonance 
imaging in the diagnosis and determination of outcome in pulmonary hypertension. 
 
The ability of CMR to distinguish IPAH from PH-HFpEF was investigated, with particular 
focus on the assessment of left atrial volume.  Distinguishing IPAH from PH-HFpEF has 
become an area of great importance over recent years as the incidence of HFpEF, with 
subsequent PH-HFpEF, is increasing annually. There has been progress in distinguishing 
isolated post-capillary PH from combined pre-capillary and post-capillary PH in HFpEF, 
along with growing awareness of PAH-specific therapies and enthusiasm for their use in 
PH-HFpEF.  Concurrently, the average age at diagnosis of IPAH is increasing, with recent 
registry data suggesting it is now a disease of middle-aged and older people.  PAH-specific 
therapies are expensive, potentially harmful in left heart disease, and current practice is to 
distinguish between these conditions with invasive RHC.   
 
In Chapter 3, left atrial volume measured using CMR was a sensitive, specific and non-
invasive method for distinguishing IPAH from PH-HFpEF.  36 out of 37 patients with 
IPAH had a LAV of less than 43 ml/m2, and all the PH-HFpEF patients had a LAV of 
more than 43 ml/m2.  The threshold of 43 ml/m2 was obtained through ROC analysis, and it 
would be important in future study to prospectively apply this threshold to a cohort of 
patients undergoing diagnostic assessment for PH, allowing evaluation of CMR based 
prediction of RHC findings and the overall utility of CMR in reaching the diagnostic 
conclusion.   
 
LAV was assessed using CMR in the Scottish Pulmonary Vascular Unit, the only specialist 
PH centre in Scotland.  Future work could be undertaken to identify if left atrial volume 
assessment performed at non-specialist centres, perhaps with echocardiography, is of 
similar utility.  It would also be useful to investigate the relationship between CMR-LAV 
and other echocardiographic measures of left ventricular diastolic function in IPAH and 
PH-HFpEF.  CMR may have a future role in distinguishing between HFpEF with “passive” 
PH versus “reactive” PH, particularly given the increased interest in the use of PAH 
therapies in the latter group.   
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The last two decades have witnessed a vast expansion in the therapeutic options available 
to treat PAH, ranging from intravenous epoprostenol to oral monotherapy or upfront 
combination therapy.  These treatments are typically approved on the basis of 
improvements in pulmonary haemodynamics or modest increases in exercise capacity, and 
less is known about their overall effect on the RV.  CMR is already established as the gold 
standard for the evaluation of RV structure and function during the diagnostic assessment 
of PAH.   
 
In Chapter 4, CMR was used to demonstrate improvements in right ventricular function 
after four and twelve months of disease-targeted PAH therapy.  This corresponded to the 
improvements observed in NYHA functional class and exercise capacity, and was 
observed in both the PDE-5 and ERA treated groups.  This study included both patients 
with PAH, and those with PH due to other conditions including hypoxic lung disease and 
chronic thromboembolic disease.  Whilst this heterogeneity reflects everyday clinical 
practice in pulmonary vascular medicine, it may be useful in future work to recruit a more 
homogenous PAH population, to minimize the impact of coexisting respiratory disease or 
other comorbidities.  However, as PAH therapies are being increasingly used in Group 3-5 
PH, it would also be important to determine if similar improvements in RV function are 
being achieved in these patients, and additional separate CMR studies would be required to 
achieve this.  Assuming a treatment-induced change in RVSVI of 4.89 ml/m2 and a SD of 
10.5 ml/m2 based on the findings in Chapter 4, the minimum sample size required to detect 
a treatment effect with 90% power and 5% two-tailed level of significance test would be 
49 patients.  
 
 
In this study PAH therapy was commenced and modified at the discretion of the local PH 
physician, resulting in significant treatment variation between centres.  Future multi-centre 
studies would likely benefit from a more standardized treatment algorithm, and this could 
potentially allow CMR to be used to investigate the impact of specific drug therapies on 
the RV.  It is clear from the baseline characteristics of the study groups in Chapter 4 that 
there is significant variability in the patient populations between centres, with those in 
Glasgow having the poorest functional class, lowest 6MWD and most severe pulmonary 
haemodynamics.  Despite this, the results observed within the Glasgow subgroup reflected 
the findings observed for the cohort as a whole, supporting the hypothesis that disease-
targeted therapies can improve RV function in both moderate and severe PH.  There has 
been significant expansion in the therapeutic options available in PAH since this study was 
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conceived, with greater use of combination therapy and the development of oral 
prostanoids, soluble guanylate cyclase activators and newer endothelin antagonists and 
PDE-5 inhibitors.  It would be essential that any future CMR studies investigating RV 
function reflected contemporary clinical practice and included patients receiving these 
newer treatments.   
 
Clinical outcomes were not routinely measured in this multi-centre study, so future work 
may involve relating on-treatment changes in RV function at CMR with a clinically 
predefined outcome, typically a combination of mortality or need for intravenous therapy.  
This would clearly increase the size, cost and complexity of such a study, and mandate the 
need for proper study oversight, but would increase the clinical significance and validity of 
the study findings.  It is likely that a prolonged follow-up period, well beyond the 12 
months of the current work, would be required for this, thereby providing an opportunity to 
investigate the impact of long-term PAH therapy on the RV.  It would also be important to 
take advantage of the more advanced CMR techniques now available for assessment of RV 
structure function and the pulmonary circulation.  These include pulmonary artery 
stiffness, right ventricular-arterial coupling or transverse shortening, and assessment of PH 
patients during exercise or dobutamine administration. CMR techniques used in the 
longitudinal assessment of RV function in PAH need to have excellent interstudy 
reproducibility, and this could be further investigated beyond the current analysis by way 
of a test-retest study.    
 
 
 
The poor survival observed in CTD-PAH, especially when compared with IPAH, has been 
an area of longstanding concern in the pulmonary vascular community.  Proposed 
explanations have included delayed diagnosis, poorer tolerance of PAH therapies, and the 
effect of coexisting cardiac or respiratory disease.     
 
In Chapter 5, it was observed that survival in CTD-PAH was significant poorer than in 
IPAH, despite similar clinical characteristics, pulmonary haemodynamics, PAH treatments, 
and the exclusion of patients with interstitial lung disease.  Using CMR, RV function at the 
time of diagnosis was found to be an important predictor of survival in both conditions, 
with impaired RV function in CTD-PAH associated with a particularly poor outcome.  The 
findings of the current study support the concept that RV failure is the main determinant of 
outcome in CTD-PAH, and highlight the need for further research into optimal treatment 
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strategies for these patients, potentially including specific therapies directed at the right 
ventricle.  The relationship between PVR and the degree of RV hypertrophy at baseline 
was the same in both conditions, but future research could determine if this altered after the 
introduction of PAH therapy.  This single centre study had a relatively small sample size 
and short duration of follow-up, limiting the extent of multivariate anlaysis, so it would be 
beneficial for future studies to have a larger number of patients, potentially across different 
PH centres, and a more prolonged follow-up period.  It would also be important to ensure 
that strict entry criteria were in place to minimize the risk of patients with underlying lung 
disease being included in the study.    
 
In the current study there was evidence to support the hypothesis of left ventricular 
problems contributing to the increased mortality in CTD-PAH, and this is in keeping with 
recent progress in our understanding of left heart disease in CTD.  Compared with IPAH, 
patients with CTD-PAH had higher LAV, a higher increase in LAV for a given RV stroke 
volume, and LV systolic dysfunction was more commonly associated with reduced 
survival.  In the current study it was not possible to comprehensively evaluate LV systolic 
and diastolic function in all patients, but this should now be considered during the routine 
diagnostic assessment of suspected CTD-PAH.  If this study was being repeated then more 
detailed CMR evaluation of LV function would be invaluable, and could help determine if 
a global cardiomyopathy is contributing to increased mortality in CTD-PAH.   
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Appendix 1 Patient Consent Form and Information Sheet 
 
 
WEST ETHICS COMMITTEE 
 
FORM OF CONSENT FOR PATIENTS/VOLUNTEERS IN CLINICAL RESEARCH PROJECT 
 
 
Title of Project:  The Assessment of Pulmonary Hypertension using Cardiac MRI 
 
 
 
 
 
 
 
 
 
 
 
 
By signing this form you give consent to your participation in the project whose title is at the top of the page. You should 
have been given a complete explanation of the project to your satisfaction and have been given the opportunity to ask 
questions. You should also have been given a copy of the patient information sheet approved by the West Ethics 
Committee to read and to keep. Even though you have agreed to take part in the research procedures you may withdraw 
this consent at any time without the need to explain why and without any prejudice to your care. 
 
 
 
 
 
 
 
 
Consent: 
 
………………………………………………………………………………(PRINT) 
 
 
of …………………………………………………………………................ 
 
 
give my consent to the research procedures above, the nature, purpose and possible consequences  
of which have been described to me 
 
 
by …………………………………………………………………………… 
 
 
Patient’s signature ………………………………………..Date……………. 
 
 
Doctor’s signature …………………………………………………………...  
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INFORMATION SHEET FOR PATIENTS/VOLUNTEERS IN CLINICAL RESEARCH PROJECT 
 
 
Brief Title of Project 
 
The Assessment of Pulmonary Hypertension using Cardiac MRI 
 
Patient’s Summary (Purpose of study, nature of procedure, discomfort and possible risks in terms which the 
patient or volunteer can understand). 
 
 
Background 
 
Pulmonary Hypertension is a rare and potentially serious condition. It is often difficult to diagnose and to 
treat. The major problem in Pulmonary Hypertension is high blood pressure in the lungs; this often leads to 
excessive stress being exerted on the right hand side of the heart. Sometimes, as a result of this, the right side 
of the heart becomes unable to pump blood into the lungs, as it should. This obviously can make the patient 
feel very unwell. 
 
We usually make the diagnosis after a number of tests have been carried out; the most important of these 
currently is a Right Heart Catheter. This involves passing a plastic catheter into the heart through a vein in 
the neck or groin. Through this catheter we can measure the blood pressure in the lungs and assess how well 
the heart is pumping. We can also assess how likely the patient is to respond to treatment. 
 
This test is very useful and generally safe, but some patients find it unpleasant and there are some risks 
involved. We therefore do not tend to repeat it to see how well or badly a patient is doing unless it is 
absolutely necessary. Instead, we use a test that measures how far a patient can walk in six minutes. We then 
compare this measurement to the last one to say whether they are better or worse. This test is useful but can 
sometimes be misleading. 
 
The Study 
 
We are conducting a study looking at new ways to diagnose and monitor patients with Pulmonary 
Hypertension. We would like to invite you to take part. The study involves the use of a relatively new 
scanning technique called MRI (Magnetic Resonance Imaging). 
 
MRI allows us to get a lot of useful information about Pulmonary Hypertension. It does not use any X-rays 
or radiation, but instead uses magnets to acquire detailed images of pulmonary blood vessels and the heart. It 
is therefore very safe. We can get a lot of the same information using MRI that we get at right heart 
catheterisation.  
 
Compared with right heart catheterisation, MRI is safer, and patients tend to fine it less unpleasant. This 
means not only could MRI be used in the diagnosis of Pulmonary Hypertension, we would be happier to 
repeat it in the future. This may allow us to better identify changes in the illness over time and so allow better 
tailoring of your treatment. 
 
In addition to the MRI we would like to measure certain proteins in your bloodstream that may go up and 
down depending on how well you are. 
 
What the study involves 
 
During your 5-day stay at the Western Infirmary you will have a number of tests, including blood samples 
and x-rays. On the Thursday you will have your right heart catheterisation. We would propose doing an MRI 
scan at some time during this week. The scan would take around 11/2hours and would not prolong your stay 
in hospital. We will take some extra blood samples in addition (around one tablespoon in total). These 
samples will be taken off at the same time as your routine bloods and will not involve any extra needles. We 
normally see patients about 3 months after their discharge in clinic and repeat the six-minute walking test. 
You will follow this normal routine. As part of the study you will also have further MRI scans 4 months 
and 12 months later, to assess your progress. If required, we will be able to organise for a taxi to pick you 
up and take you home free of charge.   
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What does the MRI involve? 
 
On arrival at the Clinical Research Initiative (CRI) a radiographer will go through a safety checklist and 
make sure that all magnetic objects (e.g. jewellery and bankcards) have been removed. Following this you 
will be asked to sign the consent form. Once you have changed into a hospital gown you will then be asked 
to lie flat on the bed that will move into the scanner. The scanner is basically tunnel shaped, like a large 
“polo” mint. You are slid into the centre of the “polo” on an electric bed and the scans are acquired. Some 
patients find it a little enclosing, but you can come out at any time.  
 
 
When you are in the scanner you will need to wear a pair of headphones, allowing you to listen to music of 
your choice (you are welcome to bring your own CD) and to allow us to communicate with you throughout 
the scan. The headphones are also necessary because of the loud knocking noise that occurs when the 
pictures are being taken. You will be given an emergency buzzer and you can very quickly be taken out the 
scanner should you feel it uncomfortable or if it is felt necessary. During the scan you will be asked to hold 
your breath at times to improve the quality of the pictures. 
 
 
What are the risks? 
 
◦ The MRI scanner is very safe as long as you have no metal implants in your body. 
  
 
NB • You should not take part in this study if you are pregnant. 
 
• If you wish to take part in this study, your General Practitioner will be advised of your 
participation and the clinical management that you will undergo. 
 
• If you do not wish to participate in this study, or wish to withdraw at any time your care will not, 
in any way, be affected. 
 
 
If you have any questions regarding the study please contact the Scottish Pulmonary Vascular Unit on 0141 
211 1812. 
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Appendix 2  World Health Organisation Functional Class 
 
Functional class I  Patients with PH but without resulting limitation of 
   physical activity. Ordinary physical activity does not 
   cause undue dyspnoea or fatigue, chest pain, or near 
   syncope. 
 
Functional class II  Patients with PH resulting in slight limitation of 
   physical activity. They are comfortable at rest. 
   Ordinary physical activity causes undue dyspnoea or 
   fatigue, chest pain, or near syncope. 
 
Functional class III  Patients with PH resulting in marked limitation of 
   physical activity. They are comfortable at rest. Less 
   than ordinary physical activity causes undue dyspnoea 
   or fatigue, chest pain, or near syncope. 
 
Functional class IV  Patients with PH with inability to carry out any 
   physical activity without symptoms. These patients 
   manifest signs of right heart failure. Dyspnoea and/or 
   fatigue may even be present at rest. Discomfort is 
   increased by any physical activity. 
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